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DEVELOPMENT AND EVALUATION OF MACHINE LEARNING AND DATA 
MINING ALGORITHMS FOR BIOMEDICAL APPLICATIONS 
by 
Turki Talal Turki 
Gene network inference and drug response prediction are two important problems in 
computational biomedicine. The former helps scientists better understand the functional 
elements and regulatory circuits of cells. The latter helps a physician gain full 
understanding of the effective treatment on patients. Both problems have been widely 
studied, though current solutions are far from perfect. More research is needed to 
improve the accuracy of existing approaches.  
This dissertation develops machine learning and data mining algorithms, and 
applies these algorithms to solve the two important biomedical problems. Specifically, to 
tackle the gene network inference problem, the dissertation proposes (i) new techniques 
for selecting topological features suitable for link prediction in gene networks;  
(ii) a graph sparsification method for network sampling; (iii) combined supervised and 
unsupervised methods to infer gene networks; and (iv) sampling and boosting techniques 
for reverse engineering gene networks. For drug sensitivity prediction problem, the 
dissertation presents (i) an instance selection technique and hybrid method for drug 
sensitivity prediction; (ii) a link prediction approach to drug sensitivity prediction;  
(iii) a noise-filtering method for drug sensitivity prediction; and (iv) transfer learning 
approaches for enhancing the performance of drug sensitivity prediction. Substantial 
experiments are conducted to evaluate the effectiveness and efficiency of the proposed 
algorithms. Experimental results demonstrate the feasibility of the algorithms and their 
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1.1   Gene Network Inference 
Inference of gene regulatory networks (GRNs) from steady-state and time-series gene 
expression data is an important biological problem that has received increasing attention 
for advancing genomics research. Many computational approaches to solving this 
problem have been developed to correctly infer gene regulatory networks from gene 
expression data. However, existing approaches are not sufficiently accurate and robust to 
convert gene expression data to regulatory relationships between transcription factors and 
target genes.  
The first part of this dissertation proposes several computational approaches for 
making accurate and robust network inference. Chapter 2 develops a supervised link 
prediction approach that combines gene expression data with topological features 
extracted from a partially known gene regulatory network, and uses machine learning 
algorithms for training and predicting unseen links in the gene regulatory network. 
Chapter 3 introduces a learning framework that receives as input a network constructed 
by an unsupervised method and employs a graph sparsification technique for network 
sampling and principal component analysis for feature selection to obtain better quality 
training data for regulatory link prediction. Chapter 4 develops a data cleaning algorithm 
that takes as input a network constructed by an unsupervised method, and produces a 
better quality training set by incorporating techniques from linear algebra and machine 
learning. Then, the training set is passed to machine learning and deep learning 




several methods for regulatory link prediction using sampling and boosting techniques. 
These methods include (i) an upward extension of AdaBoost, called Boost I, that takes as 
input a training set corresponding to a partially observed gene regulatory network and 
iteratively boosts the performance of a weighted decision tree during training and 
classifying remaining unobserved links; (ii) Boost I+U which is the same as Boost I 
except that Boost I+U adopts  an additional undersampling technique for improving 
prediction performance; (iii) Boost I+O which is the same as Boost I+U except that Boost 
I+O uses an oversampling technique instead of an undersampling technique;  
(iv) a different extension of AdaBoost, called Boost II, that iteratively boosts the 
performance of a weighted decision tree for training and testing; (v) Boost II+U which is 
the same as Boost I+U except that Boost II+U uses a different boosting technique;  
(vi) Boost II+O which also works the same as Boost I+O except that Boost II+O uses a 
different boosting technique; (vii) Boost III which is a new boosting technique that is 
different from Boost I and Boost II; (viii) Boost III+U which is the same as Boost II+U 
except that Boost III is a different boosting technique; and (ix) Boost III+O which works 
the same as Boost II+O except that Boost III is different from Boost II. 
To evaluate the performance of the proposed approaches and compare them 
against existing approaches, comprehensive experiments were conducted on many 
datasets. Experimental results showed that the proposed approaches are robust and 







1.1.1   Link Prediction in Gene Regulatory Networks 
Link prediction is an important data mining problem that finds many applications in 
social network analysis. One of the methods for solving the link prediction problem is to 
extract features from a given partially observed network and incorporate these features 
into a classifier. The links (i.e., edges) between entities (i.e., nodes or vertices) in the 
given partially observed network are labeled [1, 2]. One then uses the classifier built from 
the given partially observed network to predict the presence of links for unobserved pairs 
of entities in the network. Liben-Nowell and Kleinberg [3]  showed that topological 
features can be used to increase the accuracy of link prediction in social network analysis.  
Several authors have developed supervised methods for GRN inference [4-6]. For 
example, Gillani et al. [7] presented CompareSVM, which uses support vector machines 
(SVMs) to predict the regulatory relationship between a transcription factor (TF) and a 
target gene where the regulatory relationship is represented by a directed edge (link), and 
both the TF and target gene are nodes in a gene network. SIRENE [4, 8] is another 
supervised method, which splits the network inference problem into many binary 
classification problems using one SVM for each TF. The trained SVM classifiers are then 
used to predict which genes are regulated. The final step is to combine all SVM 
classifiers to produce a ranked list of TF-gene interactions in decreasing order, and to 
construct a network based on the ranked list. Cerulo et al. [5]  developed a SVM-based 
method for GRN inference, which uses positive and unlabeled data for training the SVM 






1.1.2   Network Inference Through Link Prediction 
Network inference through link prediction is a major research topic in computational 
social science [1, 10, 11] and biomedicine [12-14]. For example, computational biologists 
develop different methods for reconstructing gene regulatory networks (GRNs) using 
high throughput genomics data. Maetschke et al. [15] categorized  the existing GRN 
reconstruction algorithms into three groups: unsupervised, supervised and  
semi-supervised. While supervised algorithms are capable of achieving the highest 
accuracy among all the network inference methods, these algorithms require a large 
number of positive and negative training examples, which are difficult to obtain in many 
organisms [15-17]. Unsupervised algorithms infer networks based solely on gene 
expression profiles and do not need any training example; however, the accuracy of the 
unsupervised algorithms is low as they often create missing and spurious links [15]. 
GRNs inferred by unsupervised methods use time-series gene expression data. 
These methods include BANJO (Bayesian Network Inference with Java Objects) [18], 
TimeDelay-ARACNE (Algorithm for the Reconstruction of Accurate Cellular Networks) 
[19], tlCLR (Time-Lagged Context Likelihood of Relatedness) [20, 21], DFG (Dynamic 
Factor Graphs) [22], BPDS (Boolean Polynomial Dynamical Systems) [23], MIDER 
[24], Jump3 [25], ScanBMA [26], and Inferelator [27]. BANJO models networks as a 
first-order Markov process; it searches through all possible networks, seeking the 
network with the best score. TimeDelay-ARACNE infers networks from time-series data 
using mutual information from information theory. 
The tlCLR method also uses mutual information and depends on ordinary differential 




and then infers networks based on an assumed underlying, idealized gene expression 
pattern. Jump3 uses a non-parametric procedure based on decision trees to reconstruct 
GRNs. ScanBMA is a Bayesian inference method that incorporates external information 
to improve the accuracy of GRN inference. Inferelator uses ordinary differential 
equations that learn a dynamical model for each gene using time-series data. Recent 





















1.1.3   Network Inference via Supervised and Unsupervised Methods 
Current biotechnology has allowed researchers in various fields to obtain immense 
amounts of experimental information, ranging from macromolecular sequences, gene 
expression data to proteomics and metabolomics. In addition to large-scale genomic 
information obtained through such methods as third generation DNA sequencing, newer 
technology, such as RNA-seq and ChIP-seq, has allowed researchers to fine tune the 
analysis of gene expression patterns [28]. More information on interactions between 
transcription factors and DNA, both qualitative and quantitative, is increasingly emerging 
from microarray data.  
Although microarrays alone do not provide direct evidence of functional 
connections among genes, the attachment of transcription factors (TFs) and their binding 
sites (TFBSs), located at specific gene promoters, influences transcription and modulates 
RNA production from that particular gene, thus establishing a first level of functional 
interaction. Since the TFs are gene-encoded polypeptides and the target TFBSs belong to 
different genes, analyses of TFs-TFBSs interactions could uncover gene networks and 
may even contribute to elucidate unknown GRNs [29]. Besides contributing to infer and 
understand these interactions, determining GRNs also aims to provide explanatory 
models of such connections [30]. GRNs could be the basis to infer more complex 
networks, encompassing gene, protein, and metabolic spaces, as well as the entangled and 
often overlooked signaling pathways that interconnect them [14, 31, 32]. 
Maetschke et al. [33] categorized GRN inference methods into three groups: 
supervised, unsupervised and semi-supervised. While supervised algorithms are capable 




algorithms require a large number of positive and negative training examples, which are 
difficult to obtain in many organisms [5, 34, 35]. Unsupervised algorithms infer GRNs 
based solely on gene expression profiles and do not need any training example; however, 



































1.1.4   Networks Inference Using Sampling and Boosting Techniques 
Gene regulation is a series of processes that control gene expression and its extent. The 
connections among genes and their regulatory molecules, usually transcription factors, 
and a descriptive model of such connections, are known as gene regulatory networks 
(GRNs). Elucidating GRNs is crucial to understand the inner workings of the cell and the 
interactions among genes. Furthermore, GRNs could be the basis to infer more complex 
networks, encompassing gene, protein, and metabolic spaces, as well as the entangled and 
often over-looked signaling pathways that interconnect them [36-40]. 
Existing GRN inference methods can be broadly categorized into two groups: 
unsupervised and supervised [41]. Unsupervised methods infer GRNs based solely on 
gene expression data. The accuracy of these methods is usually low. By contrast, 
supervised methods use machine learning algorithms and training data to achieve higher 
accuracy. These methods work as follows. We represent a GRN by a directed graph in 
which each node is a gene or transcription factor, and a directed link or edge from node A 
to node B indicates that gene A regulates the expression of gene B. The training data 
contains a partially known network with known present edges and absent edges between 
nodes. These known present edges are positive training examples, and the known absent 
edges are negative training examples. We train a machine learning algorithm using the 
training data and apply the trained model to predict the remaining unknown edges in the 
network. With the predicted present and absent edges, we are able to infer or construct a 
complete GRN. 
GRNs are always sparse graphs. The ratio between the number of  gene 




and 2.75 regardless of the differences in phylogeny, phenotypic complexity, life history, 
and the total number of genes in an organism [42]. Thus, all GRNs have relatively few 
present edges and a lot of absent edges. This means there are few positive examples and a 
lot of negative examples when modeling the GRN inference problem as the link 
prediction problem described above. This poses an imbalanced classification problem in 
which the positive class (i.e., the minority class) is much smaller than the negative class 
(i.e., the majority class). However, existing supervised GRN inference methods [8] [43] 



















1.2   Cancer Drug Sensitivity Prediction 
The problem of cancer drug sensitivity prediction has attracted considerable recent 
attention from various domains such as computational biology, machine learning, and 
data mining. As a result, many computational approaches have been proposed to predict 
correctly the response of cancer to drugs using genomic information with the associated 
drug values, where both are modeled as a single data matrix. However, many of these 
approaches are not accurate and robust enough to connect genomic information to drug 
values and cancer response. This dissertation presents computational approaches to make 
accurate and robust cancer drug sensitivity predictions.  
The second part of this dissertation proposes different computational approaches 
to improve the prediction performance of cancer drug sensitivity prediction. Specifically, 
Chapter 6 presents: (i)  instance selection approach to select the most important samples 
(i.e., examples), which are then provided to the standard machine learning algorithm to 
train and perform prediction on new samples (i.e., test set); (ii) an oversampling approach 
to generate synthetic samples, which are provided as input along with the original 
samples to a machine learning algorithm for training and performing prediction on a 
testing set; (iii) a hybrid approach that performs a majority vote on predictions obtained 
on the test set based on models generated using machine learning algorithms trained on 
different selected samples and genes. Chapter 7 introduces: (i) a link prediction approach 
to cancer drug sensitivity prediction; (ii) an algorithm employing the link prediction 
approach and a modified version of Query by Committee to select samples and provide 
them as input to a machine learning algorithm for training and predicting a test set;  




selection using statistical leverage scores. Chapter 8 develops a noise filtering approach 
derived from numerical linear algebra and information retrieval techniques to select the 
most important samples and pass them to a standard machine learning algorithm for 
training and performing prediction on the test set. Chapter 9 proposes: (i) a transfer 
learning approach that changes the representation of auxiliary data from the related task 
to a new representation that is closer to the target training set and incorporating the data 
with changed representation and the target training set, where both are passed to a 
standard machine learning algorithm for training and performing prediction on testing; 
(ii) an extended transfer learning approach to the previous approach, which includes a 
modified version of Adaboost to boost the performance on the test set. 
To compare the proposed prediction algorithms against existing approaches, 
experimental evaluations of all approaches were performed using the Area Under the 
ROC Curve (AUC) on test sets corresponding to real clinical trial datasets of cancer 
patients. Experimental results demonstrate the stability and superiority of the proposed 











1.2.1   Approaches to Cancer Drug Sensitivity Prediction 
Cancer is a major public health problem in the world and the second leading cause of 
deaths in the Unites States of America [44]. Patients respond differently to cancer 
chemotherapy owing to genetic heterogeneity, tumor heterogeneity, and environmental 
factors, which make cancer drug discovery very difficult [45-48]. Cancer, because it 
tends to be a progressive threat, has attracted attention of researchers from various 
domains for identifying novel cancer genes and for cancer drug discovery [49-52]. 
Costello et al. [53] assessed 44 drug sensitivity prediction algorithms based on profiling 
datasets (i.e., genomic, proteomic, and epigenomic data) of patients in breast cancer cell 
lines. The training set consist of 35 cell lines (i.e., instances), where each cell line was 
associated with 28 drugs response (output) values. The test set consist of 18 cell lines 
(i.e., instances). The task of each algorithm was to predict the response (i.e., ranking 28 
drugs from most sensitive to most resistant) for each cell line of the test set. The 44 
algorithms were assigned to six categories: (i) kernel methods, (ii) nonlinear regression, 
(iii) sparse linear regression (SLR), (iv) partial least-squares or principal component 
regression, (v) ensemble/model selection and (vi) other (those methods not falling cleanly 
into the previous five categories). Georgii et al. [53], the top-performing team, presented 
Bayesian multitask multiple kernel learning (MKL) that integrates multiple profiling 
datasets and enhanced data representations into probabilistic nonlinear regression model 
to learn and predict drug sensitivity for all drugs simultaneously. Wan et al. [53], the 
second-best performing team, employed random forest regression trees to address drug 




probabilistic c-index (wpc-index) [53]. The other teams were not statistically 
significantly different according to the performed analysis on the algorithms. 
Geeleher et al. [54] proposed an approach to drug sensitivity  prediction 
performing homogenization and filtering on input data (baseline gene expression levels 
with drug response values and in vivo tumor gene expression). A Learning algorithm is 
applied to the baseline gene expression levels in the cell lines with associated drug 
response values, to learn a model. The resulting learned model is then applied to the  
baseline tumor expression data from the clinical trial, to yield drug sensitivity predictions. 
Several problems are associated with the previous supervised approaches:  
(i) The poor quality of cell lines, especially when cell lines are not screened against all 
the compounds [55]; (ii) The lack of sufficiently large and representative cancer cell 
lines, as they provide the basis to improve the accuracy of prediction algorithms. 
















1.2.2   Cancer Drug Sensitivity Prediction Through Link Prediction 
Cancer has a significant global impact on public health; it is the second leading cause of 
death in the United States of America [44]. Cancer patients respond differently to 
potential drugs (i.e., chemotherapy) due to environmental causes, tumor heterogeneity, 
and genetic factors, making cancer drug discovery difficult [45-48]. The increasing 
number of deaths associated with cancer has attracted the attention of researchers from 
numerous domains, such as computational biology, machine learning, and data mining 
[49-52]. Costello et al. [53] assessed the performance of 44 drug sensitivity prediction 
algorithms based on profiling datasets (i.e., genomic, proteomic, and epigenomic data) in 
breast cancer cell lines. The training set consists of 35 cell lines, in which each cell line is 
associated with 28 drug responses. The test set consists of 18 cell lines. The task of each 
prediction algorithm is to learn a model from the training cell lines and perform 
predictions on the test set. The predictions correspond to a ranking of the 28 drugs—from 
the most sensitive to the most resistant for each cell line on the test set. The  
top-performing approach [53] improved the performance by integrating several profiling 
datasets with improved representation with a probabilistic nonlinear regression model. 
The second-best performing approach employed random forest regression to make 
predictions on the test set. The prediction algorithms were evaluated using the weighted 
probabilistic c-index (wpc-index) and resampled Spearman correlations [53]. The 
remaining prediction algorithms were not statistically different. 
Geeleher et al. [54] proposed the following approach to drug sensitivity in which 
the input data are baseline expressions with drug IC50 values in cell lines and in vivo 




processed separately and then combined and homogenized. The homogenized expression 
data consist of cell line expression data (i.e., baseline gene expression levels in the cell 
lines) and clinical trial expression data (i.e., baseline tumor expression data from the 
clinical trial). A learning algorithm is applied to the cell line expression data with the 
associated drug IC50 values for cell lines to learn a model. The resulting model is applied 
to clinical trial expression data to yield drug sensitivity predictions. 
Two problems associated with the previous drug sensitivity prediction algorithms 
contribute to the degradation of the performance: (1) the poor quality of cell lines, 
especially when cell lines are not screened against all compounds [55]; and (2) the failure 
to adopt a new feature representation, because new feature representations provide a basis 


























1.2.3   Filtering Noisy Cancer Cell Lines for Drug Sensitivity Prediction 
Cancer has a significant impact on public health worldwide and is the second leading 
cause of death in the US [60]. In 2016, the American Cancer Society [61] predicted that 
1,685,210 new cancer cases will be diagnosed, resulting in 595,690 deaths attributable to 
cancer in the US. Many of these cancer patients respond differently to the same cancer 
drug (i.e., during chemotherapy). These response differences are attributable to 
environmental (i.e., external) factors such as tobacco, infectious organisms, and an 
unhealthy diet, as well as to genetic (i.e., internal) factors such as inherited genetic 
mutations, hormones, or immune conditions, and cancer cell heterogeneity, all of which 
make cancer drug discovery very difficult [45, 46, 48, 62]. Because of the significant 
numbers of deaths associated with cancer, its study has attracted the attention of 
researchers from numerous domains including computational biology, machine learning, 
and data mining [49, 52, 63]. 
Many existing drug sensitivity prediction algorithms do not take sample quality 
into consideration [53, 54] , which degrades their performance in the real world. Cell 
lines of poor quality exist, especially when cell lines are not screened against all of the 
compounds [55]. These existing approaches fail to remove the poor cell lines, which 
correspond to noisy samples in machine learning terms, and this failure leads to the 




1.2.4   Improving Drug Sensitivity Prediction via Transfer Learning 
Cancer has a significant impact on public health worldwide and is the second leading 
cause of death in the US [60]. In 2016, the American Cancer Society predicts that 
1,685,210 new cancer cases will be diagnosed, resulting in 595,690 deaths attributable to 
cancer in the US. Many of these cancer patients respond differently to the same cancer 
drug during chemotherapy. These response differences are attributable to not only 
environmental (i.e., external) factors such as tobacco, infectious organisms and an 
unhealthy diet, but also genetic (i.e., internal) factors such as inherited genetic mutations, 
hormones, immune conditions, and cancer cell heterogeneity, all of which make cancer 
drug discovery very difficult [45-49]. Because of the significant numbers of deaths 
associated with cancer, its study has attracted the attention of researchers from numerous 
domains including computational biology, machine learning, and data mining 
[50, 51, 63-65]. 
Traditional machine learning approaches to drug sensitivity prediction have been 
adopted to improve the performance of prediction algorithms. For example, Riddick et al. 
[66] presented an approach that employs random forests as a learning algorithm trained 
on gene expression signatures of selected cancer cell lines and the corresponding drug 
50IC  values (i.e., labels), to induce (i.e., learn) a model. The learned model is then 
applied to gene expression signatures of cancer cell lines in the test set, to yield drug 
sensitivity predictions. Geeleher et al. [54] proposed an approach to drug sensitivity 
prediction that works as follows. The input data consisted of baseline expressions with 




data for the cell lines and clinical trials were processed separately and then combined and 
homogenized. The homogenized expression data consisted of cell lines expression data 
(i.e., baseline gene expression levels in the cell lines) and clinical trial expression data 
(i.e., baseline tumor expression data from clinical trials). A learning algorithm was 
applied to the training set (cell lines expression data along with the associated drug 
50IC  
values for those cell lines), to learn a model. The resulting model was applied to the 
clinical trial expression data in the test set, to yield drug sensitivity predictions. 
Costello et al. [53] assessed the performance of 44 drug sensitivity prediction 
algorithms based on genomic, proteomic, and epigenomic profiling data for 53 breast 
cancer cell lines. The training set consisted of several profiling data for 35 cell lines, 
where each cell line was associated with responses of 28 drugs. The test set consisted of 
profiling data for 18 cell lines. The drug response data (also called the ground truth) were 
hidden for evaluation purposes. The goal of each prediction algorithm is to induce (i.e., 
learn) a model from the training set and, then perform predictions on the test set. The 
predicted drug responses corresponded to a ranked list of the most sensitive (to be ranked 
first) to the most resistant (to be ranked last) cell lines for each drug across all the 18 cell 
lines in the test set. The top-performing approach worked by integrating several profiling 
data with improved representation combined with a probabilistic nonlinear regression 
model [53]. The second-best performing approach employed random forest regression to 
learn a model from profiling data of the training set and perform prediction on the test 
set. The algorithms' predictions were evaluated against the ground truth using a weighted 




Spearman correlations for verifying the consistency between team rankings [53]. The 
remaining prediction algorithms were not statistically different. 
The previous approaches work well only under the common assumption: the 
training set and test set are in the same feature space and with the same distribution. 
However, this assumption does not hold in real-world applications [67]. As an example, 
consider the task of predicting drug sensitivity in multiple myeloma (referred to as the 
target task) where we have limited training data (called target training data). On the other 
hand, there exist an abundance of labeled auxiliary data in the task of predicting drug 
sensitivity in patients with a cancer type (referred to as the related task), where the 
auxiliary data are in a different feature space or come from a different distribution. In 
addition, collecting additional training data to improve the accuracy of prediction 
algorithms of the target task requires larger infrastructures and is associated with higher 
costs of screening size [56]. Therefore, there is a need to create high-performance 
prediction algorithms trained with more easily obtained data from a related task. This 




















CHAPTER 2  
A NEW APPROACH TO LINK PREDICTION  
IN GENE REGULATORY NETWORKS 
 
 
2.1   Introduction 
Link prediction is an important data mining problem that has many applications in 
different domains such as social network analysis and computational biology. For 
example, biologists model gene regulatory networks (GRNs) as directed graphs where 
nodes are genes and links show regulatory relationships between the genes. By predicting 
links in GRNs, biologists can gain a better understanding of the cell regulatory circuits 
and functional elements. Existing supervised methods for GRN inference work by 
building a feature-based classifier from gene expression data and using the classifier to 
predict links in the GRNs.  
Feature extraction is crucial in building efficient classifiers for link prediction [3, 
69, 70]. This chapter presents a new supervised approach for link prediction in GRNs. 
The proposed approach employs both gene expression data and topological features 
extracted from the GRNs, in combination with three machine learning algorithms 
including random forests, support vector machines and neural networks. Experimental 
results on different datasets demonstrate the good performance of the proposed approach 










2.2   Proposed Approach 
2.2.1   Feature Extraction 
Let ( , )G V E  be the directed graph that represents the topological structure of a gene 
regulatory network (GRN) where E  is the set of edges or links and V  is the set of nodes 
or vertices in G . The goal is to build a classifier that includes topological features alone 
or combined with gene expression data. There are totally sixteen topological features, 
which are described in detail below. 
Node Degree. In considering node degrees, each directed edge ( , )e u v E   has four 
topological features, ( )indeg u , ( )outdeg u , ( )indeg v , and ( )outdeg v , which are defined 
as the number of edges entering u , leaving u , entering v , and leaving v , respectively. 
Normalized Closeness Centrality. Normalized closeness centrality measures the 
closeness between a node and all other nodes in the graph G . For each node or vertex 
v V , the normalized closeness centrality ( )inC v  is defined as 













                                                 (2.1)  
where ( , )d i v , i v , is the distance from i V  to v V , and | |V  is the number of 
vertices in the graph G  [71]. The distance from i  to v  is the number of edges on the 
shortest path from i  to v . If no such path exists, then the distance is set equal to  . 
Since G  is a directed graph, the distance from i  to v  is not necessarily the same as the 


















where ( , )d v i , v i , is the distance from v V  to i V . In considering normalized 
closeness centrality, each directed edge ( , )e u v E   has four topological features, 
( )inC u , ( )outC u , ( )inC v , and ( )outC v . 
Eccentricity. The eccentricity of a vertex v V  is the maximum distance between v  and 
any other vertex i V  [72]. For each vertex v V , the eccentricity ( )inv  is defined as  
 ( ) max ( , )in i Vv d i v   (2.3) 
The eccentricity ( )outv  is defined as  
 ( ) max ( , )out i Vv d v i   (2.4) 
In considering eccentricity, each directed edge ( , )e u v E   has four topological 
features, ( )inu , ( )outu , ( )inv , and ( )outv . 
Betweenness Centrality. Betweenness centrality measures the centrality of a vertex  
in the graph G  [73]. For each vertex v V , the betweenness centrality of v , denoted 














   (2.5) 
where ,i j  is the total number of shortest paths from vertex i  to vertex j  and , ( )i j v  is 
the total number of shortest paths from vertex i  to vertex j  that pass through v  [71, 73]. 
In considering betweenness centrality, each directed edge ( , )e u v E   has two 
topological features, ( )Between u  and ( )Between v . 
Eigenvector Centrality. Eigenvector centrality is another centrality measure where 
vertices in the graph have different importance. A vertex connected to a very important 




incorporated into eigenvector centrality [74]. For each vertex v V , the eigenvector 
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  (2.6) 
where   is a constant and A  = ,( )v ia  is the adjacency matrix, i.e., ,v ia  = 1 if vertex v  is 
linked to vertex i , and ,v ia  = 0 otherwise. The above eigenvector centrality formula can 
be rewritten in the matrix form as  
  Ax x   (2.7) 
where x  is the eigenvector of the adjacency matrix A  with the eigenvalue  . In 
considering eigenvector centrality, each directed edge ( , )e u v E   has two topological 
features, ( )Eigen u  and ( )Eigen v . 
2.2.2   Feature Vector Construction 
Given n  genes where each gene has p  expression values. The gene expression profiles 
of these genes is denoted by 
n pG R  , which contains n  rows, each row corresponding 
to a gene, and p  columns, each column corresponding to an expression value [8]. To 
train a classifier, the regulatory relationships among some genes have to be known. 
Suppose these regulatory relationships are stored in a matrix 3mH R  . H  contains m  
rows, where each row shows a known regulatory relationship between two genes, and 
three columns. The first column shows a transcription factor (TF). The second column 
shows a target gene. The third column shows the label, which is 1  if the TF is known to 




The matrix H  represents a partially observed or known gene regulatory network for the 
n  genes. If the label of a row in H  is 1 , then the TF in that row regulates the target 
gene in that row, and hence that row represents a link or edge of the network. If the label 
of a row in H  is 1 , then there is no link between the corresponding TF and target gene 
in that row. 
Given a pair of genes 
1g  and 2g  where the regulatory relationship between 1g  
and 2g  is unknown, the goal is to use the trained classifier to predict the label of the gene 
pair. The predicted label is either 1  (i.e., a link is predicted to be present between 1g  
and 2g ) or 1  (i.e., a link is predicted to be missing between 1g  and 2g ). Using 
biological terms, the present link means 1g  (transcription factor) regulates 2g  (target 
gene) whereas the missing link means 1g  does not regulate 2g .  
To perform training and predictions, a feature matrix 2k pD R   is constructed 
with k  feature vectors based on the gene expression profiles G . For a pair of genes 1g  
and 2g , their feature vector d is created, which is stored in the feature matrix D , denoted 
by dD  and defined as  
 1 2 1 21 1 1 2 2 2[ , , , , , , , ]
p p
dD g g g g g g     (2.8) 
where 1 21 1 1, , ,
pg g g  are the gene expression values of 1g , and 
1 2
2 2 2, , ,
pg g g  are the gene 
expression values of 2g .The above feature vector definition has been used by the existing 
supervised network inference methods [4, 5, 7, 8]. In the rest of this paper the above 
technique for constructing feature vectors is referred to as Ge, indicating that it is based 




In addition, another feature matrix  ' 16kD R   is constructed. Each feature vector 
d  in the feature matrix 'D , denoted by 'dD , is defined as  
 ' 1 2[ , ]dD t t   (2.9) 
1 1 1 1 1 1 1 1 1( ), ( ), ( ), ( ), ( ), ( ), ( ), ( )
in in out outt indeg g C g g outdeg g C g g Between g Eigen g   (2.10) 
2 2 2 2 2 2 2 2 2( ), ( ), ( ), ( ), ( ), ( ), ( ), ( )
in in out outt indeg g C g g C g g Between g Eigen g outdeg g   (2.11) 
This feature vector construction technique is referred to as To, indicating that it is based 
on the sixteen topological features proposed in the paper. 
Finally, the third feature matrix '' (2 16)k pD R    is constructed. Each feature vector 
d  in the feature matrix ''D , denoted by ''dD , contains both gene expression data and 
topological features, and is defined as  
 '' 1 2 1 21 1 1 2 2 2 1 2[ , ,..., , , ,..., , , ]
p p
dD g g g g g g t t   (2.12) 
This feature vector construction technique is referred to as All, indicating that it is based 
on all the features described in the paper. 
 
2.3   Experiments and Results 
This section conducts a series of experiments to evaluate the performance of the approach 
and compare it with the existing methods for gene regulatory network (GRN) inference 





2.3.1   Datasets 
GeneNetWeaver [77]  is used to generate the datasets related to yeast and E. coli. We first 
built five different networks are first built and taken from yeast, where the networks 
contained 50, 100, 150, 200, 250 genes (or nodes) respectively.  For each network, three 
files of gene expression data are generated. These files were labeled as knockouts, 
knockdowns and multifactorial, respectively. A knockout is a technique to deactivate the 
expression of a gene, which is simulated by setting the transcription rate of this gene to 
zero [7, 77]. A knockdown is a technique to reduce the expression of a gene, which is 
simulated by reducing the transcription rate of this gene by half [7, 77].Multifactorial 
perturbations are simulated by randomly increasing or decreasing the activation of the 
genes in a network simultaneously [77]. 
Table 2.1 presents details of the yeast networks, showing the number of nodes 
(edges, respectively) in each network. The edges or links in a network form positive 
examples. In addition, the same number of negative examples is randomly picked where 
each negative example corresponds to a missing link in the network. The networks and 
gene expression profiles for E. coli were generated similarly. Table 2.2 presents details of 
the networks generated from E. coli.  
Table 2.1 Yeast Networks Used in the Experiments 
Network Directed #Nodes #Edges #Pos examples #Neg examples 
Yeast 50 Yes 50 63 63 63 
Yeast 100 Yes 100 281 281 281 
Yeast 150 Yes 150 333 333 333 
Yeast 200 Yes 200 517 517 517 





Table 2.2 E. Coli Networks Used in the Experiments 
Network Directed #Nodes #Edges #Pos examples #Neg examples 
E. coli 50 Yes 50 68 68 68 
E. coli 100 Yes 100 177 177 177 
E. coli 150 Yes 150 270 270 270 
E. coli 200 Yes 200 415 415 415 
E. coli 250 Yes 250 552 552 552 
      
2.3.2   Experimental Methodology 
This section considers nine classification algorithms, denoted by RF+All, NN+All, 
SVM+All, RF+Ge, NN+Ge, SVM+Ge, RF+To, NN+To, SVM+To, respectively. Table 
2.3 lists these algorithms and their abbreviations. RF+All (RF+Ge, RF+To, respectively) 
represents the random forest algorithm combined with all features including both gene 
expression data and topological features (RF combined with only gene expression data, 
RF combined with only topological features, respectively). NN+All (NN+Ge, NN+To, 
respectively) represents the neural network algorithm combined with all features (NN 
combined with only gene expression data, NN combined with only topological features, 
respectively). SVM+All (SVM+Ge, SVM+To, respectively) represents the support vector 
machine algorithm combined with all features (SVM combined with only gene 
expression data, SVM combined with only topological features, respectively). SVM+Ge 








Table 2.3 Nine Classification Algorithms and Their Abbreviations 
Abbreviation Classification algorithm and features 
RF + All Random Forests with all features 
NN + All Neural Networks with all features 
SVM + All Support Vector Machines with all features 
RF + Ge Random Forests with gene expression features 
NN + Ge Neural Networks with gene expression features 
SVM + Ge Support Vector Machines with gene expression features 
RF + To Random Forests with topological features 
NN + To Neural Networks with topological features 
SVM + To Support Vector Machines with topological features 
 
Software used in this work included: the random forest package in R [78], the 
neuralnet package in R [79], and the SVM with linear kernel in the LIBSVM package 
[80]. We used R to write some utility tools for performing the experiments, and employed 
the package, igraph, to extract topological features from a network [81] . 
The performance of each classification algorithm was evaluated through 10-fold 
cross validation. The size of each fold was approximately the same, and each fold 
contained the same number of positive and negative examples. On each fold, the 
balanced error rate [76, 82] (BER) of a classification algorithm was calculated where the 





TP FN FP TN
  
 
  (2.13) 
FN is the number of false negatives (i.e., present links that were mistakenly predicted as 
missing links).TP is the number of true positives (i.e., present links that were correctly 
predicted as present links). FP is the number of false positives (i.e., missing links that 
were mistakenly predicted as present links). TN is the number of true negatives (i.e., 
missing links that were correctly predicted as missing links). For each algorithm, the 




an algorithm has, the better performance that algorithm achieves. Statistically significant 
performance differences between classification algorithms were calculated using 
Wilcoxon signed rank tests [76, 83] .As in [84, 85], p-values below 0.05 are considered to 
be statistically significant. 
2.3.3   Experimental Results 
Table 2.4 shows the MBERs of the nine classifications on the fifteen yeast datasets used 
in the experiments. For each dataset, the algorithm having the best performance (i.e., with 
the lowest MBER) is in boldface. Table 2.5 shows, for each yeast dataset, the p-values of 
Wilcoxon signed rank tests between the best algorithm, represented by '-', and the other 
algorithms. A p-value in boldface (p   0.05) indicates that the corresponding result is 
significant. It can be seen from Table 2.4 that random forests performed better than 
support vector machines and neural networks. In particular, random forests combined 
with all features (i.e., RF+All) performed the best on 10 out of 15 yeast datasets. For the 
other five yeast datasets, RF+All was not statistically different from the best algorithms 
according to Wilcoxon signed rank tests (p > 0.05); cf. Table 2.5. 
Table 2.6 shows the MBERs of the nine classification algorithms on the fifteen  
E. coli datasets used in the experiments. Table 2.7 shows, for each E. coli dataset, the  
p-values of Wilcoxon signed rank tests between the best algorithm, represented by '-', and 
the other algorithms. It can be seen from Table 2.6 that random forests combined with 
topological features (i.e., RF+To) performed the best on 6 out of 15 E. coli datasets. For 
the other nine E. coli datasets, RF+To was not statistically different from the best 























Yeast 50 knockouts 16.6 15.0 20.0 18.3 15.8 20.0 17.7 16.3 19.4 
Yeast 50 knockdowns 16.6 17.5 20.0 19.1 22.7 16.9 17.7 18.8 19.4 
Yeast 50 multifactorial 16.1 17.5 20.8 15.5 24.7 17.2 17.7 16.6 19.4 
Yeast 100 knockouts 12.8 13.7 17.3 14.4 20.0 16.7 11.6 22.2 14.5 
Yeast 100 knockdowns 14.2 14.9 15.2 14.1 29.4 14.1 11.8 17.5 14.5 
Yeast 100 multifactorial 12.0 17.8 18.0 12.3 21.3 18.4 11.4 20.0 14.5 
Yeast 150 knockouts 5.10 10.7 14.1 5.40 10.4 13.6 6.10 15.4 11.0 
Yeast 150 knockdowns 5.00 10.5 10.4 5.80 14.7 10.9 5.80 16.0 11.0 
Yeast 150 multifactorial 4.10 12.4 13.9 4.10 15.1 16.1 5.80 10.8 11.0 
Yeast 200 knockouts 1.90 4.00 5.30 1.90 4.90 5.60 2.50 13.7 3.70 
Yeast 200 knockdowns 1.90 5.10 5.80 1.90 6.30 10.5 2.70 9.80 3.70 
Yeast 200 multifactorial 1.90 6.80 10.1 1.90 4.70 14.3 2.50 5.50 3.70 
Yeast 250 knockouts 3.80 8.40 7.60 4.10 5.50 7.20 7.40 10.6 10.4 
Yeast 250 knockdowns 4.00 9.70 7.40 4.00 6.20 7.30 8.10 7.70 10.4 
Yeast 250 multifactorial 4.00 8.50 8.50 3.90 6.00 9.00 7.50 11.3 10.4 
 
Table 2.5 P-Values of Wilcoxon Signed Rank Tests between the Best Algorithm, 





























Yeast 50 knockouts 0.75 - 0.28 0.44 0.67 0.07 0.46 0.78 0.27 
Yeast 50 knockdowns - 0.79 0.46 0.17 0.13 0.52 0.58 0.86 0.33 
Yeast 50 multifactorial - 0.7 0.28 0.89 0.07 0.68 0.58 0.68 0.33 
Yeast 100 knockouts 0.34 0.44 0.05 0.14 0.01 0.02 - 0.04 0.15 
Yeast 100 knockdowns 0.22 0.24 0.16 0.22 0.00 0.03 - 0.08 0.12 
Yeast 100 multifactorial 0.46 0.13 0.02 0.27 0.01 0.04 - 0.00 0.12 
Yeast 150 knockouts - 0.01 0.02 1.00 0.01 0.01 0.10 0.01 0.02 
Yeast 150 knockdowns - 0.02 0.02 0.17 0.03 0.01 0.17 0.00 0.02 
Yeast 150 multifactorial - 0.01 0.01 - 0.01 0.01 0.17 0.01 0.02 
Yeast 200 knockouts - 0.01 0.01 - 0.01 0.02 0.50 0.01 0.17 
Yeast 200 knockdowns - 0.04 0.01 - 0.01 0.02 0.10 0.01 0.17 
Yeast 200 multifactorial - 0.04 0.01 - 0.06 0.00 0.50 0.01 0.17 
Yeast 250 knockouts - 0.03 0.20 0.17 0.06 0.10 0.17 0.09 0.02 
Yeast 250 knockdowns - 0.01 0.10 - 0.06 0.05 0.07 0.20 0.05 


































E. coli 50 knockouts 14.5 5.70 9.80 18.8 22.0 21.5 5.00 11.6 18.4 
E. coli 50 knockdowns 14.5 9.50 10.7 19.1 19.0 16.7 5.00 10.8 18.4 
E. coli 50 multifactorial 15.3 10.3 8.20 15.7 22.9 18.0 5.00 10.3 18.4 
E. coli 100 knockouts 10.3 9.50 14.2 12.0 14.4 17.7 5.60 6.00 13.6 
E. coli 100 knockdowns 10.6 11.6 14.2 11.4 14.1 18.0 5.40 9.80 13.6 
E. coli 100 multifactorial 9.80 10.4 11.4 9.80 12.4 13.6 7.10 9.90 13.6 
E. coli 150 knockouts 2.40 4.40 2.90 2.40 8.80 5.90 2.70 5.90 3.30 
E. coli 150 knockdowns 2.20 4.40 2.70 2.20 8.10 3.70 2.70 3.80 3.30 
E. coli 150 multifactorial 2.20 3.80 2.40 2.20 8.70 2.40 2.70 3.30 3.30 
E. coli 200 knockouts 5.50 5.50 5.10 5.50 4.60 4.60 6.40 11.0 6.00 
E. coli 200 knockdowns 5.30 5.00 5.80 6.10 4.40 5.50 6.40 8.50 6.00 
E. coli 200 multifactorial 5.00 4.20 3.90 4.90 2.80 3.40 6.40 8.00 6.00 
E. coli 250 knockouts 6.60 10.3 7.00 7.70 8.80 8.00 6.30 12.7 10.0 
E. coli 250 knockdowns 5.30 9.30 5.90 5.10 6.70 7.50 6.20 11.9 10.0 
E. coli 250 multifactorial 5.40 11.1 8.00 5.20 11.0 9.70 6.30 10.6 10.0 
 
Table 2.7 P-Values of Wilcoxon signed Rank Tests between the Best Algorithm, 






























E. coli 50 knockouts 0.06 1.00 0.46 0.03 0.00 0.01 - 0.10 0.04 
E. coli 50 knockdowns 0.06 0.07 0.46 0.01 0.01 0.01 - 0.46 0.04 
E. coli 50 multifactorial 0.06 0.49 0.46 0.08 0.01 0.04 - 0.04 0.04 
E. coli 100 knockouts 0.08 0.04 0.01 0.01 0.00 0.01 - 0.68 0.04 
E. coli 100 knockdowns 0.02 0.16 0.01 0.01 0.01 0.01 - 0.27 0.04 
E. coli 100 multifactorial 0.67 0.22 0.17 0.67 0.11 0.06 - 0.79 0.17 
E. coli 150 knockouts - 0.10 0.25 - 0.02 0.06 0.65 0.04 0.65 
E. coli 150 knockdowns - 0.04 0.17 - 0.06 0.06 1.00 0.1.00 1.00 
E. coli 150 multifactorial - 0.06 1.00 - 0.10 1.00 1.00 0.100 1.00 
E. coli 200 knockouts 0.91 0.50 0.46 0.91 0.68 - 0.41 0.03 0.46 
E. coli 200 knockdowns 0.89 0.50 0.27 0.75 - 0.46 0.46 0.11 0.68 
E. coli 200 multifactorial 0.67 0.09 0.14 0.67 - 0.28 0.13 0.13 0.20 
E. coli 250 knockouts - 0.02 0.23 0.65 0.00 0.12 0.71 0.12 0.05 
E. coli 250 knockdowns 0.17 0.02 0.02 - 0.02 0.02 0.10 0.02 0.01 




These results show that using random forests with the proposed topological 
features alone or combined with gene expression data performed well. In particular, the 
RF+All algorithm achieved the best performance on 14 out of all 30 datasets. This is far 
better than the SVM+Ge algorithm used by the existing supervised network inference 
methods [4, 5, 7, 8] which achieved the best performance on one dataset only (i.e., the  
E. coli 200 knockouts dataset in Table 2.6).  
It is worth pointing out that, for a fixed dataset size (e.g., 200), the SVM+To 
algorithm always yielded the same mean balanced error rate (MBER) regardless of which 
technique (knockout, knockdown or multifactorial) was used to generate the gene 
expression profiles. This happens because these different gene expression profiles 
correspond to the same network, and SVM+To uses only the topological features 
extracted from the network without considering the gene expression data. On the other 
hand, due to the randomness introduced in random forests and neural networks, RF+To 
and NN+To yielded different MBERs even for the same network. 
 
2.4   Summary 
This chapter presents a new approach to network inference through link prediction with 
topological features. The experimental results showed that using the topological features 
alone or combined with gene expression data performs better than the existing network 
inference methods that use only gene expression data. This work assumes that there are 
exactly the same number of positive examples (i.e., links that are present) and negative 





























CHAPTER 3  




3.1   Introduction 
Network inference through link prediction is an important data mining problem that finds 
many applications in computational social science and biomedicine. For example, by 
predicting links, i.e., regulatory relationships, between genes to infer gene regulatory 
networks (GRNs), computational biologists gain a better understanding of the functional 
elements and regulatory circuits in cells. Unsupervised methods have been widely used to 
infer GRNs; however, these methods often create missing and spurious links. This 
chapter proposes a learning framework to improve the unsupervised methods. Given a 
network constructed by an unsupervised method, the proposed framework employs a 
graph sparsification technique for network sampling and principal component analysis for 
feature selection to obtain better quality training data, which guides three classifiers to 
predict and clean the links of the given network. The three classifiers include neural 
networks, random forests and support vector machines. Experimental results on several 
datasets demonstrate the good performance of the proposed learning framework and the 
classifiers used in the framework. 
 
3.2   The Learning Framework 
3.2.1   Graph Sparsification 
The input of the proposed learning framework is a weighted directed graph ( , )G V E  




(GRN) constructed by Inferelator based on a time series gene expression dataset. E  is the 
set of edges or links, and V  is the set of vertices or nodes in G ,where each link 
represents a regulatory relationship and each node represents a gene. Each edge 
( , )e u v E   is associated with a weight, denoted by ( )W e , where 0 ( ) 1W e  . 
The proposed graph sparsification method, named GeneProbe (reminiscent of 
LinkProbe [86] for social network analysis), takes as input the graph G  and two genes of 
interest: an origin or regulator gene, and a destination or regulated gene. GeneProbe 
creates six sets of genes, described below, and produces as output an inference subgraph 
that contains all genes in the six sets and all edges in E  that connect the genes in the six 
sets. 
Two sets of k -backbone genes. These include one set of k -backbone hub genes and 
one set of k -backbone authority genes. The k -backbone hub genes include all genes 
whose weighted outgoing degree is greater than or equal to a user-specified positive real 
value hubk
 . The weighted outgoing degree of a gene or node u  is defined as the sum 
of edge weights for all outgoing edges of u . Likewise, the k -backbone authority genes 
include all genes whose weighted incoming degree is greater than or equal to a  
user-specified value authorityk
 . The weighted incoming degree of a node u  is defined 
as the sum of edge weights for all incoming edges of u . (In the study presented here, hubk  
= 15 and authorityk  = 10.) Intuitively few ``highly social'' individuals who would represent 
``social hubs/authorities'' for inference across geographical regions are selected. The 
genes most likely to be regulators (with the largest weighted outgoing degrees) are 
selected as the ``hubs'' of the network G  for inclusion in the inference subgraph. 




incoming degrees) are selected as the ``authorities'' of the network G  for inclusion in the 
inference subgraph. 
Formally, let ( )W out u  ( (W in u), respectively) denote the weighted outgoing 
(incoming, respectively) degree of node u. Then 
    
( )
( ) ( )
e E out u
W out u W e
 




( ) ( )
e E in u
W in u W e
 
     (3.2) 
where ( )W e  is the weight of edge e , and ( )E out u  ( ( )E in u , respectively) denotes 
the set of edges leaving (entering, respectively) u . GeneProbe retrieves all genes u G  
where ( ) hubW out u k   and ( ) authorityW in u k  . 
Two sets of d -local genes.  These include one set of d -local genes for the origin and 
one set of d -local genes for the destination. The d -local genes are the genes adjacent to 
each of the two genes of interest, i.e., the origin and destination, with incident edge 
weights greater than or equal to a user-specified positive real value d
 . (In the study 
presented here, d  = 0.95.)Intuitively, the d -local genes represent the genes most likely 
to be regulated by and most likely to regulate the two genes of interest. 
Two sets of random walk metropolis genes. These include one set of random walk 
metropolis genes for the origin and one set of random walk metropolis genes for the 
destination. The random walk metropolis (RWM) genes provide a stochastic path from 
the genes of interest back to a k -backbone gene (if possible). The RWM does not 
differentiate between k -backbone hub and k -backbone authority genes. All of the genes 




regulator gene, the random walk is a walk along outgoing edges towards the k -backbone, 
whereas the random walk for the destination or regulated gene is a backtrack to the  
k -backbone along incoming edges.  Each step along the random walk metropolis is 
selected based on a randomized chance until a k -backbone gene is reached (or a 
maximum number of tries is exceeded). 
The randomized chance at each step along the random walk for the regulator gene 
(i.e., origin) can be characterized as follows. Given a current gene u , a random edge 
from the list of outgoing edges of gene u  is selected. Let w  represent the gene at the end 
of the randomly selected outgoing edge. The random walk will proceed from gene u  to 
gene w  if a randomly selected number between 0 and 1 is less than or equal to the 
minimum of 1 and the weighted outgoing degree of w  divided by the weighted outgoing 
degree of u . That is, w  is accepted as the next state with the probability of less than or 
equal to an acceptance rate 
out . Otherwise, another random outgoing edge of gene u  is 
selected and similar calculations are performed. This move can be formalized in Equation 












   (3.3) 
This process is repeated until a maximum number of tries is reached (or a k -backbone 
gene is reached). Note that given enough chances in a connected gene regulatory 
network, the random walks will always reach a k -backbone gene. It logically follows 
that a setting that includes few k -backbone genes will likely generate many RWM genes 





The randomized chance at each step along the random walk for the regulated gene 
(i.e., destination) can be characterized as follows. Given a current gene v , a random edge 
from the list of incoming edges of gene v  is selected. Let w  represent the gene at the end 
of the randomly selected incoming edge. The random walk will backtrack from gene v  to 
gene w  if a randomly selected number between 0 and 1 is less than or equal to the 
minimum of 1 and the weighted incoming degree of w  divided by the weighted incoming 
degree of v . That is, w  is accepted as the next state with the probability of less than or 
equal to an acceptance rate 
in . Otherwise, another random incoming edge of gene v  is 
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
  (3.4) 
where ( )P w v  is the probability that a random walk moves backward from v  to w . 
This process is repeated until a maximum number of tries is reached (or a k -backbone 





Figure 3.1 Example of an inference subgraph containing an origin (green), a destination 
(purple), d -local genes (black), k -backbone genes (blue) and random walk metropolis 
genes (red).  
 
 
3.2.2   Feature Selection 
An inference subgraph may still have missing and spurious links. We select a more 
reliable sample from the inference subgraph where the weight of each edge in the sample 
is greater than or equal to 0.5. For each pair of genes u , v  in the sample graph, a feature 
vector B is created by concatenating the gene expression profiles of u  and v , as in [4, 
16]. That is,  




where 1 2, , , pu u u  are the gene expression values of u , and  1 2, , , pv v v  are the gene 
expression values of v . Each gene expression value is a feature. 
 
We employ principal component analysis (PCA) to reduce the dimensionality of 
the feature vectors of a sample graph [87]. Specifically, the feature vectors are combined 
into a 2 p N  matrix X  where 2p is the total number of features and N  is the number of 
links in the sample graph. Let the rank of the matrix X  be r  where the rank represents 
the maximum number  of uncorrelated column vectors in X  [88]. We represent X  
through singular value decomposition (SVD) as 
 
TX U S V     (3.6) 
Both U  and V  are orthogonal matrices. Each column of U  is one of the 
eigenvectors of the covariance matrix TX X  where TX  is the transpose of X . Each 
column of V is one of the eigenvectors of the matrix TX X . The r r  matrix S  
contains eigenvalues of X  on the diagonal line of S . 
In this case, each column vector of the matrix X  representsa (present or missing) 
link of the sample graph. That is, each link of the sample graph is a vector in the  
2 p dimensional Euclidean space. The dot product between two column vectors reflects 
the extent to which the two corresponding links share similar feature occurrences. Thus, 
the dot product can be used to get pairwise link distances. Let M  contain pairwise link 
distances, i.e., ijM  is the dot product distance between link iL  and link jL . Then M  can 
be derived by: 





which can be generalized as:  
 ( ) ( )T T TM U S V U S V        (3.8) 
 ( ) ( )T TV S U U S V        (3.9) 
 2 TV S V     (3.10)  
 ( ) ( )TV S V S      (3.11) 
The new representation of the matrix M  shows that the pairwise link comparison matrix 
M  can be obtained through the dot product of ( )V S  and ( )TV S . That is, the i th row 
of the N r  matrix ( )V S  is an r -dimensional vector representing the i th link in the 
sample graph. This result indicates that after performing projection transformation with 
respect to the matrix V , pairwise distances are kept between link-vectors as in the 
original setting. 
SVD reduces the dimensionality (from 2 p  to r  where (2 , )r min p N ) of a  
link-vector. However, the reduced r -dimensional link-vector might still contain 
redundant dimensions.  In practice, the dimensionality of these link-vectors could be 
further reduced without losing characteristics of the link-vectors in the original 
2 p  dimensional Euclidean space. Specifically, based on the optimal solution of the 
squared-error criterion of PCA [87], an r -dimensional vector could be projected onto a 
k -dimensional subspace, k r , spanned by the eigenvectors corresponding to the k  
largest eigenvalues of the covariance matrix TX X . As a result, kX can be obtained, 
which is an approximation of the original matrix X , by keeping the k  largest 
eigenvalues of the covariance matrix TX X  and replacing the remaining eigenvalues 
with zeros. Then, Equation (3.6) can be rewritten as  
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Therefore, the N k  matrix ( )k kV S  replaces the matrix ( )V S  in Equation (3.11), 
where the i th row of the matrix ( )k kV S  is a k  dimensional vector that represents the 
i th link in the sample graph.(In the study presented here, k  = 10.) 
3.2.3   The Link Prediction Algorithm 
After explaining the concepts of graph sparsification and feature selection, the proposed 
learning framework (i.e., link prediction algorithm) is now described as how it works. 
The main assumption here is that the network G  constructed by Inferelator is not 
accurate, and there are many missing and spurious links in G . A missing link or edge me  
refers to a regulatory relationship that exists in the ground truth but is not inferred by 
Inferelator, and hence me G . A spurious link se  refers to a regulatory relationship that 
does not exist in the ground truth, but is inferred by Inferelator, and hence se G . The 
goal here is for the link prediction algorithm to detect these missing and spurious links, so 
as to clean them. To achieve this goal, the algorithm predicts whether there is a link 
between two nodes and uses the predicted outcome to replace the result obtained from 
Inferelator if the predicted outcome differs from Inferelator's result. 
Let ( , )G V E  be the gene regulatory network (GRN) constructed by 
Inferelatorbased on a time series gene expression dataset. The proposed algorithm first 
creates two subgraphs ( , )G V E    and ( , )G V E    where V  (V , respectively) 
contains incident nodes of the edges in E  ( E , respectively),the weight of each edge in 
E  ( E , respectively) is greater than or equal to (less than, respectively) the median of 




likely to be positive instances and the edges in G  are likely to be negative instances. 
Note, however, that in practice these two subgraphs G  and G  have low quality 
data,i.e., they contain many missing and spurious links. 
The proposed link-prediction algorithm consists of five steps. 
Step 1: Suppose the algorithm aims to predict whether there is a link from node/gene u  
to node/gene v . There are two cases to consider. In case 1, the gene pair ( , )u v  is in G . 
Then the algorithm creates an inference subgraph I G   by invoking GeneProbe and 
using G , the origin u  and the destination v  as input. In addition, the algorithm 
randomly selects a pair of genes x , y  in G , and creates an inference subgraph I G   
by invoking GeneProbe and using G , the origin x  and the destination y  as input. In 
case 2, the gene pair ( , )u v  is in G . Then the algorithm creates an inference subgraph 
I G   by invoking GeneProbe and using G , the origin u  and the destination v  as 
input. In addition, the algorithm randomly selects a pair of genes x , y  in G , and creates 
an inference subgraph I G   by invoking GeneProbe and using G , the origin x  and 
the destination y  as input. Without loss of generality, case 1 is assumed to hold and case 
1 will be used to describe the following steps. Thus, the algorithm creates dual graph 
sparsifications I  and I  in step 1. 
Step 2: Create a sample graph 
'I I  . where 
'I  does not contain the testing gene pair 
( , )u v , and the weight of each edge in 'I  is greater than or equal to 0.5. We consider the 
edges in 'I  to have higher quality and are more likely to be positive instances. Suppose 




randomly selected edges to form a sample graph 'I I  . In training the three classifiers 
including neural networks, random forests and support vector machines, the edges in 'I  
are used as positive training examples, and use the edges in 'I  as negative training 
examples. The dual sample graphs 'I  and 
'I  together form the training dataset. 
Step 3: Construct a feature vector for the testing gene pair ( , )u v  by concatenating the 
gene expression values of u  and v , as shown in Equation (3.5). Also, construct a feature 
vector for each gene pair ( , )p q  in the training dataset by concatenating the gene 
expression values of p  and q . 
Step 4: Reduce the dimensionality of the feature vectors constructed in step 3 using 
principal component analysis (PCA), as described in Section 3.2.2. 
Step 5: Use the training examples (reduced feature vectors obtained from step 4) to train 
three classifiers including neural networks, random forests and support vector machines. 
Use the trained models to predict whether there is a link from gene u  to gene v .  
 
3.3   Experiments and Results 
We conducted a series of experiments to evaluate the performance of the proposed 
learning framework and the three classifiers used in the framework. Below, the datasets 
and experimental methodology used in the study are described, and then the experimental 




3.3.1   Datasets 
We adopted the five time-series gene expression datasets available in the DREAM4  
100-gene insilico  network inference challenge [21, 77, 89, 90]. Each dataset contains 10 
times series, where each time series has 21 time points, for 100 genes. Each gene has (10 
  21) = 210 gene expression values. Each link consists of two genes, and hence is 
represented by a 420-dimensional feature vector; cf. Equation (3.5). Through principal 
component analysis, each reduced feature vector has only 10 dimensions.  
Each time-series dataset is associated with a gold standard file, where the gold 
standard represents the ground truth of the network structure for the time-series data. 
Each link in the gold standard represents a true regulatory relationship between two 
genes. For a given time-series dataset, Inferelator [27] constructs a directed network, in 
which each link has a weight and represents an inferred regulatory relationship between 
two genes. 
Table 3.1 presents details of the five networks, true and inferred, used in the 
experiments. The table shows the numbers of true present and missing links in each gold 
standard, and the numbers of inferred present and missing links in each network 
constructed by Inferelator. Each network contains 100 nodes or genes, which form 9,900 
ordered gene pairs totally. 
Table 3.1 Networks Used in the Experiments 
 
 
Net1 Net2 Net3 Net4 Net5 
Directed Yes Yes Yes Yes Yes 
Nodes 100 100 100 100 100 
True present links 176 249 195 211 193 
True missing links 9,724 9,651 9,705 9,689 9,707 
Inferred present links 6,232 6,066 6,186 5,930 6,180 





For each network, four sets of testing data are created. Each testing dataset 
contains 50 randomly selected links from the gold standard. Among the 50 links, 25 are 
true present links and 25 are true missing links in the gold standard. The label (+1 or -1) 
of each selected link is known, where +1 represents a true present link and -1 represents a 
true missing link. These testing data were excluded from the training datasets used to 
train the classifiers studied in the paper. There were 20 testing datasets totally. 
3.3.2   Experimental Methodology 
Three classification algorithms are considered, namely neural networks (NN), random 
forests (RF) and support vector machines (SVM). Software used in this work included: 
the neuralnet package in R [79], the random forest package in R [78], and the SVM 
program with the polynomial kernel of degree 2 in the LIBSVM package [80]. The 
principal component analysis (PCA) program was based on the prcomp function in R 
[91]. The graph sparsification method (GeneProbe) was implemented in C++. In addition, 
R was used to write some utility tools for performing the experiments.  
The performance of each classification algorithm was evaluated as follows. Each 
classification algorithm was trained as described in Section 3.2.3. For each link in a 
testing dataset, the trained model is used to predict its label. In evaluating the link 
prediction algorithm, a true positive is defined to be a true present link that is predicted as 
a present link. A false positive is a true missing link that is predicted as a present link. A 
true negative is a true missing link that is predicted as a missing link. A false negative is a 
true present link that is predicted as a missing link. In evaluating Inferelator, a true 




is a true missing link that is an inferred present link. A true negative is a true missing link 
that is an inferred missing link. A false negative is a true present link that is an inferred 
missing link. Let TP (FP, TN, FN, respectively) denote the number of true positives (false 
positives, true negatives, false negatives, respectively) for a testing dataset. The balanced 





TP FN FP TN
  
 
  (3.13)  
Each classification algorithm was applied to each testing dataset and recorded the BER 
for that testing dataset. The lower BER a classification algorithm has, the better 
performance that algorithm achieves. The improvement rate, denoted IR, is defined on a 
testing dataset to be *( ) 100%P P   where *P  is the BER of Inferelator and P is the BER 
of a classification algorithm  (NN, RF or SVM) for that dataset. Statistically significant 
performance differences were calculated using Wilcoxon signed rank tests [83] . As in 
[87], p-values below 0.05 are considered to be statistically significant. 
3.3.3   Experimental Results 
Table 3.2 shows the improvement rate (IR) each classification algorithm achieves on each 
of the 20 testing datasets. A positive (negative, respectively) IR for a classification 
algorithm indicates that the algorithm performs better (worse, respectively) than 
Inferelator. The larger the positive IR a classification algorithm has, the more 
improvement over Inferelator that algorithm achieves. For each testing dataset, the 
classification algorithm with the best performance, i.e., the largest positive IR, is shown 
in boldface. It can be seen from Table 3.2 that SVM (support vector machines) 




Inferelator on 16 testing datasets, and the improvement is statistically significant 
according to Wilcoxon signed rank tests (p < 0.05). NN improves Inferelator on 12 
testing datasets; however, the improvement is not statistically significant according to 
Wilcoxon signed rank tests (p > 0.05). 
Table 3.2 Improvement Rates of Three Classification Algorithms on Twenty Datasets 
Dataset NN RF SVM 
Net1.test1 +11.10% +0.90% +17.90% 
Net1.test2 +17.00% +1.80% +12.30% 
Net1.test3 +7.10% +4.90% +13.60% 
Net1.test4 +5.20% +2.10% +9.20% 
Net2.test1 +5.80% +1.80% -1.60% 
Net2.test2 +14.80% -6.20% +0.90% 
Net2.test3 +4.40% -12.10% +1.20% 
Net2.test4 -0.60% +1.20% +5.20% 
Net3.test1 +0.20% -9.40% -1.10% 
Net3.test2 +0.00% +8.00% +4.00% 
Net3.test3 -8.00% -6.00% +2.00% 
Net3.test4 -2.00% -10.00% +8.00% 
Net4.test1 +10.40% -4.80% +3.00% 
Net4.test2 -5.70% -6.00% +4.50% 
Net4.test3 +10.80% +2.50% +5.20% 
Net4.test4 -3.00% +8.20% +2.60% 
Net5.test1 +1.20% -5.00% +7.10% 
Net5.test2 -1.70% -13.10% +2.90% 
Net5.test3 -7.00% -13.30% -3.50% 
Net5.test4 -3.00% -7.20% -1.10% 
 
Experiments were also carried out to evaluate the performance of different SVM 
kernel functions, including the linear kernel (SVM_L), polynomial kernel of degree 2 
(SVM_P2), polynomial kernel of degree 15 (SVM_P15), Gaussian kernel (SVM_G), and 




datasets, for the different kernel functions. It can be seen that SVM with the polynomial 
kernel of degree 2 (SVM_P2) used in this study performs the best. 
Finally, experiments are conducted to evaluate the effectiveness of the 
components of the proposed learning framework. There are two core components: graph 
sparsification (GeneProbe) and feature selection (PCA). Figure 3.3 compares the 
approach with graph sparsification (GS) only, the approach with feature selection  
(FS) only, and the proposed approach, which combines both graph sparsification  
(GS) and feature selection (FS). Each bar represents the average BER over the 20 testing 
datasets. The classifier used to generate the results was the SVM program with the 
polynomial kernel of degree 2. It can be seen from Figure 3.3 that the proposed approach 
combining GS and FS performs the best.  
 





Figure 3.3 Effectiveness of the components of the proposed learning framework. 
 
 
3.4   Summary 
Given gene regulatory networks constructed by unsupervised network inference methods, 
the goal is to predict and clean the links in the networks. To achieve this goal, a learning 
framework is proposed, which employs (i) a graph sparsification technique (GeneProbe) 
for generating inference subgraphs from a given network, and (ii) principal component 
analysis (PCA) for selecting significant features from high-dimensional feature vectors. 
The selected feature values are then used to train three classifiers including neural 
networks (NN), random forests (RF) and support vector machines (SVM) for performing 
link prediction and link cleaning in the given network. 
In this case study, the proposed framework is able to learn better quality training 
data from noisy networks constructed by a widely used network inference tool 




the polynomial kernel of degree 2 outperforms NN and RF in terms of improving the 
accuracy of Inferelator. This kernel is the best among all SVM kernel functions tested 
here. Experimental results also show that combining both graph sparsification and PCA is 
better than using PCA or graph sparsification alone. 
To the best of found knowledge, this is the first study to predict and clean the 



















CHAPTER 4  
INFERRING GENE REGULATORY NETWORKS BY COMBINING 
SUPERVISED AND UNSUPERVISED METHODS 
 
 
4.1   Introduction 
Supervised methods for inferring gene regulatory networks (GRNs) perform well with good 
training data. However, when training data is absent, these methods are not applicable. 
Unsupervised methods do not need training data but their accuracy is low. In this chapter, 
supervised and unsupervised methods are combined to infer GRNs using time-series gene 
expression data. Specifically, results obtained from unsupervised methods are used to train 
supervised methods. Since the results contain noise, a data cleaning algorithm is developed to 
remove noise, hence improving the quality of the training data. These refined training data 
are then used to guide classifiers including support vector machines and deep learning tools 
to infer GRNs through link prediction. Experimental results on several data sets demonstrate 
the good performance of the classifiers and the effectiveness of the proposed data cleaning 
algorithm.  
 
4.2   Related Work 
Widely used unsupervised methods for time-series gene expression data include BANJO 
(Bayesian Network Inference with Java Objects) [18], TimeDelay-ARACNE (Algorithm 
for the Reconstruction of Accurate Cellular Networks) [92], tlCLR (Time-Lagged 
Context Likelihood of Relatedness) [93, 94], DFG (Dynamic Factor Graphs) [22], Jump3 





BANJO models GRNs as a first-order Markov process; it searches through all 
possible GRNs, seeking the network with the best score. TimeDelay-ARACNE infers 
GRNs from time-series data using mutual information from information theory. The 
tlCLR method also uses mutual information and depends on ordinary differential 
equations to model time-series data. DFG models experimental noise as a fitted Gaussian 
and then infers GRNs based on an assumed underlying, idealized gene expression pattern. 
Jump3 uses a non-parametric procedure based on decision trees to reconstruct GRNs. 
ScanBMA is a Bayesian inference method that incorporates external information to 
improve the accuracy of GRN inference. Inferelator uses ordinary differential equations 
that learn a dynamical model for each gene using time-series data. Recent extensions of 
Inferelator incorporate prior knowledge into the tool, and are resilient to noisy inputs. 
On the other hand, supervised methods use training data along with a 
classification algorithm such as support vector machines (SVMs) [5, 34, 43, 96]. The 
training data includes known regulatory relationships between genes, also called links, 
which are used to guide the classification algorithm to reconstruct GRNs through link 
prediction. The performance of the supervised methods depends on the quality and the 
amount of available training data.      
 
4.3   Background and Overview 
Central to the proposed approach of combining supervised and unsupervised methods for 
GRN inference is a linear algebra-based data cleaning algorithm. The input of the data 
cleaning algorithm contains a portion of a weighted directed graph G = (V, E) that 




method based on a time-series gene expression dataset. E is the set of directed edges or 
links, and V is the set of vertices or nodes in G, where each link represents a regulatory 
relationship and each node represents a gene. Each edge e = ( , )u v E  is associated with 
a weight, denoted by W(e), where 0 (e) 1.W   As a case study, Inferelator [27] is used 
as the unsupervised method in this paper. Inferelator is one of the most widely used 
unsupervised methods in the field. 
The main drawback of employing an unsupervised method such as Inferelator for 
GRN inference is that the method often creates missing and spurious links [33]. Let G be 
a network constructed by Inferelator. A missing link or edge me  refers to a regulatory 
relationship that exists in the ground truth but is not created by Inferelator, and hence 
.me G  A spurious link se  refers to a regulatory relationship that does not exist in the 
ground truth, but is created by Inferelator, and hence .se G  These missing and spurious 
links will be used to train supervised methods. The goal is to develop a data cleaning 
algorithm for removing the errors or noises in the links to get better quality training data. 
Since an inferred network is sizable, m links are selected with the largest weights and m 
links with the smallest weights to form an original training set. Then, feature vectors are 
constructed for the selected 2m links in the training set.  
The proposed data cleaning algorithm consists of three steps. First, a distance 
matrix is calculated for the feature vectors using Laplacian kernel function. Second, a 
linear algebra technique is adopted to project the training set onto the eigenvectors of the 
distance matrix to obtain noise-removed features. Third, important features are selected 
from the noise-removed features. The feature vectors containing the selected important 




Classifiers are built using the cleaned training set and apply these classifiers to 
predicting links in a regulatory network. The classification algorithms considered here 
include support vector machines and variants of deep neural networks. Support vector 
machines are commonly used in bioinformatics [97] while deep neural networks have 
recently received increasing attention for deep learning. This case study shows how the 
proposed data cleaning algorithm improves the quality of training examples used to guide 
the classifiers for inferring GRNs through link prediction. 
 
4.4   Methodology 
4.4.1   Feature Vector Construction 
A sample of links is selected from the weighted network constructed by Inferelator. The 
sample contains m links (positive training examples) with the largest weights and m links 
(negative training examples) with the smallest weights in the constructed network. These 
2m links form the original training set. (In the study presented here, m = 100.) For each 
ordered pair of genes ,u v  in a selected link, a feature vector x is created by 
concatenating the gene expression profiles of u  and v  as done in [4, 5]. That is, 
 1 2 1 2x [ , ,..., , , ,..., ]p pu u u v v v   (4.1) 
where 
1 2, ,..., pu u u  are the gene expression values of u , and 1 2, ,..., pv v v  are the gene 




4.4.2   Data Cleaning 
To facilitate the discussion of the proposed data cleaning algorithm, the mathematical 
symbols and notation used here are first summarized. Matrices (vectors, respectively) are 
denoted by uppercase (lowercase, respectively) letters. The notation xi denotes the ith 
vector in matrix X. Elements of a vector are denoted by italic lowercase with a 
superscript, e.g., ix  is the ith element of vector x; scalars are denoted by italic lowercase. 




 is constructed in which each row corresponds to a 
link (feature vector) in the original training set. The proposed data cleaning algorithm 
consists of three steps. 
Step 1: Compute the distance matrix D in Equation (4.2): 
 2 2D [ (x ,x )]i j ij
m md     (4.2) 
where  
  (x ,x ) exp || x x || , , 1,...,2 .i j i jd i j m       (4.3) 
Here x (x ,i j  respectively) is the ith (jth, respectively) feature vector of the feature matrix 
X, || x x ||i j  is the Euclidean distance between xi  and x ,j  and   is a user-determined 
parameter. (In the study presented here, 1.)  The element of the distance matrix in the 
left hand side of Equation (4.3) corresponds to the element of the kernel K calculated 
using the Laplacian kernel function [58, 98] in Equation (4.4) below: 
 2 2K [ (x ,x )]i j ij
m mk     (4.4) 
where 




Step 2: Denote by 1 2 2... m       the eigenvalues of the distance matrix D, and 
1 2 2v ,v ,...,v m  the corresponding eigenvectors. According to Courant-Fischer Theorem 




v arg min z Dz 





2 1 2 1spanz:||z|| 1,z {v ,v ,...,v }




   (4.7) 
Here 2z|| ||  is the 2-norm of the eigenvector z, i.e.  














                               (4.8) 
The notation 1 2 1{ , ,..., }span v v vl  is the span of the set of orthonormal eigenvectors, 
1 2 1z span{v , v ,..., v }l  represents that the orthonormal eigenvector z  is perpendicular to the 
span of the set of orthonormal eigenvectors, 1 2 1{ , ,..., }span v v vl  [100, 101]. 
Step 3: Let 
2 ,V m tt

 1 2 ,t m   be the matrix whose columns are the first t 
eigenvectors of the distance matrix D with the smallest eigenvalues. (In the study 
presented here, 1.)t  X is projected onto Vt  to obtain 
2 2C m p with noise-removed 
features. That is, 
 




p are calculated using Equation (4.10): 





where 1  is a 2m-dimensional column vector of all ones. The bottom k elements in M  
corresponding to the k minimum values in M  are selected and their positions are stored 
in .P k  (In the study presented here, 10.)k   Construct feature vectors by selecting 
only k features, based on the positions in P, from the feature vectors in ,C and store the 
feature vectors of k features in the transformed (cleaned) training set, C.  
4.4.3   Link Prediction 
The cleaned training set C (with feature vectors of k features obtained from step 3 above) 
is used to train classification algorithms including support vector machines [58, 98], deep 
neural networks with weights initialized by deep belief networks, and deep belief 
networks with weights initialized by stacked AutoEncoder [102]. Given a testing set with 
n ordered gene pairs whose labels are unknown, the goal here is to predict the label of 
each gene pair (u, v) in the testing set using a trained classification model. That is, the 
classification model will predict whether there is a link from gene u to gene v. The 
predicted label is +1 if it is predicted that there is a link from u to v, and −1 otherwise. 
To perform the link prediction, a feature vector is constructed for each gene pair 
(u, v) in the testing set by concatenating the gene expression values of u and v as shown 
in Equation (4.1). A feature matrix S is created for the testing set, selecting k features 
based on the positions in P,  and store the feature vectors of k features of the testing set in 





4.5   Experiments and Results 
4.5.1   Datasets 
A series of experiments are carried out to evaluate the performance of the proposed 
approach, using three time-series gene expression datasets available in the DREAM4 
100-gene in silico network inference challenge [20, 21]. Each dataset contains 10 times 
series, where each time series has 21 time points, for 100 genes. Each gene has (10 × 21) 
= 210 gene expression values. Each link consists of two genes, and hence is represented 
by a 420-dimensional feature vector.  
Each time-series dataset is associated with a gold standard file, where the gold 
standard represents the ground truth of the network structure for the time-series data. 
Each link in the gold standard represents a true regulatory relationship between two 
genes. For a given time-series dataset, Inferelator [27] outputs a list of ordered gene pairs 
where each gene pair is associated with a positive, non-zero weight. Gene pairs not 
shown in the output list are assumed to have a weight of −1. m gene pairs (positive 
training examples) with the largest weights and m gene pairs (negative training examples) 
with the smallest weights are selected in the output list of Inferelator. These 2m links 
formed the original training set. The proposed data cleaning algorithm is then used to 
clean the 2m links to obtain a cleaned training set.  
Table 4.1 presents details of the data used in the experiments. The table shows the 
numbers of true present and true missing links in each gold standard network, as well as 
the numbers of gene pairs in the output list of Inferelator and the numbers of gene pairs 
not shown in the output list of Inferelator for each time-series dataset. Each network 




Table 4.1 Data Used in the Experiments 
 Net1 Net2 Net3 
Directed Yes Yes Yes 
Nodes 100 100 100 
True present links 176 249 195 
True missing links 9,724 9,651 9,705 
Gene pairs in output 6,232 6,066 6,186 
Gene pairs not in output 3,668 3,834 3,714 
 
For each network, three sets of testing data are generated. Each testing set 
contains 50 randomly selected links from the gold standard. Among the 50 links, 25 are 
true present links and 25 are true missing links in the gold standard. The label (+1 or −1) 
of each selected link is known, where +1 represents a true present link and −1 represents 
a true missing link. These testing data were excluded from the training sets, so the testing 
sets and training sets were disjoint. There were 9 testing sets totally. 
4.5.2   Experimental Setup 
Three classification algorithms are considered, namely support vector machines (SVM), 
deep neural networks with weights initialized by deep belief networks (DNN_DBN), and 
deep neural networks with weights initialized by stacked AutoEncoder (DNN_Auto). 
Software used in this work included: the deepnet package in R [103], the SVM program 
with the linear kernel in the LIBSVM package [104] and other kernel functions in the 
kernlab package [105]. In addition, R is used to write some utility tools for performing 
the experiments. 
The performance of each classification algorithm was evaluated as follows. As in 
[104], each classification program is trained where the option of probability estimation in 




probability of x being in the positive class C ,  i.e., P( C |x). Each gene pair in a testing 
test is predicted to have the label +1 (i.e., predicted as a present link) if its probability is 
greater than or equal to the median of the probability estimates produced by the program. 
The gene pair is predicted to have the label −1 (i.e., predicted as a missing link) if its 
probability is less than the median probability. In evaluating the classification algorithms, 
a true positive is defined to be a true present link that is predicted as a present link. A 
false positive is a true missing link that is predicted as a present link. A true negative is a 
true missing link that is predicted as a missing link. A false negative is a true present link 
that is predicted as a missing link.  
In evaluating Inferelator, a gene pair is considered as an inferred present link if its 
weight is greater than or equal to the median of the weighs produced by Inferelator. The 
gene pair is an inferred missing link if its weight is less than the median weight. A true 
positive is defined to be a true present link that is an inferred present link. A false positive 
is a true missing link that is an inferred present link. A true negative is a true missing link 
that is an inferred missing link. A false negative is a true present link that is an inferred 
missing link.  
Let TP (FP, TN, FN, respectively) denote the number of true positives (false 
positives, true negatives, false negatives, respectively) for a testing set. The performance 








   (4.11) 
Each classification algorithm is applied to each testing set and the AUC the 
algorithm obtains is recorded for the testing set. The larger AUC a classification 




the mean of the AUC values averaged over the three testing sets generated from a 
network, and use AMAUC to denote the average of the MAUC values over the three 
networks used in the experiments.   
4.5.3   Experimental Results 
Experiments are conducted first to evaluate the performance of SVM with different 
kernel functions, including the linear kernel (SVM_L), Gaussian kernel (SVM_G), 
sigmoid kernel (SVM_S), and polynomial kernel of degree 2 (SVM_P). Figure 4.1 shows 
the AMAUC values of SVM with the different kernels. It can be seen from Figure 4.1 
that SVM with the linear kernel (SVM_L) performs the best. The non-linear kernels 
including SVM_G, SVM_S and SVM_P yield smaller AMAUC values, and hence 
perform worse, than SVM_L.  
 
Figure 4.1 Comparison of the AMAUC values of SVM with four different kernels 
including the linear kernel (SVM_L), Gaussian kernel (SVM_G), sigmoid kernel 
(SVM_S), and polynomial kernel of degree 2 (SVM_P). 
 
 
In subsequent experiments, the SVM kernel is fixed at the linear kernel. Table 4.2 
lists the MAUC values of SVM_L, deep neural networks with weights initialized by deep 




AutoEncoder (DNN_Auto), and Inferelator (Inf). For each network, the classification 
algorithm with the best performance, i.e., the largest MAUC, is highlighted in boldface. 
Table 4.2 MAUC Values of Three Classifiers and Inferelator 
Dataset SVM_L DNN_DBN DNN_Auto Inf 
Net1 0.726 0.626 0.546 0.380 
Net2 0.460 0.440 0.480 0.353 
Net3 0.506 0.546 0.506 0.380 
Average 0.564 0.537 0.511 0.371 
 
 
It can be seen from Table 4.2 that SVM_L is the best classifier for Net1 and 
yields the largest average MAUC (i.e., AMAUC) of 0.564. DNN_DBN is the best 
classifier for Net3 and yields the second largest average MAUC of 0.537. DNN_Auto is 
the best classifier for Net2 with the average MAUC of 0.511. All the three classifiers 
(i.e., supervised methods) perform better than the unsupervised method, Inferelator, 
whose average MAUC is 0.371. 
It is worth noting that the kernel-based program, SVM_L, performs better than the 
deep learning programs DNN_DBN and DNN_Auto. Deep learning is a powerful tool for 
image classification on big data with hundreds of classes. The deep learning programs 
model high-level abstractions in data through multiple non-linear transformations. In 
contrast, this work focuses on binary classification with relatively small datasets in which 
the learned linear relationship between feature vectors and labels was shown to be 
effective in testing data classification. As a consequence, the deep learning programs 
perform worse than the kernel-based program.   
Figure 4.2 shows the AMAUC values of the three classifiers, SVM_L, 




incorporated. Thus, the classifiers were trained by uncleaned data. Comparing Figure 4.2 
with Table 4.2 where data was cleaned, one can see that the AMAUC values in Figure 
4.2 are smaller than those in Table 4.2. The performance of the classifiers degrades when 
running on uncleaned data, showing the effectiveness of the proposed data cleaning 
algorithm. Notably, SVM_L suffers the most when data is not cleaned. 
 
Figure 4.2 Comparison of the AMAUC values of three classifiers SVM_L, DNN_DBN 




One component of the data cleaning algorithm is feature selection where Equation 
(4.10) is used to select k most important features to form feature vectors of k features. 
Figure 4.3 shows the AMAUC values of the three classifiers, SVM_L, DNN_DBN and 
DNN_Auto, for varying k values. It can be seen from Figure 4.3 that SVM_L continues 
to be the best classifier when k values change. Its behavior is stable with respect to k.  
Selecting k features makes the proposed approach computationally efficient for large 
datasets with good predictive performance.  
We also tested on different values for the parameters m in Equation (4.2),  in 




results obtained were similar to those of using the default values for these parameters (m 
= 100, 1,   1),t   and the qualitative conclusion remains the same. 
 
 
Figure 4.3 Impact of the number of selected features, k, on the performance of three 
classifiers SVM_L, DNN_DBN and DNN_Auto. 
 
 
4.6   Summary 
Machine learning in biomedicine has received increasing attention recently [16, 106, 
107]. In this paper a hybrid approach is presented for learning gene regulatory networks 
(GRNs) by combining supervised and unsupervised methods. Central to the proposed 
approach is a linear algebra-based algorithm for cleaning the results of unsupervised 
methods. The cleaned results are then used to train supervised methods to perform GRN 
inference through link prediction. In this case study, a widely used unsupervised method 
is adopted, Inferelator, as well as three popular classifiers including support vector 
machines (SVM), deep neural networks with weights initialized by deep belief networks 
(DNN_DBN) and deep neural networks with weights initialized by stacked AutoEncoder 
(DNN_Auto). The experimental results show the superiority of the proposed hybrid 
approach over the unsupervised method. Among the three classifiers, SVM with the 




DNN_Auto. This linear kernel is the best among all SVM kernel functions tested here. 
The experimental results also show the effectiveness of the proposed data cleaning 
algorithm. 
This data cleaning algorithm is related to the noise-filtering algorithm developed 
by Ouyang et al. [108]. While both algorithms aim to improve the quality of network 
data, they differ in two major ways. First, Ouyang et al.’s method is designed for 
undirected networks and employs the Laplacian matrix, which is symmetric for 
undirected networks. The eigenvalues of the symmetric matrix are real numbers, and the 
corresponding eigenvectors are orthonormal. In contrast, the networks considered here 
are directed networks. When applying Ouyang et al.’s method to directed networks, one 
would get a non-symmetric Laplacian matrix, whose eigenvalues may contain complex 
numbers. In such a situation, an orthonormal set of eigenvectors cannot be found, nor 
even any pair of eigenvectors that are orthogonal (except perhaps by rare chance) [109]. 
Thus, instead of using the Laplacian matrix, a distance matrix D is introduced as shown 
in Equation (4.2), which can be calculated by using the Laplacian kernel function as 
shown in Equation (4.5). The eigenvalues of this symmetric positive semidefinite 
distance matrix D are real, non-negative numbers, and the corresponding eigenvectors are 
orthonormal. Second, Ouyang et al.’s method does not include feature selection. In 
contrast, Equation (4.10) is used to select k most important features and use the selected 
features for link prediction. It should also be pointed out that the work of Ouyang et al. 
did not consider machine learning algorithms. In contrast, data cleaning algorithm is used 
here to get better quality training data, which are then used to guide machine learning 




To the best of found knowledge, the proposed hybrid approach is the first work to 




















CHAPTER 5  
REVERSE ENGINEERING GENE REGULATORY NETWORKS USING 
SAMPLING AND BOOSTING TECHNIQUES 
 
 
5.1   Introduction 
Reverse engineering gene regulatory networks (GRNs), also known as network inference, 
refers to the process of reconstructing GRNs from gene expression data. Biologists model 
a GRN as a directed graph in which nodes represent genes and links show regulatory 
relationships between the genes. By predicting the links to infer a GRN, biologists can 
gain a better understanding of regulatory circuits and functional elements in cells. 
Existing supervised GRN inference methods work by building a feature-based classifier 
from gene expression data and using the classifier to predict the links in GRNs. 
Observing that GRNs are sparse graphs with few links between nodes, this chapter 
presents a new approach to supervised GRN inference. The imbalanced classification 
problem is tackled by using sampling techniques, including under-sampling and  
over-sampling, to obtain a balanced training set. This balanced training set, containing 
the same number of positive and negative training examples, is used to train a machine 
learning algorithm to make predictions. Furthermore, several boosting techniques are 
developed to enhance the prediction performance. As the experimental results show later, 





5.2   Methods 
5.2.1   Problem Statement 
n  genes are given where each gene has p  expression values. The gene expression 
profile of these n  genes is denoted by n pG R  , which contains n  rows, each row 
corresponding to a gene, and p  columns, each column corresponding to an expression 
value [8, 16, 17, 43, 110]. In addition, known regulatory relationships or links among 
some genes are given. Suppose these known regulatory relationships are stored in a 
matrix 
3mX R  , which forms the training dataset. X  contains m  rows, where each row 
shows a known regulatory relationship between two genes, and three columns. The first 
column shows a transcription factor (TF). The second column shows a target gene. The 
third column shows the label, which is 1  if the TF is known to regulate the expression 
of the target gene or 1  if the TF is known not to regulate the expression of the target 
gene. The matrix X  represents a partially observed or known gene regulatory network 
for the n  genes. If the label of a row in X  is 1 , then the TF in that row regulates the 
expression of the target gene in that row, and hence that row represents a directed link or 
edge of the network. That row is a positive training example. If the label of a row in X  is 
1 , then there is no link between the corresponding TF and target gene in that row. That 
row is a negative training example. The positive and negative training examples in X  are 
used to train a machine learning or classification algorithm. There are much more 
negative training examples than positive training examples in X . 
The test dataset contains ordered pairs of genes 1 2( , )g g  where the regulatory 





1 2( , )g g  in the test dataset, the goal of link prediction is to use the trained classifier 
to predict the label of the test example. The predicted label is either 1  (i.e., a directed 
link is predicted to be present from 
1g  to 2g ) or 1  (i.e., a directed link is predicted to be 
absent from 
1g  to 2g ). Here, the present link means 1g  (a transcription factor) regulates 
the expression of 
2g  (a target gene) whereas the absent link means 1g  does not regulate 
the expression of 
2g . 
5.2.2   Feature Vector Construction 
To perform training and prediction, a feature matrix  2q pD R   with q  feature vectors 
based on the gene expression profile G  is constructed. Let 
1g  and 2g  be two genes. Let 
1 2
1 1 1, ,...,
pg g g  be the gene expression values of 1g  and 
1 2
2 2 2, ,...,
pg g g  be the gene expression 
values of 2g . The feature vector of the ordered pair of genes 1 2( , )g g , denoted dD , is 
stored in the feature matrix D  and constructed by concatenating their gene expression 
values as follows: 
 1 2 1 21 1 1 2 2 2( , ,..., , , ,..., )
p p
dD g g g g g g   (5.1) 
Thus, the ordered pair of genes 1 2( , )g g  corresponds to a point in 2p-dimensional 
space.  Each training and test example is represented by a 2p-dimensional feature vector. 
For a positive training example, the label of its feature vector is 1 . For a negative 
training example, the label of its feature vector is 1 . For a test example, the label of its 
feature vector is unknown and to be predicted. This feature vector construction method 




5.2.3   Under-sampling 
Given is a training dataset X  that is the union of two disjoint subsets X  and X . X  is 
the minority class, containing positive training examples (i.e., known present links). X  
is the majority class, containing negative training examples (i.e., known absent links). 
X  is much smaller than X . The under-sampling method works as follows [111-113]. It 
samples a random subset sX X   such that the size of 
sX   is equal to the size of X  
(i.e., | |sX  = | |X ). Thus, 
sX  = sX X   forms a balanced dataset. Then 
sX  is used to 
train a machine learning algorithm. The trained model will be used to predict the labels of 
test examples.  
5.2.4   Over-sampling 
The over-sampling method is based on SMOTE [111, 114, 115]. Given is the training 
dataset X  = X X   as described above. The proposed over-sampling method creates a 
new dataset X  that contains all examples in X  and many synthetic examples 













  (5.2) 
Here, Euclidean distances are calculated to find the h -nearest neighbors. Denote these 





A new synthetic example 
newx  along the line between ix  and rx , 1 r h  , is 
created as follows: 
 ( )new i r ix x x x      (5.3) 
 
where (0,1)  is a random number. 
newx  is added to X . Generating and adding such 
synthetic examples to X  is continued until X  is larger than X .  Then a random 
subset sX X   is selected such that the size of 
sX  is equal to the size of X  (i.e., 
| |sX  = | |X ). Thus, 
sX  = sX X   forms a balanced dataset. 
sX  is then used to train 
a machine learning algorithm. The trained model will be used to predict the labels of test 
examples.  
5.2.5   Boosting 
The performance of the proposed link prediction algorithms is further improved through 
boosting.  Boosting algorithms such as AdaBoost [116-119], described below, have been 
used in various domains with great success. A weighted decision tree [120] is used as the 
base learning algorithm and a strong classifier is created through an iterative procedure as 
follows. Let X  be the set of training examples  1 2, ,..., mx x x . The label associated with 
example ix  is iy  such that 
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+1 if  is a positive example (i.e., present link)











  (5.4) 









by calling the base learning algorithm on the training set X  with weights kW . Then kH  
is used to classify each training example 
ix  as either 1  (i.e., ix  is a predicted present 
link) or 1  (i.e., ix  is a predicted absent link). That is, 
 
+1 if classifies as a positive example (i.e.,presentlink)
( )










  (5.5) 







    (5.6) 














  (5.7) 
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  (5.8) 
where kZ  is a normalization factor chosen so that 1kW   is normally distributed. The 
weights of incorrectly classified examples will increase in iteration 1k  . Then, in 
iteration 1k  , AdaBoost generates a base learner 1kH   by calling the base learning 
algorithm again on the training set X  with weights 1kW  . Such a process is repeated K  
times. Using this technique, each weak classifier 1kH   should have greater accuracy than 




the weighted weak classifiers 
kH , 1 k K  , where the weight k  of a weak classifier 
kH  is calculated as shown in Equation (5.7). 
Specifically, given an unlabeled test example x̂ , ( )ˆH x  is calculated as follows: 
 
1




H x sign H x

    (5.9) 
The sign function indicates that if the sum of the results of the weighted K  weak 
classifiers is greater than or equal to zero, then H classifies x̂  as +1(i.e., x̂  is a predicted 
present link); otherwise H classifies x̂  as -1 (i.e., x̂  is a predicted absent link). 
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  (5.12) 
 
where C  is the number of examples in the majority class (i.e., negative class) divided by 
the number of examples in the minority class (i.e., positive class) in the training set. 
Each one of the above variants is taken as a new boosting technique. Boost I is a 
simplified version of AdaBoost. For each training example ix , 1 i m  , Boost I does not 
consider ( )k iW x  when calculating 1( )k iW x . Boost II is an accumulative version of 
AdaBoost. It considers all weak classifiers jH , 1 j k  , obtained in the previous k  
iterations when calculating the weight 1( )k iW x . Specifically, Boost II will increase the 
weight of a training example ix  in iteration 1k  if the majority of the weak classifiers 
obtained in the previous k  iterations incorrectly classify ix . Boost III can be regarded as 
a cost-sensitive boosting technique. For an imbalanced dataset, positive examples (i.e., 
those with labels of 1 ) are much fewer than negative examples (i.e., those with labels of 
1 ). The objective here is to improve the classification performance on the minority (i.e., 
positive) class. Hence the cost C  is introduced, giving more weights to misclassified 




have labels of 1 . For a training example ix  that is correctly classified in iteration k , its 
weight is decreased in iteration 1k  so that the next classifier 
1kH   pays less attention to 
ix  while focusing more on the other examples that are incorrectly classified in iteration 
k . 
5.2.6   The Proposed Approach 
Figure 5.1 presents an overview of the proposed approach. In (A), a training set is given 
containing imbalanced labeled links. These labeled links include few positive examples 
(i.e., known present links with labels of 1 ) and a lot of negative examples (i.e., known 
absent links with labels of 1 ). In addition, a test set is given in which each test example 
is an unlabeled ordered gene pair. Feature vectors are constructed for both training 
examples and test examples as described in Section 8.2.2. In (B), a sampling technique is 
applied, either under-sampling as described in Section 8.2.3 or over-sampling as 
described in Section 8.2.4, to the training set to obtain a balanced training set. In  
(C), a boosting technique is applied as described in Section 8.2.5 to the balanced training 
set to learn K  models (weak classifiers). These models predict the labels of the test 
examples. In (D), the weighted majority vote is taken from the weak classifiers as shown 
in Equation (5.9) to make final predictions of the labels of the test examples. A test 
example is a predicted present link if its predicted label is 1 ; a test example is a 









5.3   Experiments and Results 
5.3.1   Datasets 
GeneNetWeaver  [77] is used to generate the datasets related to yeast and E. coli. 
Specifically four different networks are built for each organism where the networks 
contained 50, 100, 150, 200 genes (or nodes) respectively. Table 5.1 presents details of 
the yeast networks, showing the number of nodes (edges, respectively) in each network. 
The present edges or links in a network form positive examples. The absent edges or 







Table 5.1 Yeast Networks Used in the Experiments 
Network Directed #Nodes #Edges #Positive examples #Negative examples 
Yeast 50 Yes 50 63 63 2387 
Yeast 100 Yes 100 281 281 9619 
Yeast 150 Yes 150 333 333 22017 
Yeast 200 Yes 200 517 517 39283 
 
For each network, three files of gene expression data are generated. These files 
were labeled as knockouts, knockdowns and multifactorial, respectively.  
Table 5.2 E. Coli Networks Used in the Experiments 
Network Directed #Nodes #Edges #Positive examples #Negative examples 
E. coli 50 Yes 50 68 68 2382 
E. coli 100 Yes 100 177 177 9723 
E. coli 150 Yes 150 270 270 22080 
E. coli 200 Yes 200 415 415 39385 
 
 
A knockout is a technique to deactivate the expression of a gene, which is simulated by 
setting the transcription rate of this gene to zero  [7]. A knockdown is a technique to 
reduce the expression of a gene, which is simulated by reducing the transcription rate of 
this gene by half  [7]. Multifactorial perturbations are simulated by randomly increasing 
or decreasing the activation of the genes in a network simultaneously [7]. Totally there 
were twelve gene expression datasets for yeast and E. coli respectively. 
5.3.2   Experimental Methodology 
The proposed approach is compared with existing supervised GRN inference methods [7, 
8]. The existing methods employ support vector machines (SVM) and use the same 
feature vector construction method as the proposed approach (cf. Section 8.2.2); 




the fifteen algorithms that have been evaluated and compared in this study where twelve 
algorithms are boosting-related and three algorithms are SVM-related. 
Table 5.3 Abbreviations of the Fifteen Algorithms Studied in This Paper 
Abbreviation Algorithm 
AdaBoost AdaBoost technique 
AdaBoost+U AdaBoost with under-sampling technique 
AdaBoost+O AdaBoost with over-sampling technique 
Boost I Boost I technique 
Boost I+U Boost I with under-sampling technique 
Boost I+O Boost I with over-sampling technique 
Boost II Boost II technique 
Boost II+U Boost II with under-sampling technique 
Boost II+O Boost II with over-sampling technique 
Boost III Boost III technique 
Boost III+U Boost III with under-sampling technique 
Boost III+O Boost III with over-sampling technique 
SVM SVM technique 
SVM+U SVM with under-sampling technique 
SVM+O SVM with over-sampling technique 
 
 
The performance of each algorithm was evaluated through 10-fold cross 
validation. The positive examples (negative examples, respectively) were evenly 
distributed to the ten folds. When testing a fold, the Area Under the ROC Curve (AUC) 




2 TP FN TN FP
 
   
  
  (5.13) 
Here TP (FP, TN, FN, respectively) denotes the number of true positives (false positives, 
true negatives, false negatives, respectively) for the test set. A true positive (true 
negative, respectively) is a predicted present link (a predicted absent link, respectively) 




(false negative, respectively) is a predicted present link (a predicted absent link, 
respectively) that is in fact a known absent link (a known present link, respectively). For 
each algorithm, the mean AUC, denoted MAUC, over the ten folds was computed and 
recorded. The higher MAUC an algorithm has, the better performance that algorithm 
achieves. 
5.3.3   Experimental Results 
Experiments are first conducted to evaluate the performance of SVM with different 
kernel functions, including the linear kernel, polynomial kernel of degree 2, Gaussian 
kernel, and sigmoid kernel. It was observed that the Gaussian kernel performed the best. 
In subsequent experiments, the SVM kernel is fixed at the Gaussian kernel. 
Figure 5.2 shows the AMAUC values of the three SVM-related algorithms, 
namely SVM, SVM+U, SVM+O, on the twelve yeast datasets used in the experiments. 
For each algorithm, the AMAUC was calculated by taking the average of the MAUC 
values the algorithm received over the twelve yeast datasets. It can be seen from Figure 
5.2 that SVM+U performed better than SVM+O and SVM. Figure 5.3 shows the 
AMAUC values of the twelve boosting-related algorithms on the twelve yeast datasets 
used in the experiments. It can be seen from Figure 5.3 that Boost III+U performed the 
best on the twelve yeast datasets. 
Table 5.4 shows the MAUC values of Boost III+U and SVM+U, and compares 
them with the existing approaches using SVM only [7, 8] on the twelve yeast datasets. 
For each dataset, the algorithm with the best performance (i.e., the highest MAUC) is 




performance on the yeast datasets, and beats the existing approaches using SVM only [7, 
8]. 
Figure 5.4 shows the AMAUC values of the three SVM-related algorithms, 
namely SVM, SVM+U, SVM+O, on the twelve E. coli datasets used in the experiments. 
It can be seen that SVM+O outperformed SVM+U and SVM. Figure 5.5 shows the 
AMAUC values of the twelve boosting-related algorithms on the twelve E. coli datasets 
used in the experiments. It can be seen from Figure 5.5 that Boost II+U performed the 
best among the twelve boosting-related algorithms. Table 5.5 shows the MAUC values of 
Boost II+U and SVM+O, and compares them with the existing approaches using SVM 
only [7, 8] on the twelve E. coli datasets. It can be seen from Table 5.5 that Boost II+U 
has the best overall performance on the E. coli datasets, and beats the existing approaches 
using SVM only [7, 8]. 
 










Table 5.4 MAUC Values of Three Algorithms on Twelve Yeast Datasets 
Dataset Boost III+U SVM+U SVM 
Yeast 50 knockouts 0.709 0.802 0.534 
Yeast 50 knockdowns 0.664 0.79 0.529 
Yeast 50 multifactorial 0.679 0.736 0.526 
Yeast 100 knockouts 0.729 0.638 0.487 
Yeast 100 knockdowns 0.706 0.69 0.489 
Yeast 100 multifactorial 0.701 0.639 0.472 
Yeast 150 knockouts 0.633 0.529 0.486 
Yeast 150 knockdowns 0.673 0.519 0.494 
Yeast 150 multifactorial 0.68 0.538 0.474 
Yeast 200 knockouts 0.599 0.622 0.49 
Yeast 200 knockdowns 0.612 0.623 0.49 
Yeast 200 multifactorial 0.608 0.54 0.471 







Figure 5.4 AMAUC values of three SVM-related algorithms on twelve E. coli datasets. 
 











Table 5.5 MAUC Values of Three Algorithms on Twelve E. Coli Datasets 
Dataset Boost II+U SVM+O SVM 
E. coli 50 knockouts 0.872 0.767 0.669 
E. coli 50 knockdowns 0.866 0.776 0.505 
E. coli 50 multifactorial 0.879 0.819 0.706 
E. coli 100 knockouts 0.77 0.708 0.493 
E. coli 100 knockdowns 0.758 0.712 0.492 
E. coli 100 multifactorial 0.75 0.711 0.49 
E. coli 150 knockouts 0.625 0.567 0.498 
E. coli 150 knockdowns 0.597 0.596 0.5 
E. coli 150 multifactorial 0.636 0.584 0.508 
E. coli 200 knockouts 0.702 0.683 0.504 
E. coli 200 knockdowns 0.705 0.682 0.495 
E. coli 200 multifactorial 0.678 0.666 0.495 
AMAUC 0.736 0.689 0.529 
 
 
To summarize, one of the proposed boosting methods coupled with the  
under-sampling technique achieves the best performance among all the fifteen algorithms 
studied in this paper on the yeast and E. coli datasets respectively. For the yeast datasets, 
this proposed boosting method is Boost III. For the E. coli datasets, this proposed 
boosting method is Boost II. Both boosting methods coupled with the under-sampling 
technique are superior to the existing approaches using SVM only [7, 8]. 
The proposed boosting techniques are based on a weighted decision tree [120]. 
The boosting techniques are combined with other machine learning algorithms including 
random forests [121], SVM with the linear kernel, SVM with the sigmoid kernel, SVM 
with the Gaussian kernel, and SVM with the polynomial kernel of degree 2. However, the 
performance of these other machine learning algorithms is inferior to the performance of 
the weighted decision tree used in this paper. As a consequence, the results from the other 




To evaluate the effectiveness of the proposed sampling and boosting techniques, 
the following four algorithms have also been tested and compared: (i) the weighted 
decision tree without boosting and sampling techniques; (ii) the weighted decision tree 
with boosting techniques only; (iii) the weighted decision tree with sampling techniques 
only; and (iv) the weighted decision tree with both boosting and sampling techniques. 
The results from the yeast and E. coli datasets are similar. For example, for the yeast 
datasets, the AMAUC value for the weighted decision tree without boosting and 
sampling techniques is 0.45. This is lower than the existing approaches using SVM only 
(with AMAUC being 0.495 as shown in Table 5.4). When the weighted decision tree is 
coupled with only the Boost III technique, its AMAUC value is 0.53. When the weighted 
decision tree is coupled with only the under-sampling technique, its AMAUC value is 
0.61. When the weighted decision tree is coupled with both Boost III and under-sampling 
techniques, its AMAUC value is 0.666 as shown in Table 5.4, which is much higher than 
the AMAUC value of 0.45 achieved by the weighted decision tree without boosting and 
sampling techniques. 
 
5.4   Summary 
In this chapter a new approach is presented to gene network inference through regulatory 
link prediction. The proposed approach uses a weighted decision tree as the base learning 
algorithm coupled with sampling and boosting techniques to improve prediction 
performance. Experimental results demonstrated the superiority of the proposed approach 





CHAPTER 6  
LEARNING APPROACHES TO IMPROVE PREDICTION OF DRUG 
SENSITIVITY IN BREAST CANCER PATIENTS 
 
 
6.1   Introduction 
Predicting drug response to cancer disease is an important problem in modern clinical 
oncology that attracted increasing recent attention from various domains such as  
computational biology, machine learning, and data mining. Cancer patients respond 
differently to each cancer therapy owing to disease diversity, genetic factors, and 
environmental causes. Thus, oncologists aim to identify the effective therapies for cancer 
patients and avoid adverse drug reactions in patients. By predicting the drug response to 
cancer, oncologists gain full understanding of the effective treatments on each patient, 
which leads to better personalized treatment. This chapter presents three learning 
approaches to address the problems. The instance selection approach selects 
representative training cell lines for guiding the learning model through utilizing a 
learning scenario. The oversampling approach generates synthetic cell lines to improve 
the accuracy of prediction algorithms. The hybrid approach selects the top-k genes and 
then selects cell lines as in the first approach. Experimental results show later, the three 
approaches statistically significantly outperform the baseline drug sensitivity prediction 





6.2   Proposed Approaches 
6.2.1   The Instance Selection Approach 
Figure 6.1 outlines the instance selection approach, which works as follows. (A) Given 
expression profiles denoted by xRm nX , which contains m cell lines, each cell line  
corresponding to a sample, and n columns, each column corresponding to a gene. To 
learn a model, the continuous real-values drug responses Y (i.e., drug IC50 values) are 
needed to be known, where R .mY  A training set is defined as 
1 1 2 2{( , ),( , ),...,( ,y )}m mx y x y xS  where ix X and .iy Y  Similarly, for given expression 
profiles denoted by xR p n'X , containing p samples and n genes. The test set is defined 
as ' ' '1 2{ , ,..., }.px x x
'X  (B) Slight modification of IPRed is adapted [122], to select 
representative training cell lines, consisting of the following two steps 
1. Store m distances, which correspond to the m minimum distances between each 
training cell line ix X  and all tumors of patients (i.e.,  instances) in
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  is the Euclidean distance. 
 
2. Let 1 2( ( ), ( ),..., ( )).mw x w x w xW Each cell line ix X is selected, s.t. ( ) c,iw x   
where c= percentile( ,W %75), =1,..., .i m That is, each cell line whose weight is 
below the 75th percentile of W  is selected. All cell lines satisfying the condition 
are then stored in .
'S  Eventually, 
' xRm n'S where 




is applied on 'S , to induce model h1. (C) Model h1 is applied to perform 
prediction on the test set. In the rest of the paper the approach is referred to as the 
instance selection approach employing machine learning algorithms (SVR and 
RR) as: IS+SVR+L, IS+SVR+S, and IS+RR (abbreviations are listed in Table 
6.1). 
 
Table 6.1  Abbreviation of Drug Sensitivity Prediction Algorithms 
Abbreviation Prediction Algorithm 
IS+SVR+L 
The instance selection approach using support vector regression with 
linear kernel 
IS+SVR+S 
The instance selection approach using support vector regression with 
sigmoid kernel 
IS+RR The instance selection approach using ridge regression 
O+SVR+L 
The oversampling approach using support vector regression with linear 
kernel 
O+SVR+S 
The oversampling approach using support vector regression with sigmoid 
kernel 
O+RR The oversampling approach using ridge regression 
C+SVR+L The hybrid approach using support vector regression with linear kernel 
C+SVR+S The hybrid approach using support vector regression with sigmoid kernel 
C+RR The hybrid approach using ridge regression 
SVR+L The baseline approach using support vector regression using linear kernel 
SVR+S 
The baseline approach using support vector regression using sigmoid ker-
nel 
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Figure 6.1 Data flow diagram showing the instance selection approach to predicting in 
vivo drug sensitivity. 
 
6.2.2   The Oversampling Approach 
As shown in Figure 6.2, (A) The oversampling approach receives training set S  and test 
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Figure 6.2 Data flow diagram showing the oversampling approach to predicting in vivo 
drug sensitivity. 
 
(B) Synthetic Minority Oversampling Approach (SMOTE) is employed [123] for 




1. Find k nearest neighbors * * *1 2, ,..., kx x x  of each ixS . (In the study presented here, 
k=1.) 
2. Generate synthetic cell lines along the lines between the randomly selected k 
nearest neighbors and each 
ix  by the following lines of code: 
2.2. for  i=1 to m  
2.1. for  j=1 to k  
2.1.1.   *( )new i j ix x x x      
2.1.2.   Label( ) Label( )new ix x   
2.1.3.   Store 
newx  in 
++X   
2.2. end for 
                2.3. end for 
 
Where   .is a random number. A learning algorithm is called on { , } ++S' X S , to induce 
model h. (C) Model h is applied for the prediction on the test set. For brevity, the 
following abbreviations are assigned to the oversampling approach employing machine 
learning algorithms: O+SVR+L, O+SVR+S, and O+RR (see Table 6.1). 
6.2.3   The Hybrid Approach 
Figure 6.3 shows the data flow diagram of the hybrid approach. (A) Given training set S  
and test set
'X , which are described as in Section 4.2.1. (B) LASSO (least absolute 
shrinkage and selection operator) has been used successfully in genomics, which 




Given cell lines Rnix   and the drug response values R,iy  1,..., .i m  The objective 
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β β
β   (6.2) 
where 0  is the tuning parameter
1 1
0




   penalty. In LASSO penalty, it is 
expected to have many coefficients in β  to be close to zero, and small subset to be larger 
and nonzero [126]. Coordinate descent is applied to solve the problem in Equation 6.2 
minimizing one-at-a-time one parameter and fixing all others [127], which works as 
follows: 
1. Initialize all 0j    
2. Cycle over  j= 0,1,2,…,n,0,1,2,…, till convergence: 
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Step 2.1 measures the correlation of the jth gene (xij
 ) and the partial residual of the 





 ) and the true value (yi). Higher 
* value means that jth gene (feature) is regarded as more correlated and an important 
gene. Similarly, lower 
*  value means that jth gene (feature) is regarded as less 







j β are stored, i.e., consisting of all coefficients except coefficient 0 , 
produced by coordinate descent in U . Then rerun coordinate descent q-1 times (in this 
study for model h1, q=10), where each β  is stored in .U That is, xRq nU , where U 
contains q different β  coefficients produced through rerunning coordinate descent. Then 
the columns sum is performed as: 
 
TM 1 U   (6.3)    
where 1  is the q-dimensional column vector of all ones, and RnM . The top-k in M 
corresponding to the k maximum values are then selected and their positions are in 
R .kI (In the study presented here, k=50.) Top-k genes in the training set are selected 
using positions in I . Cell lines are then selected as in Section 4.2.1 and stored in .'S  A 
learning algorithm is called on
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Figure 6.3 Data flow diagram showing the hybrid approach to predicting in vivo drug 
sensitivity. 
 
(C) Top-k genes in the test set are selected using positions of ,I and model h1 is applied 
on the test set. Such processes (A, B, C) as in Figure 6.3 are repeated T times except that 
q=15 (q=20, respectively) for t=2 (t=3, respectively). (In the study presented here, T=3.) 
(D) For each test instance ' where 1,...,ix i p 
'X , the final prediction is obtained by 








H x h x
T 
    (6.4) 
  
6.3   Experiments and Results 
In this section, the performance of the learning approaches is evaluated and compared 




datasets in the study are described, experimental methodology, and then present 
experimental results. 
6.3.1   Experimental Datasets 
The training set 
482 x 6539RS consists of 
482RY drug IC50 values and cell lines 
expression data 482 x 6538RX (i.e., 482 cell lines and 6538 genes). The test set 
24 x 6538R ,'X which contains 24 breast cancer tumors of patients and 6538 genes. Both 
the training set and test set were downloaded and processed according to the approach 
proposed by Geeleher et al. [54] as follows. The drug IC50 values for docetaxel 
(chemotherapy drug) [129, 130] were downloaded from 
(http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/). The cell lines expression  
data were downloaded from ArrayExpress repository  
[131] (accession number is E-MTAB-783 or available at 
https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-783/?query=EMTAB783). 
Clinical trial data were downloaded from Gene Expression Omnibus (GEO) repository 
(http://www.ncbi.nlm.nih.gov/geo/) with accession numbers GSE350 and GSE349  
[132-134]. Data with accession number GSE350 (GSE349, respectively) contain 10 (14, 
respectively) samples (i.e., instances). If the remaining of tumor was 25%  ( 25% , 
respectively), breast cancer patient would be considered as sensitive (resistant, 





6.3.2   Experimental Methodology 
12 drug sensitivity prediction algorithms are considered, which are listed and abbreviated 
in Table 6.1. SVR+L (SVR+S, respectively) employs the same proposed approach by 
Geeleher et al. [54]. RR is the baseline approach [54]. The remaining prediction 
algorithms correspond to the prediction algorithms employing the proposed approaches. 
Software used in this work included: support vector regression with linear and 
sigmoid kernels [80], ridge regression [54], LASSO [135], R code for processing datasets 
and performance evaluation [54].  
R is used to write SMOTE [123], IPRed [122], and perform the experiments. The 
Area Under the ROC Curve (AUC) [54] is employed to measure the accuracy of 
prediction algorithms. The higher AUC an algorithm has, the better performance that 
algorithm achieves. We assess the stability of prediction algorithm, where stable 
prediction algorithm is the one for which prediction accuracy on the test set does not 
change dramatically by small changes to the training set  [136, 137]. This kind of 
assessment is important, where the best prediction algorithm is the one that outperforms 
other algorithms many times. Statistical significance is measured between all pairs of the 
prediction algorithms [76, 83]. 
6.3.3   Experimental Results 
Table 6.2 shows the AUC of six prediction algorithms on several runs of the clinical trial 
data used in the experiment. IS+SVR+L, O+SVR+S and IS+RR represent the top-3  
prediction algorithms employing the learning approaches. The other three prediction 
algorithms employ the existing approach: SVR+S, RR, and SVR+L. For each run, the 




bold. Table 6.3 shows the p-values of Wilcox rank test (two tailed) between all pairs of 
algorithms, where the algorithm with statistical significance is shown in bold. It can be 
seen from Table 6.2 that IS+SVR+L is better than the prediction algorithms including 
RR, the proposed approach by Geeleher et al. [54]. In particular, IS+SVR+L gives the 
highest mean AUC (MAUC) of 0.907 and performed the best in 11 out of 11 runs. The 
second best is O+SVR+S that gives MAUC of 0.883. The third best is IS+RR that 
achieves MAUC of 0.874. SVR+S performs better than RR giving MAUC of 0.855. The 
remaining prediction algorithms, RR and SVR+L, yield MAUC of 0.828 and 0.825, 
respectively. IS+SVR+L and IS+RR keep approximately 75% of the cell lines provided 
during learning the model (see column (“m+IS”) in Table 6.2). The removing of 25% cell 
lines did not degrade the performance of IS+SVR+L and IS+RR, compared to the 
baseline RR. Column (“m+O”) shows the number of cell lines which consists of all | |m  
cell lines in the training set plus | |m generated synthetic cell lines. Combining the 
generated synthetic cell lines with the cell lines in the learning stage improved the 
performance of O+SVR+S when compared to RR (results shown in Table 6.2). These 
results show the stable performance of the learning approaches under different settings of 
the training set size. 
In Table 6.3, the p-values of Wilcox rank test are reported to measure the 
statistical significance between algorithms [76]. The p-values indicate that IS+SVR+L 







Table 6.2  AUC of Prediction Algorithms on the Test Set. The Column (“m”) Shows the 
Number of Cell Lines (Instances) in the Training Set That Were Provided to Each 
Prediction Algorithm. Column (“m+o”) Shows the Number of Cell Lines Used in 
O+SVR+S. Column (“m+IS”) Shows the Number of Cell Lines Used in IS+SVR+L and 























482 0.871 0.864 964 0.850 361 0.842 0.814 0.835 
478 0.878 0.864 956 0.871 358 0.871 0.814 0.814 
473 0.900 0.871 946 0.871 354 0.864 0.821 0.800 
468 0.907 0.892 936 0.871 351 0.857 0.821 0.821 
463 0.892 0.871 926 0.871 347 0.857 0.821 0.835 
458 0.900 0.892 916 0.871 343 0.857 0.821 0.850 
453 0.914 0.878 906 0.885 339 0.842 0.835 0.828 
448 0.921 0.892 896 0.885 336 0.864 0.835 0.835 
443 0.928 0.914 886 0.878 332 0.857 0.842 0.814 
438 0.942 0.907 876 0.878 328 0.857 0.842 0.821 
433 0.921 0.871 866 0.878 324 0.842 0.842 0.828 




Table 6.3 P-Values of Wilcox Rank Test (Two-Tailed) between All Pairs of Prediction 
Algorithms. Shown in Bold Is the Prediction Algorithm with Statistical Significance 
Where p<0.05 
 
 O+SVR+S IS+RR SVR+S RR SVR+L 
IS+SVR+L 0.0033 0.0033 0.0033 0.0033 0.0033 
O+SVR+S - 0.0727 0.0051 0.0033 0.0033 
IS+RR - - 0.0051 0.0033 0.0033 
SVR+S - - - 0.0051 0.0033 
RR - - - - 0.7789 
 
In Figure 6.4 all prediction algorithms are ranked from the highest to the lowest 
MAUC. Each MAUC is calculated over the 11 runs on the clinical data. It can be seen 
from Figure 6.4 that the three proposed approaches outperform RR [54] ranked the 9th 





Figure 6.4 Mean AUC (MAUC) of prediction algorithms. Prediction algorithm with 
highest MAUC (to be ranked first from left) and lowest MAUC (to be ranked the last 
from the left. 
 
Figure 6.5 shows the predictions of three prediction algorithms on the test set 
(clinical data of 24 breast cancer patients.) using training set with m=482 (i.e., the 
complete training set without any change). Figure 6.5(a) (Figure 6.5(b), Figure 6.5(c), 
respectively) shows the predictions of IS+SVR+L (SVR+S, RR, respectively). Figures 
6.5(a) and 6.5(b) show the difference between the predicted drug sensitivity in breast 
cancer patients was statistically significant (P= 0.001 from a t-test) between trial-defined 
sensitivity and resistant groups for IS+SVR+L and SVR+S, respectively. RR (see Figure 
6.5(c)) achieved statistical significance (P= 0.004 from a t-test). Training set size is 482 
when learning a model. In Figure 6.5(d) the ROC reveals AUC of 0.871, 0.842, and 0.814 






























It is worth mentioning that the performance of other machine learning algorithms 
are assessed, including random forests [78], support vector regression with polynomial 
kernel of degree 2, support vector regression with Gaussian kernel. However, these 





Figure 6.5 Prediction of docetaxel sensitivity in breast cancer patients. Strip chart a 
(b,c, respectively) showing the difference in predicted drug sensitivity for individuals 
sensitive or resistant to docetaxel treatment using IS+SVR+L (SVR+S, RR, 
respectively) prediction algorithm. (d) ROC curves of prediction algorithms showing 
the proportion of true positives against the proportion of false positives. ROC, 





6.4   Summary 
This chapter introduces three learning approaches to improve the prediction of drug 
sensitivity. The first learning approach employs (i) IPRed algorithm to select cell lines. 
The second learning approach employs (i) SMOTE algorithm to generate synthetic cell 
lines. The third learning approach employs (i) LASSO for gene selection, (ii) IPRed 
algorithm to select cell lines, and (iii) ensemble averaging of predictions obtained from 
different models. 
The learning approaches use two machine learning algorithms: support vector 
regression and ridge regression. The experimental results on clinical trial data of breast 
cancer patients demonstrate the stable performance of the learning approaches achieving 














CHAPTER 7  




7.1   Introduction 
Predicting the response to a drug for cancer disease patients based on genomic 
information is an important problem in modern clinical oncology. This problem occurs in 
part because many available drug sensitivity prediction algorithms do not consider better 
quality cancer cell lines and the adoption of new feature representations; both lead to the 
accurate prediction of drug responses. By predicting accurate drug responses to cancer, 
oncologists gain a more complete understanding of the effective treatments for each 
patient, which is a core goal in precision medicine. 
In this chapter, cancer drug sensitivity is modeled as a link prediction, which is 
shown to be an effective technique.   The proposed link prediction algorithms are 
evaluated and compared with an existing drug sensitivity prediction approach based on 
clinical trial data. The experimental results based on the clinical trial data show the 
stability of the proposed link prediction algorithms, which yield the highest area under 
the ROC curve (AUC) and are statistically significant. 
 
7.2   Related Work 
7.2.1   Link Prediction in Gene Regulatory Networks 
Given m genes, in which each gene has n expression values, their gene expression 
profiles can be denoted by m nG , which contains m rows—each row corresponds to a 




To learn a model, the regulatory relationships (i.e., labels) among the genes are needed to 
be known, which are stored in the matrix 
3pH . H  contains p rows—each row 
shows a known regulatory relationship between two genes—and three columns. The first 
column shows the source gene (i.e., the transcription factor). The second column shows 
the target gene, and the third column shows the label, which is denoted as +1 (i.e., present 
link) when the source gene regulates the target gene or -1 (i.e., missing link) when the 
source gene does not regulate the target gene. Thus, H represents the observed (i.e., 
known) gene regulatory network. To learn a model, the training set
2 1p n D is needed 
to be constructed. The p examples in D are constructed as follows: For each pair of genes 
with the associated label in matrix H , the n expression values of each pair of genes in 
matrix G  are extracted, and the concatenation of the n expression values of each pair of 
genes and the corresponding label is performed. For example, consider the ith example in 
the training set D, which is denoted by iD  and defined as 
                                         [ , ]
n n
i i i i l l l iyD
1 2 1 2










g ,g ,...,g  are the n expression values of lg , and {1, 1}iy   . The 
ith example of the test set, ,T  is denoted by iT  and constructed as follows: 
                                          [ ]n ni i i i j j jT
1 2 1 2









g ,g ,...,g  are the n 
expression values of jg . These feature vector definitions have been used by the existing 




the feature vectors, the learning algorithm is applied to D  to induce (i.e., learn) the model 
h. The resulting model is used to perform prediction on T . The known regulations among 
genes enable using the induction principle to predict new regulations (i.e., labels): If gene 
jg  has an expression profile that is similar to gene lg , which is known to be regulated by 
ig , then jg  is likely to be regulated by ig  [8]. Genes with similar expression profiles 
that are likely to be co-regulated have been used in the unsupervised clustering of 
expression profiles [138-140]. 
7.2.2   Cancer Drug Sensitivity Prediction 
The gene expression profiles denoted by X p n , which contains p rows—each row 
corresponds to a cell line or a sample—and n columns—each column corresponds to a 
gene. 1Y ( ,..., )
T
py y consists of the corresponding real-value drug responses (i.e., drug 
IC50 values) to X , where Y
p (i.e., the p-dimensional column vector). IC50 is defined 
as the concentration of a compound that is required to produce 50% cancer cell growth 
inhibition after 48 hours of treatment [66]. A training set is defined as 1D={( , )}
p
i i iy g , 
where Xand Y.i iy g  Let the ith example of the training set D , denoted by iD , be 
defined as 
                                                     [ , ]
n
i i i i iyD
1 2





g ,g ,...,g  represent the n genes of the cancer cell line ig (also called the 





The ith example of the test set ,T  denoted by iT , is constructed as follows: 
                                                      [ ]ni j j jT
1 2
g ,g ,...,g .          (7.4) 
These feature vector definitions have been used by existing supervised cancer drug 
sensitivity prediction algorithms [52-54, 56, 66, 141, 142]. A learning algorithm is 
applied to D  to induce model h, which is subsequently used to perform predictions on 
T . Known cancer cell lines with associated drug responses enabled the use of the 
induction principle: If tumor jg  has an expression profile similar to ig , then jg  is likely 
to have a drug response value closer to the drug response value associated with ig . 
 
7.3   Methods 
The fundamental task of cancer drug sensitivity prediction is to correctly predict the 
response of a tumor to the drug. This prediction is typically achieved based on how 
closely this tumor (also referred to as the test example) is related to a known cancer cell 
line with the associated drug response. Proximity, which is a measure of closeness, lies at 
the heart of both link prediction in gene regulatory networks and cancer drug sensitivity 
prediction [8, 143]. 
7.3.1   Feature Vector Construction 
To bridge link prediction and cancer drug sensitivity, the feature representations of 
Equations (7.3) and (7.4) are transformed to the corresponding Equations (7.1) and (7.2) 
as follows: Let 1{( , )}
p
i i iy   Dg  be the cancer cell lines, where




3. Find the k’ nearest neighbors '
* * *
1 2, ,..., kg g g  of each ig  in D . (In this study 
k’=1.) 
4. Generate synthetic cell lines along the lines between the randomly selected k’ 
nearest neighbors and each ig  using the following lines of code: 
 
2.1 for i=1 to p  
                       2.1.1 for j=1 to k’  
                              2.1.1.1 1b b   
                              2.1.1.2 *( )b i j i   g g g g   
                              2.1.1.3 Store [ , , ]i b iyg g  in G   
           2.1.2 end for 
                2.2 end for 
 
where the index b refers to only those synthetic cell lines (e.g., 1pg  when the index 
b=p+1) that differ from the cell lines in D , whose indexes run from 1 to p, 0.3  , 
and
2 1p n G  is the new feature representation of the cell lines of the training set. 
Step 2.1.1.2 creates the synthetic cell line bg . Let iG  be the ith row of G , defined as 
                                1 1 1[ , ]
n n
i i i i p p p iy  G
1 2 1 2





g ,g ,...,g  represent n genes of the cancer cell line ig , 
1 1 1
n
p p p  
1 2
g ,g ,...,g  represent the synthetic n genes of the synthetic cancer cell line 




response value. Let 1{( , )}
q
i i iy   Tg  be the test set of tumors, where .
q nT  Note 
that Steps 1–2 are similar to the Synthetic Minority Oversampling Approach (SMOTE) 
[123, 144], However, Step 2.1.1.3 is a different core step in which the dimensionality 
(i.e., the number of features) is increased instead of the size, as SMOTE does. We then 
apply the previous steps (i.e., Steps 1 and 2—changing Step 2.1 to i=1 to q and Step 
2.1.1.3 to Store [ , ]i bg g in 
'G ) to T  to obtain 2q n'G . 'G  is the new feature 
representation of the clinical trial expression data of the test set. Let 
'
iG  be the ith row of 
'G , which is defined as 
                               
' ' '
'
2 1 2 1 2 1
[ ]n ni j j j p k p k p k     G
1 2 1 2
g ,g ,...,g ,g ,g ,...,g .     (7.6) 
where nj j j
1 2
g ,g ,...,g  represent n genes of tumor jg , and ' ' '2 1 2 1 2 1,
n
p k p k p k     
1 2
g g ,...,g  
represent n synthetic genes of the synthetic tumor '2 1p k g . A learning algorithm is called 
on the training set, G  to induce the model h, which is subsequently used to perform 
predictions on the test set 'G . The logic behind the mechanism of the induction principle 
is as follows: If the expression profiles of the pair of tumors '2 1( , )j p k g g  are similar to 
those of the cell lines 1( , )i pg g , then '2 1( , )j p k g g  is likely to have a drug response value 
closer to the drug response value associated with 1( , )i pg g . In machine learning terms, let 
2 1




 g g  be a row feature vector that encodes information about the pair of 
cancer cell lines 1( , )i pg g . Given a new pair of tumors encoded by '2 1( , )j p k g g , if 
'2 1
( , )j p k g g  has feature values similar to 1( , )i pg g , whose label is ,iy  then '2 1( , )j p k g g  




7.3.2   Notations and Algorithms 
7.3.2.1   Notations. To provide a better understanding of the proposed prediction 
algorithms, the notations used throughout the remainder of this paper are summarized as 
follows: Matrices are denoted by boldface uppercase letters, e.g., matrix X . The row 
vectors of a matrix is denoted by boldface uppercase letters with a subscript, e.g., jX  is 
the jth row of matrix X . Vectors are denoted by boldface lowercase letters, e.g., vector v . 
Vector entries are denoted by italic lowercase letters with a subscript, e.g., iv  is the ith 
entry of vector v . The number of entries of a vector is denoted by the cardinality symbol, 
e.g. | |v  is the number of elements of vector v . Scalars are denoted by italic lowercase 
letters, e.g., m. *, ,andf f h  are reserved letters, where f  refers to a learning algorithm 
(e.g., SVR), *f  refers to an induced (i.e., learned) model, and h  is an induced model 
used to perform predictions on the test set. specific learning algorithms and induced 
models are referred to using subscripts. For example, 
*( , respectively)i if f  denotes the ith 
learning algorithm and induced model, respectively.  
7.3.2.2   The Supervised Link Prediction Algorithm (A1).  Figure 7.1 outlines the 
supervised link prediction algorithm, which is designated as A1, as follows. (A) Given a 
training set of cancer cell lines with associated drug responses 
1p n D  and a test set of 
tumors 
q nT  that are described as in cancer drug sensitivity prediction subsection. 
 (B) Transform D  and T  using the feature vector construction method described in 
feature vector construction subsection, to obtain a new feature representation 
2 1p n G  
for the training set and a new feature representation 
2q n'G  for the test set. 




works as follows: Each row (i.e., feature vector) in the new representations G  and 
'G  
can be viewed as a cell line or tumor, represented by a 2n-dimensional row vector when 
the drug responses of the training set G are excluded. Each cell line [122] ig  in the 
training set G  is weighted by the minimum distance from the cell line ig  to all tumors 
'
jg  in the testing set 
'G : 
                                      *
' * '
{1,..., }




 g g g g ,  (7.7) 
where 2ni g ,
' 2n
j g , iw  is the weight assigned to ig , and *
'dist( , )i jg g  is the 
Euclidean distance. Let 
1 2( )pw w ww , ,..., .  Then, the following steps are performed to 
select better quality training cell lines using the modified version of Query by Committee 
(QBC) [145-147]: 
1. Let med be the median of the w  vector of weights of each ig  in G   
2. Let {( ) | ( ) and }i i i i iy y w med  X Gg, g,   
3. Let ' { | in and }i i iw med X Gg g  
4. Let {( ) | ( ) and }i i i i iy y w med  Z Gg, g,  
5. Let ' { | in and }i i iw med Z Gg g  
6. Apply the learning algorithm, 1f  or 2f , to X  or Z , respectively, to induce the model 
* *
1 2( , respectively)f f . (In this study, ridge regression is chosen as the learning algorithm) 
7. Apply the model * *1 2 ,  respectiv( )elyf f  to perform predictions on 
'Z  or X′, 
respectively) and store predictions in v or b respectively) 




9. Let ( , )TP v b  
10. Let { | in }and { | in }i i i iy y y y r Z e X  
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j q





















QBC aims to partition the training set G  into S  and U , where S  or U is treated 
as the labeled or unlabeled set, respectively. QBC is accompanied by two major items: 
(1) the set of models (i.e., the committee) that are consistent with all labeled cell lines in 
S ; and (2) given the unlabeled set, U , the QBC applies the models (i.e., the committee) 
to U  to select the unlabeled tumor that maximizes the disagreement because it represents 
the most important tumor that will be added to S , in addition to querying the drug 
response value associated with the tumor. The main obstacle of the first major step of 
QBC is to find models that agree on all the labels of set S  with reasonable computational 
complexity [147]. Thus, the first major step is relaxed according to Steps 1–14, where 
relaxation is practiced to address the first major step [145]. Steps 1–5 partition the 
training set into X  and Z  using the median as a threshold, where X  or Z contains cell 
lines from G  that are near or far, respectively, from the test set 
'G . Steps 6–14 aim to 
assign the set of cell lines where the model incurred fewer errors (or more errors, 




that S  or U, respectively, is wanted to contain the set of cell lines that are more or less, 
respectively, correctly labeled by one model (i.e., one member of the committee). Steps 
1–14 are motivated by other QBC approaches [145-147], in which the success of the 
second major step of QBC is dependent on the first major step. 
15.  Repeat k’’ times  
15.1.  Apply the learning algorithms 1 2, ,..., tf f f  on S  to induce the models (i.e.,   
committee) * * *1 2, ,..., tf f f . (In this study, t=3, and the learning algorithms include 
support vector regression with a linear kernel (SVR+L), SVR with a polynomial 
kernel of degree 5, and SVR with a sigmoid kernel (SVR+S)) 
15.2.  Let 'iw  be the weight of the ith model 
*














w w w   ) 
15.3.  For each jg  in ,U let 
' ' *
1
( ) ( )
t




g gw  where *( )i jf g  is the prediction of  
the ith learned model on the jth cell line jg , and 
'( )jf g  is the weighted ensemble 
average of the jth cell line jg . 
15.4.  Find the cell line *jg  that maximizes the disagreement: 
15.4.1.   j*
' * ' 2
1{1,...,| |}
argmax ( ( ) ( ))
t






g gw  
15.5.  Find the label *jy  of *jg  in U  
15.6.  Add the pair *( ),*j jy Ug  to S  and remove the pair *,( )*j jyg  from U  




16.  Return S   
 
Figure 7.1 Data flow diagram that shows the proposed supervised link prediction 
algorithm to predict in vivo drug sensitivity. 
 
Steps 15.1–15.4.1 return the index of the cell line in set U  that maximizes the 
disagreement, where disagreement is defined in Step 15.4.1 [148]. Then, *,( )*j jyg  is 
added to or removed from S  or U respectively, as shown in Steps 15.5–15.6. (In this 
study, k’’=5.) Step 15.7 updates |v| as the size of U is reduced after each iteration. S (Step 
16) is the returned set that will be used as the training set. (D) A learning algorithm is 
applied on S  to induce the model h. Finally (i.e., (E in Figure 7.1)), model h is applied to 
perform predictions on the test set 
'G  (i.e., the set of new feature representations of the 
clinical trial expression data). In the remainder of this paper, the supervised link 
prediction algorithms that employ the following machine learning algorithms (SVR and 







Table 7.1 Abbreviations of the Drug Sensitivity Prediction Algorithms 
Abbreviation Prediction Algorithm 
A1+SVR+L The supervised link prediction algorithm using support vector regression 
with a linear kernel 
A1+SVR+S The supervised link prediction algorithm using support vector regression 
with a sigmoid kernel 
A1+RR The supervised link prediction algorithm using ridge regression 
A2+SVR+L The extended supervised link prediction algorithm using support vector 
regression with a linear kernel 
A2+SVR+S The extended supervised link prediction algorithm using support vector 
regression with a sigmoid kernel 
A2+RR The extended supervised link prediction algorithm using ridge regression 
B+SVR+L The baseline approach using support vector regression with a linear kernel  
B+SVR+S The baseline approach using support vector regression with a sigmoid 
kernel 
B+RR The baseline approach using ridge regression 
 
7.3.2.3   The Extended Supervised Link Prediction Algorithm (A2).    Figure 7.2 
shows the data flow diagram of the extended supervised link prediction (A2). Steps (A), 
(B), and (C) are the same as Steps (A), (B), and (C) of the supervised link prediction 
algorithm. (D) Mahoney et al. [149] proposed CUR matrix decomposition as a 
dimensionality reduction paradigm that aims to obtain a low rank approximation of 
matrix S , which is expressed in terms of the actual rows and columns of the original 
matrix S : 
S CUR ,  (7.8) 
where C  consists of a small number of the actual columns of S , R  consists of a small 
number of the actual rows, and U is a constructed matrix that guarantees that CUR is 
close to S . k genes are selected based on their importance score (refer to Equation 7.9), 
which depends on matrix S  and the input rank parameter l (in this study, the default 
parameter value for l in CUR function is used [150].) If jv





th   right singular vector of S , then the normalized statistical leverage scores are equal 
to 









     (7.9) 







  . Statistical leverage scores have been successfully employed 
in data analysis to identify the most influential genes and outlier detection [149]. A high 
statistical leverage score for a given gene indicates that the gene is regarded as an 
important (i.e., influential) gene. A low statistical leverage score for a given gene 
indicates that the gene is regarded as a less important gene. The indexes of the highest k 
leverage scores are stored in I ; these correspond to the positions of the k most influential 
genes in matrix S . k genes are selected from the training set S  using their positions in I  
and store subsampled cell line expression data with k genes in 'S . (E) A learning 
algorithm is called on 
'S  to induce model h. (F) The k genes in the test set 
'G  are 
selected using their positions in I  and stored in 





Figure 7.2 Data flow diagram showing the major steps in the proposed extended 
supervised link prediction algorithm to predict in vivo drug sensitivity. 
 
 
Model h is applied on the test set 
''G  to perform predictions. The extended supervised 
link prediction algorithms that employ machine learning algorithms is referred to as 
A2+SVR+L, A2+SVR+S, and A2+RR (see Table 7.1). 
 
7.4   Experiments and Results 
The proposed approach is empirically evaluated and compared against the baseline 
approach proposed by Geeleher et al. [54] on clinical trial datasets. This section first 
describes the datasets and experimental methodology and presents the experimental 
results. 
7.4.1   Datasets 
Data Pertaining to Breast Cancer. The training set 482  6539D  contains 482 cancer 




vector. The test set 24  6538T  consists of 24 breast cancer tumors and 6538 genes. The 
drug IC50 values for docetaxel (a chemotherapy drug) [129, 130] were downloaded from 
(http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/). The cell line expression data 
were downloaded from the ArrayExpress repository [131]  
(accession number is E-MTAB-783, also available at 
https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-783/?query=EMTAB783). 
The clinical trial data corresponding to the test set were downloaded from the Gene 
Expression Omnibus (GEO) repository (http://www.ncbi.nlm.nih.gov/geo/) with accession 
numbers GSE350 and GSE349 [132-134]. The data with accession numbers GSE350 and 
GSE349 contain 10 and 14 samples, respectively. If the remaining tumor was <25% or 
≥25%, a breast cancer patient is considered to be sensitive or resistant, respectively, to 
docetaxel treatment. All the data were downloaded and processed according to the 
approach proposed by Geeleher et al. [54]. 
Data Pertaining to Multiple Myeloma. The training set 280  9115D  contains 280 
cancer cell lines, 9,114 genes, and drug IC50 values that correspond to a 280-dimensional 
column vector. The test set  188  9114T  is composed of 188 multiple myeloma patients 
and 9,114 genes. The drug IC50 values for bortezomib [151, 152] were downloaded from 
(http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/), and the data for the cancer cell 
lines were downloaded from the ArrayExpress repository  
(accession number is E-MTAB-783 or available at 
https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-783/?query=EMTAB783). 
The clinical trial data corresponding to the test set were downloaded from the Gene 




number GSE9782 [153]. The data were downloaded, processed and mapped according to 
Geeleher et al. [54]. 
Data pertaining to non-small cell lung cancer and triple-negative breast cancer. The 
training sets correspond to an 258  9508   matrix and an 497  9621  matrix for  
non-small cell lung cancer and triple-negative breast cancer, respectively. The test sets 
correspond to an 25 9507 matrix (excluding labels) and an 24 9620 matrix 
(excluding labels) for non-small cell lung cancer and triple-negative breast cancer, 
respectively. The data were downloaded from 
(http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/) [54]. 
7.4.2   Experimental Methodology 
Kernel-based methods, such as SVM and support vector regression (SVR), are popular 
machine learning algorithms and exhibit state-of-art performance in many applications 
[154, 155], including biological fields [156]. Therefore, in the experiments, SVR with 
linear kernel (SVR+L) and sigmoid kernel (SVR+S) are used as machine learning 
algorithms, coupled with the proposed link prediction algorithms (A1 or A2). The 
proposed link prediction algorithms are also employed with linear ridge regression (RR). 
In total, 9 drug sensitivity prediction algorithms are considered, as summarized in Table 
7.1. 
Each prediction algorithm was trained on the same training set, whose labels are 
continuous to yield models (see Methods section). Then, each model is applied to the 
same test set to yield predictions, as discussed in Methods section. The test set consists of 
the clinical trial expression data of patients, including baseline tumor expression data 




(i.e., labels) of the test set are categorical (e.g., either “sensitive” or “resistant”). These 
labels were clinically evaluated by the degree of reduction in tumor size to the given drug 
[54].  
To evaluate whether the proposed approach exhibits stable superior performance 
as the sample size changes, the sample size for the training set was gradually reduced by 
1% to 4% in each run. That is, 5 runs with sample sizes of 482, 478, 473, 468, and 463 
and 280, 278, 275, 272, and 269 were performed for the two datasets, respectively. 
The accuracy of the prediction algorithms is measured using the Area Under the 
ROC Curve (AUC), as shown in [54]. The higher is the AUC of an algorithm is, the 
better the performance that it achieved is. The mean of the AUC values averaged over the 
five runs of the test set is denoted as the MAUC. A run of the test set is defined as 
predictions of a learned model on the test set, such that the model is learned from the 
training set. The size of this training set is varied to assess the stability of prediction 
algorithms, in which a stable prediction algorithm is one for which the prediction 
accuracy on the test set does not change dramatically due to small changes in the size of 
the training set [136, 137]. This type of assessment is important in biological systems, in 
which the best prediction algorithm outperforms other algorithms many times in the 
conducted experiments. Statistical significance is measured between all pairs of the 
prediction algorithms. 
The software employed in this study included support vector regressions with 
linear and sigmoid kernels in the LIBSVM package [80], ridge regression [54], gene 




for processing the datasets and performance evaluation [54]. R is used to write the code 
for the link prediction algorithms and perform the experiments.  
7.4.3   Experimental Results 
Tables 7.2 and 7.3 show the AUC of 9 docetaxel and bortezomib, respectively, sensitivity 
prediction algorithms on clinical breast cancer or multiple myeloma trial data. For each 
variation in training set size the prediction algorithm with the best performance (i.e., the 
highest AUC) on the clinical trial data is shown in bold. 
Table 7.2 shows that the proposed prediction algorithms perform better than the 
baseline prediction algorithms (i.e., B+SVR+L and B+SVR+S) including B+RR, which 
is a prediction algorithm proposed by Geeleher et al. Row “m” and “d”, shows the 
number of cell lines or genes, respectively, in the training set that were provided to each 
prediction algorithm. The same training set was provided to each prediction algorithm. 
Rows “m+A1” and “m+A2”, or “d+A1” and “d+A2” show the number of selected cell 
lines or genes, respectively, that were used in the prediction algorithms that employed the 
proposed approach for learning the models. The results of the proposed prediction 
algorithms are dominant compared with the baseline prediction algorithms that employ 
clinical trial data of breast cancer in terms of the AUC of four runs and the MAUC. In 
contrast to the baseline prediction algorithms, the performance of the proposed prediction 
algorithms on the test set outperforms in terms of the AUC when the training set size is 
reduced. 
Table 7.3 shows that the proposed prediction algorithms perform better than the 
baseline prediction algorithms (i.e., B+SVR+L and B+SVR+S) and B+RR, which is a 




the number of cell lines or genes, respectively, in the training set that were provided to 
each prediction algorithm. The same training set is provided to each prediction algorithm. 
Rows “m+A1” and “m+A2” or “d+A1” and “d+A2” show the number of selected cell 
lines or genes, respectively, used in the prediction algorithms that employ the proposed 
approach for learning the models. The results of the proposed prediction algorithms are 
dominant compared with the baseline prediction algorithms on the clinical breast cancer 
trial data in terms of the AUC of each run and the MAUC. In particular, A2+RR achieves  
the highest mean AUC (MAUC) of 0.693 and performed the best in all runs. In contrast 
to the baseline prediction algorithms, the performance of A2+RR on the test results in the 
best AUC as the training set size is reduced, which indicates that A2+RR has a stable 
performance. 
 
Table 7.2 AUC Scores of Docetaxel Sensitivity Prediction Algorithms in Breast Cancer 
Patients on the Test Set. The Algorithm with the Highest AUC Is Shown in Bold. MAUC 
= Mean AUC 
 
M 482 478 473 468 463 MAUC 
D 6538 6538 6538 6538 6538 - 
A1+SVR+L 0.878 0.864 0.871 0.857 0.871 0.868 
A1+SVR+S 0.871 0.857 0.814 0.828 0.878 0.849 
A1+RR 0.850 0.828 0.821 0.850 0.842 0.838 
m+A1 246 244 242 239 237 - 
d+A1 13076 13076 13076 13076 13076 - 
A2+SVR+L 0.892 0.857 0.864 0.864 0.864 0.868 
A2+SVR+S 0.871 0.850 0.814 0.814 0.878 0.845 
A2+RR 0.857 0.842 0.835 0.835 0.835 0.841 
m+A2 246 244 242 239 237 - 
d+A2 13000 13000 13000 13000 13000 - 
B+SVR+L 0.835 0.814 0.800 0.821 0.835 0.821 
B+SVR+S 0.842 0.871 0.864 0.857 0.857 0.858 








Table 7.3 AUC Scores of Bortezomib Sensitivity Prediction Algorithms in Multiple 
Myeloma Patients on the Test Set. The Algorithm with the Highest AUC Is Shown in 
Bold. MAUC = Mean AUC 
 
m 280 278 275 272 269 MAUC 
d 9114 9114 9114 9114 9114 - 
A1+SVR+L 0.668 0.669 0.665 0.663 0.656 0.664 
A1+SVR+S 0.638 0.623 0.637 0.642 0.662 0.640 
A1+RR 0.685 0.673 0.679 0.677 0.690 0.681 
m+A1 145 144 143 141 140 - 
d+A1 18228 18228 18228 18228 18228 - 
A2+SVR+L 0.678 0.678 0.671 0.668 0.654 0.670 
A2+SVR+S 0.661 0.657 0.659 0.659 0.668 0.661 
A2+RR 0.686 0.689 0.696 0.695 0.699 0.693 
m+A2 145 144 143 141 140 - 
d+A2 9114 9114 9114 9114 9114 - 
B+SVR+L 0.613 0.609 0.622 0.628 0.632 0.621 
B+SVR+S 0.602 0.600 0.601 0.605 0.598 0.601 
B+RR 0.614 0.611 0.603 0.607 0.606 0.608 
 
Table 7.4 shows the p-values of the two-tailed Wilcoxon signed rank test [76, 83] 
to measure the statistical significance between the prediction algorithms using clinical 
trial data of breast cancer and multiple myeloma patients. The p-values indicate that 
A1+SVR+L and A2+SVR+L prediction algorithms significantly outperformed the 
baseline prediction algorithms B+SVR+L, B+SVR+S, and B+RR. The remaining 








Table 7.4 P-Values of Wilcoxon Signed Rank Test (Two-Tailed) between All Pairs of 
Prediction Algorithms. Values with Statistical Significance (p<0.05) Are Shown in Bold 
 
 A1+SVR+S A1+RR A2+SVR+L A2+SVR+S A2+RR B+SVR+L B+SVR+S B+RR 
A1+SVR+L 0.0160 0.5092 0.3077 0.0836 0.8807 0.0051 0.0149 0.0051 
A1+SVR+S - 0.1675 0.0208 0.1282 0.0929 0.0051 0.1830 0.0080 
A1+RR - - 0.2846 0.5418 0.0672 0.0051 0.1388 0.0076 
A2+SVR+L - - - 0.0587 0.5754 0.0051 0.0207 0.0047 
A2+SVR+S - - - - 0.1388 0.0069 0.0836 0.0124 
A2+RR - - - - - 0.0076 0.1675 0.0051 
B+SVR+L - - - - - - 0.5754 0.1609 
B+SVR+S - - - - - - - 0.2040 
 
Figures 7.3 and 7.4 show the ranking of all prediction algorithms from the highest 
to the lowest MAUC using clinical trial data pertaining to breast cancer and multiple 
myeloma patients, respectively. Each MAUC is calculated over the 5 runs of the clinical 
trial data. As shown in Figures 7.3 and 7.4, the proposed prediction algorithms 
outperform the baseline prediction algorithms [54] w.r.t the MAUC. 
Figure 7.5 shows the predictions of three prediction algorithms on the test set 
(clinical data samples of 24 breast cancer patients) when the prediction algorithms were 





         
Figure 7.3 Mean AUC (MAUC) results of docetaxel sensitivity prediction algorithms in 
breast cancer patients ranked from the highest MAUC (left) to the lowest MAUC (right). 
 
 
Figure 7.4 Mean AUC (MAUC) of bortezomib sensitivity prediction algorithms in 





















































Figure 7.5(a), Figure 7.5(b) and Figure 7.5(c) show the predictions of A2+SVR+L 
A1+SVR+L and B+SVR+S, respectively. For A2+SVR+L in Figure 7.5(a), the 
difference between the predicted drug sensitivity in breast cancer patients was highly 
statistically significant (P= 6472 10  from the result of a t-test) between the trial-defined 
sensitive and resistant groups. The result of A1+SVR+L in Figure 7.5(b) was also highly 
    
    
 
Figure 7.5 Prediction of docetaxel sensitivity in breast cancer patients. Strip charts and 
boxplots in (a), (b), and (c) show the differences in predicted drug sensitivity for 
individuals who are sensitive or resistant to docetaxel treatment using the prediction 
algorithms A2+SVR+L, A1+SVR+L and B+SVR+S, respectively, while (d) shows the 
ROC curves of prediction algorithms, revealing the proportion of true positives 




statistically significant (P= 6614 10  from a t-test). B+SVR+S in Figure 7.5(c) achieved 
statistical significance (P= 61176 10  from a t-test). Higher sensitivity or higher resistance, 
respectively, denote the greater or lesser effectiveness of the drug. In Figure 7.5(d), the 
ROC reveals AUC values of 0.892, 0.878 and 0.842 for A2+SVR+L, A1+SVR+L, and 
B+SVR+S, respectively, as shown in Table 7.2. 
In Figure 7.6, the predictions of three prediction algorithms are reported on the 
test set (clinical trial data of 188 multiple myeloma samples of patients) when prediction 
algorithms learned models from a training set of size m=280 (i.e., the training set without 
any reductions). Figure 7.6(a) Figure 7.6(b) and Figure 7.6(c) show the predictions of the 
A2+RR, A1+RR, and B+RR, algorithms, respectively. For A2+RR (Figure 7.6(a)), the 
difference between the predicted drug sensitivity in multiple myeloma patients was 
highly significant (P= 68 10  from a t-test) between trial-defined responder groups and 
non-responder groups. The result of A1+RR was also highly significant (P= 611 10  from 
a t-test), while B+RR achieved statistically significant result (P= 62612 10  from a t-test). 
Figure 7.6(d), Figure 7.6(e), and Figure 7.6(f)) break down the responders and  
non-responders of Figure 7.6(a), Figure 7.6(b), and Figure 7.6(c), respectively, to CR, 
PR, MR, NC or PD. In Figure 7.6 (g), The ROC reveals AUCs of 0.686, 0.685, and 0.614 


































    
Figure 7.6 Prediction of bortezomib sensitivity in multiple myeloma 
patients. Strip charts and boxplots in (a), (b), and (c) show predicted drug 
sensitivity for in vivo responders and non-responders to bortezomib 
using A2+RR, A1+RR and B+RR prediction algorithms, respectively. 
Strip charts and boxplots d, e, and f further break down responders and 
non-responders of  strip charts and boxplots a, b, and c as showing CR, 
PR, MR, NC or PD using A2+RR, A1+RR and B+RR, respectively, 
prediction algorithms. (g) ROC curves illustrating estimated prediction 
accuracy of prediction algorithms. CR, complete response; PR, partial 






The performance of prediction algorithms is also evaluated on the clinical trial 
data pertaining to non-small cell lung cancer patients and the triple-negative breast cancer 
patients. Similar results are observed that the proposed prediction algorithms noticeably 
outperform the baseline prediction algorithms (See Appendix A: Table A.1 and Table 
A.2). 
It is worth mentioning that the performance of other machine learning algorithms 
was also assessed, including random forests [121], support vector regression with a 
polynomial kernel of degree 2, and support vector regression with a Gaussian kernel. 
Moreover, other dimensionality reduction methods were applied such as principal 
component analysis (PCA) [157] based on the prcomp package in R [91], sparse PCA 
[158, 159], non-negative and sparse cumulative PCA, and negative and sparse PCA [160, 
161]. However, they did not exhibit acceptable predictive performance; consequently, 
their results are not included in this paper. 
 
7.5   Summary 
In this chapter, a link prediction approach to cancer drug sensitivity prediction is 
introduced. The benefit of introducing a link prediction approach is to obtain satisfactory 
feature representation for better prediction performance. Two algorithms that employ the 
link prediction approach are proposed: (1) A supervised link prediction algorithm, which 
selects better quality training cancer cell lines using a modified version of QBC; and  
(2) An extended supervised link prediction, which selects both better training cancer cell 




In this study, the link prediction algorithms use two machine learning algorithms: 
support vector regression and ridge regression. The experimental results demonstrate the 
stability of the proposed link prediction algorithms, which outperform drug sensitivity 
prediction algorithms of an existing approach as measured by their higher and statistically 
significant AUC scores. 
Gene (feature) selection is important to the success of the proposed method. After 
many years of biomedical research, some signaling pathways have been known for being 
implicated in various cancers. It is tempted to exploit this pathway information for feature 
selection. For example, adding the signaling pathways might be considered as a 
constraint to get reliable feature sets. Consequently, the performance of the proposed 
prediction algorithms was assessed using only the genes in the signaling pathways that 
are known to the cancers. Inferior results were obtained (See Appendix B for details). It 
is noted that the current pathway information is limited. If those signaling genes are only 
considered, those important genes not identified yet by domain knowledge may be 
missed. This may hurt the overall performance as shown in this case. Therefore, a better 













CHAPTER 8  




8.1   Introduction 
Accurately predicting drug responses to cancer is an important problem hindering 
oncologists' efforts to find the most effective drugs to treat cancer, which is a core goal in 
precision medicine. The scientific community has focused on improving this prediction 
based on genomic, epigenomic, and proteomic datasets measured in human cancer cell 
lines. Real-world cancer cell lines contain noise, which degrades the performance of 
machine learning algorithms. This problem is rarely addressed in the existing approaches. 
In this chapter, a learning approach is proposed that removes the noisiest cell lines, 
allowing a model to be learned from better quality cell lines to improve the predictive 
performance. The proposed approach consists of three steps. First, a distance matrix is 
calculated that corresponds to all the inner products of the rows of a given matrix 
constructed using the Manhattan distance of the training input. Second, technique from 
linear algebra is adopted to project the training input on the eigenvectors of the distance 
matrix to yield transformed training input that corresponds to feature vectors with  
noise-filtered features. Third, information retrieval technique [162] is adopted to retrieve 
(i.e., select) a subset of better quality cell lines with the associated drug responses from 
the training set using the degrees between the training input cell lines and the 
corresponding transformed training input cell lines, where smaller degrees denote better 
quality cell lines. Then, a learning algorithm is applied to the better quality training set to 




considered here are support vector regression and ridge regression [54, 98]. Other 
learning algorithms are excluded such as random forests [121] because of their poor 
performance, as in  [54]. As the experimental results show, the proposed approach 
outperforms the baseline prediction algorithms proposed by Geeleher et al. [54]. 
 
8.2   The Proposed Approach 
Figure 8.1 outlines the proposed approach, which works as follows. Consider the gene 
expression profiles denoted by X m n ., which consists of m  cell lines (i.e., samples) 
and n  genes. 1Y ( ,..., )
T
my y  consists of the corresponding real-value drug responses to 
X . A training set is define as 1S= { (x , )}
m
i i iy  , x Xand Y.i iy   A test set is defined as 
'
1T {x  } ,
p
i i where 
'x .ni   (B) The distance matrix D is computed as 
 D LLT   (8.1) 
Where 
 L [ (x ,x )]i j ij
m ml     (8.2) 
and 
 1(x ,x ) || x x || , , 1,..., .i j i jl i j m      (8.3) 
Note that D ,m m  x (x ,i j respectively) is the i th ( j th, respectively) feature vector of 
feature matrix S, and 1 1|| x x || | |
n a a
i j i ja
x x

    is the Manhattan distance between 
x and xi j . The eigenvalues of the distance matrix D are denoted by 1 2 ... m     , and 
1 2v ,v ,...,vm  denote the corresponding eigenvectors. According to the Courant-Fischer 
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and 
 
2 1 2 1z:||z|| 1,z span{v ,v ,...,v }





   (8.5) 
Let 1 2V [v ,v ,...,v ]t t  be the matrix whose columns are the first t  eigenvectors of the 
distance matrix D with the smallest eigenvalues (in this study, 1.)t   The training input 
of cell lines X  is projected onto Vt  to obtain the transformed training input X
m n  
with noise-filtered features. That is, 
 X VV X.Tt t   (8.6) 
(C) Compute the degrees between each training input x Xi   and the corresponding 
transformed training input x Xi   for i =1.. m  
 *
{1,2,..., }
























  (8.8) 
In this case, *i  is the index of *xi X , whose degree is *i . Denote by 
* * * 1




   the reduced training set whose q  feature vectors correspond to the 
training set with the smallest q  degrees (i.e., * * *1 2 ...i i i q        where q m ).  
(D) A learning algorithm is called on the training set S  of size q  to induce model h .  
(E)  Model h  is applied to make predictions on the test set. In the rest of this paper, the 
prediction algorithms that employ the proposed approach using the abbreviations will be 
referred to as PA+SVR+L, PA+SVR+S, and PA+RR (see Table 8.1). 
Table 8.1 Abbreviation of Drug Sensitivity Prediction Algorithms 
 
Abbreviation Prediction Algorithm 
PA+SVR+L The proposed approach using support vector regression with a linear 
kernel 
PA+SVR+S The proposed approach using support vector regression with a sigmoid 
kernel 
PA+RR The proposed approach using ridge regression 
B+SVR+L The baseline approach using support vector regression with a linear 
kernel 
B+SVR+S The baseline approach using support vector regression with a sigmoid 
kernel 






8.3   Experiments and Results 
8.3.1   Datasets 
The training sets correspond to an 482 6539  matrix and an 280 9115  matrix for 
breast cancer and multiple myeloma, respectively. The test sets correspond to an 
24 6538  matrix (excluding labels) and an 188 9114  matrix (excluding labels) for 
breast cancer and multiple myeloma, respectively. Cell lines expression data for breast 
cancer and multiple myeloma were download from the ArrayExpress repository 
(accession number E-MTAB-783). The drug 50IC  values for docetaxel and bortezomib 
were downloaded from (http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/). The 
clinical trial data for breast cancer (multiple myeloma, respectively) were downloaded 
from the Gene Expression Omnibus (GEO) repository with accession numbers GSE350 
and GSE349 (GSE9782, respectively) [132, 133]. The responses (i.e., labels) of the 
clinical trial data are categorical (e.g., “sensitive” or “resistant”). These labels were 
clinically evaluated by the degree of reduction in tumor size to the given drug [54]. The 
downloaded data were processed according to Geeleher et al. [54]. 
8.3.2   Experimental Methodology 
10-fold cross validation is not suitable in this study as labels of the testing sets are 
categorical while the labels of the corresponding training sets are real values. Hence, to 
evaluate whether the proposed approach exhibits stable superior performances as sample 
size changes, the sample size for the training set was reduced by 1% for each run, until 




468, 463) and (280, 278, 275, 272, 269) were performed for the two real datasets, 
respectively. 
Each prediction algorithm was trained on the same given training set, whose 
labels were continuous, to yield models. Then, each model was applied to the same test 
set to yield predictions, where the accuracy of the prediction algorithms were measured 
using the Are Under the ROC Curve (AUC) as in [54]. 
The software used in this work included support vector regression with linear and 
sigmoid kernels in the LIBSVM package [104], ridge regression [54], and R code for 
processing the datasets and performance evaluation [54]. R was used to write code for the 
prediction algorithms and to perform the experiments. 
8.3.3   Experimental Results 
Table 8.2 and Table 8.3 show the AUCs of 6 docetaxel and bortezomib sensitivity 
prediction algorithms on the clinical trial data for breast cancer and multiple myeloma, 
respectively. Columns “ m ” and “ d ” show the number of cell lines and genes, 
respectively, in the training sets that were provided to each prediction algorithm; the 
same training sets were provided to each prediction algorithm. Column “ q +PA” shows 
the number of selected (i.e., retrieved) cell lines that were used in PA+SVR+L, 
PA+SVR+S, and PA+RR to learn the models. 
Table 8.2 and Table 8.3 show that the proposed prediction algorithms perform 
better than the baseline prediction algorithms (i.e., B+SVR+L and B+SVR+S) and 
B+RR, the proposed prediction algorithm by Geeleher et al [54]. The results are 




the AUC of each run and of MAUC. These results indicate the stability of the proposed 
prediction algorithms. 
Table 8.2 The AUC of Docetaxel Sensitivity Prediction Algorithms for Breast Cancer 
Patients on the Test Set. The Algorithm with the Highest AUC Is Shown in Bold. MAUC 
Is the Mean AUC 
 
m d PA+SVR+L PA+SVR+S PA+RR q+PA B+SVR+L B+SVR+S B+RR 
482 6,538 0.842 0.878 0.821 478 0.835 0.842 0.814 
478 6,538 0.807 0.871 0.814 474 0.814 0.871 0.814 
473 6,538 0.814 0.878 0.821 469 0.800 0.864 0.821 
468 6,538 0.828 0.864 0.828 464 0.821 0.857 0.821 
463 6,538 0.857 0.864 0.821 459 0.835 0.857 0.821 
MAUC     - 0.829 0.871 0.821 - 0.821 0.858 0.818 
 
Table 8.3 The AUC of Bortezomib Sensitivity Prediction Algorithms for Multiple 
Myeloma Patients on the Test Set. The Algorithm with the Highest AUC Is Shown in 
Bold. The MAUC Is the Mean AUC 
 
m d PA+SVR+L PA+SVR+S PA+RR q+PA B+SVR+L B+SVR+S B+RR 
280 9,114 0.659 0.635 0.654 210 0.613 0.602 0.614 
278 9,114 0.656 0.623 0.65 209 0.609 0.600 0.611 
275 9,114 0.679 0.626 0.647 207 0.622 0.601 0.603 
272 9,114 0.685 0.641 0.653 204 0.628 0.605 0.607 
269 9,114 0.681 0.658 0.657 202 0.632 0.598 0.606 
MAUC - 0.672 0.636 0.652 - 0.62 0.601 0.608 
 
Figures 8.2 and  8.3 show the predictions of three prediction algorithms on the test 
sets when the prediction algorithms learned models from the training sets with sizes 
m =482 and m =280, respectively. For PA+SVR+S in Figure 8.2(a), the difference 
between the predicted drug sensitivity in breast cancer patients was highly statistically 
significant ( 567 10P    from a t -test) between trial-defined sensitivity and resistant 
groups. The B+SVR+S (Figure 8.2(b)) and B+RR (Figure 8.2(c)) achieved significant 




(Figure 8.3(a)) achieved highly significant results ( 510 10P    from a t -test).  The 
results of B+RR (Figure 8.3(b)) and B+SVR+L (Figure 8.3(c)) were also significant with 
























 Figure 8.2 Predictions of docetaxel sensitivity in breast cancer patients. Strip 
charts (a), (b), and (c) show the differences in predicted drug sensitivity for 
individuals sensitive or resistant to docetaxel treatment using PA+SVR+S, 
B+SVR+S, and B+RR prediction algorithms, while (d) shows the ROC curves of 
the prediction algorithms, which reveal the proportion of true positives compared 






























Figure 8.3 Prediction of bortezomib sensitivity in multiple myeloma patients. The 
strip charts and boxplots in (a), (b), and (c) show predicted drug sensitivity for in 
vivo responders and non-responders to bortezomib using the PA+SVR+L, B+RR, 
and B+SVR+L prediction algorithms, respectively. The ROC curve in (d) illustrates 





8.4   Summary 
In this chapter, a noise-filtering approach is proposed that blends the following 
techniques: (1) Numerical linear algebra to yield transformed training input 
corresponding to noise-filtered features; (2) Information retrieval to retrieve better quality 
cancer cell lines from the training set according to the minimum degrees between the 
training input and the transformed training input; (3) Machine learning to learn a model 
from better quality, reduced-size training sets and perform predictions on test sets. The 
proposed approach uses two machine learning algorithms: support vector regression and 
ridge regression. Compared to an existing drug sensitivity approach, the proposed 


















CHAPTER 9  
TRANSFER LEARNING APPROACHES TO IMPROVE DRUG SENSITIVITY 
PREDICTION IN MULTIPLE MYELOMA PATIENTS 
 
 
9.1   Introduction 
Traditional machine learning approaches to drug sensitivity prediction assume that 
training data and test data must be in the same feature space and have the same 
underlying distribution. However, in real-world applications, this assumption does not 
hold. For example, we sometimes have limited training data for the task of drug 
sensitivity prediction in multiple myeloma patients (target task), but we have sufficient 
auxiliary data for the task of drug sensitivity prediction in patients with another cancer 
type (related task), where the auxiliary data for the related task are in a different feature 
space or come from a different distribution. In such cases, transfer learning, if applied 
correctly, would improve the performance of the prediction algorithms on the test data of 
the target task via leveraging the auxiliary data from the related task. In this chapter, 
transfer learning approaches are presented that combine the auxiliary data from the 
related task with the training data of the target task to improve the prediction performance 
on the test data of the target task. The performance of the proposed transfer learning 
approaches is evaluated exploiting three auxiliary datasets and compare them against 
baseline approaches using the area under the ROC curve (AUC) on test data of the target 
task. Experimental results demonstrate the good performance of the proposed approaches 




In the sequel, the terms "sensitive" ("resistant", respectively) and "responder" 
("non-responder", respectively) are used interchangeably. The terms "genes" and 
"features" are also used interchangeably throughout the paper. 
 
9.2   Background 
This section provides an introduction to the methods related to the proposed work: 
synthetic minority over-sampling technique (SMOTE) [123] and CUR matrix 
decomposition [149]. Each of them is introduced respectively after summarizing 
notations used in the paper. 
9.2.1   Notations 
To give a better understanding of the algorithms, the notations used in the paper are first 
summarized. Matrices are written as uppercase letters, e.g., matrix X . Vectors are 
denoted by lowercase letters, e.g., x . Vector elements are denoted by italic lowercase 
letters as scalars, e.g., iy  or x . A transpose of a matrix or a vector is indicated by T . So, 
for example, if x  is a row vector, xT  is the corresponding column vector. 
9.2.2   Synthetic Minority Over-sampling Technique (SMOTE) 
SMOTE [123] is a popular and a powerful over-sampling method that has shown a great 
deal of success in many applications [163-165]. Here, we are given a dataset D D  . 
D m d  contains examples from the minority class, D
n d
  contains examples 
from the majority class, and m n . For each example x Di  , SMOTE finds the  
k -nearest neighbors 1 2x ,x ,...,xki i i  of x Di  , where x
j d




nearest neighbor of the ith example xi  in D .  Then SMOTE generates synthetic 
examples 1 2z ,z ,...,zki i i  along the line between each minority example x Di   and its 
selected k  nearest neighbors in the minority class as follows: 
1. for i  = 1 to m  
1.1. for j  = 1 to k  
1.1.1. z x (x x )ji i i
j
i     
1.1.2. Store [ z ji ,+] in D  
1.2. end for 
2. end for 
where z j di   refers to the  jth synthetic example generated from the ith example 
x D , (0,1)i    is a random number, and the + sign indicates that synthetic examples 
are labeled with the minority class label. A random subset 'D D   is then selected, 
where 'D  consists of n-m synthetic examples. A learning algorithm could be called on 
the balanced dataset 'D D D ,    to induce a model and perform predictions on a 
given test set. 
9.2.3   CUR Matrix Decomposition 
Suppose that a dataset F m p  is given. Mahoney et al. [149] proposed CUR matrix 
decomposition as a dimensionality reduction paradigm that aims to obtain a low rank 
approximation of matrix F , which is expressed in terms of the actual rows and columns 




 F CUR,   (9.1) 
where C  consists of a small number of the actual columns of F , R  consists of a small 
number of the actual rows of F , and U  is a constructed matrix that guarantees that CUR  
is close to F . Let jv
  be the jth element of the th  right singular vector of F.  Let l be the 










   (9.2) 






 . C , U , and R  matrices are constructed after calling 
COLUMNSELECT algorithm of Mahoney et al., which takes an input matrix F , a rank 
parameter l , and an error parameter  , and then performs the following steps: 
1. Compute 1 2v ,v ,...,vl  (the top l  right singular vectors of F) and the normalized 
statistical leverage scores of Eq. 9.2. 
2. Keep the j th column of F with probability min{1, }j jp c   for all j =1.. p , where 
2( log / )c O l l  . 
3. Return the matrix C  consisting of the selected columns of F .  
In step 1, the singular value decomposition SVD of F  is computed, which decomposes F  
to U V
T , where U
m l  is orthogonal matrix containing the top l  left singular vectors 
of  F, l l  is diagonal matrix containing singular values of F , V
T l p  is 
orthogonal matrix containing the top l  right singular vectors of  F, and l  is the rank of F . 
The columns of U  are pairwise orthogonal and normal (i.e., orthonormal), but its rows 
are not orthonormal as Euclidean norm is between 0 and 1. The rows of V
T
 are pairwise 




Euclidean norm is between 0 and 1 [166]. The other matrices (i.e., R , and U ) are 
constructed as follows: 
1. Run COLUMNSELECT on FT  with 2( log / )c O l l   to choose rows of F (columns 
of FT ) and construct matrix R. 
2. Matrix U is defined as U=C FR  , where C
  and R  denote the Moore–Penrose 
generalized inverse of the matrix C and R, respectively. 
 
Statistical leverage scores have been successfully employed in data analysis to identify 
the most influential genes and outlier detection [149]. A high statistical leverage score for 
a given gene indicates that the gene is regarded as an important (i.e., influential) gene. A 
low statistical leverage score for a given gene indicates that the gene is regarded as an 
unimportant gene. To select the q most important genes from matrix F , where q p , we 
find the highest q  statistical leverage scores used in computing matrix C of F, which 
correspond to the q  most influential (i.e., important) genes. 
 
9.3   Proposed Approaches 
9.3.1   The Transfer Learning Approach 
Figure 9.1 illustrates the proposed transfer learning approach, which works as follows. 
Suppose that we are given a target training set 1 1F = { (x , ),...,(x , )}m my y  and a target test 
set 1T = { t ,..., t }r . In the target training set, x
p
i   is the ith target training example with 
p genes (i.e., features), iy   is the corresponding label of xi , and t
p
i   is the i th 




where m  and r  are the numbers of training and testing examples in the target task, 
respectively. In addition, we also have an auxiliary dataset 
1 1 lS= { (s , ),...,(s , )}lu u , where 
s ni   is the ith example (i.e., cell line of a cancer type) with n  genes, iu   is the 
corresponding label of si , and n , the number of genes in the auxiliary data, is different 
from p , the number of genes used in the target task. Our goal is to improve the 
prediction performance on the target test set T  of the target task (prediction of 
bortezomib sensitivity in multiple myeloma patients) via learning an accurate model 
using the auxiliary dataset S  and the target training set F . We summarize the problem 
definition in Table 9.1.  
To incorporate the auxiliary data with the target training set, the following steps 
are performed. 
(i) If the number of genes p  in the target training set F  is greater than the number of 
genes n  in the auxiliary data S , then gene (i.e., feature) selection is performed on F  as 
explained in step (ii). Otherwise, gene selection is performed on S . Assume without loss 
of generality that p n .  
(ii) q  genes are selected from F  based on their importance scores as defined in Equation 
(9.2), which depends on computing matrix C of F  and the input rank parameter l  (in this 
study, q n  and the default parameter values are used for l , c , and   in CUR function 
[150].) Then, the indexes of the highest q  leverage scores are stored in I  (where q p ); 
these correspond to the positions of the q  most influential genes in matrix F . q  genes 
are selected from the target training set F  using their positions in I  and stored in 
' ' ' ' '




Table 9.1 Problem Formulation 
 
Learning objective Make predictions on the target test set of the target task 
Target task Prediction of bortezomib sensitivity in multiple myeloma patients 
Related task Prediction of specific drug sensitivity in patients with a cancer type 
Target task data 
Target Training set: 1F = { (x , ) } 
m
i i iy   
Target Test set: 1T= { t  } 
r
i i  
Related task data 
Auxiliary Data: 1S = { (s , )} 
l
i i iu   
Cancer Types: Breast Cancer, Triple-Negative Breast Cancer, and 
Non-Small Cell Lung Cancer 
 
 






(iii) The following steps are based on a modified version of SMOTE [123] where each 
example in the auxiliary dataset gets a representation closer to the target training set 'F : 
1. Select b  examples from the auxiliary dataset S. (In the study presented here, 
100.b  ) For each example si , 1 i b  , selected from S,  pick one of s 'si  nearest 
target training examples from 'F , denoted *x i , such that the picked example is 
different from all the target training examples previously picked for s j , 1 j i  . 
More precisely, suppose s 'si k nearest target training examples are among the target 
training examples previously picked for s j , 1 j i  . Then 
*x i  is s 'si  (k + 1)th 
nearest target training example from 'F . Let 'iy  be the corresponding label of 
*x i . 
2. Change the representation of the examples selected from S  using the following lines 
of code: 
2.1 for i  = 1 to b  
2.1.1 * *s s (x s )i i i i     
2.1.2 Store * '[s ,( )] in Si iy
  
2.2 end for 
where 0.99 , 0.01,  and S  contains the new representations of the auxiliary data. 
Let 
'D =  S F   contain the combined cell lines expression data, where 
'
D m n , and 
' .m m b    
(iv) A learning algorithm is called on D  to induce a model h . 
(v) The n  genes in the target test set T  are selected using their positions in I  and stored 
in 




9.3.2   The Boosted Transfer Learning Approach 
Figure 9.2 illustrates the proposed boosted transfer learning approach. Steps (i), (ii), and 
(iii) are the same as steps (i), (ii), and (iii) of the transfer learning approach. Steps  
(iv) and (v) work as follows. 
(iv) A modification of AdaBoost [116-118, 167] is employed, which works as follows. 
Initially, each training example (x , ) Di iy   is assigned a weight 1iw   for i  = 
'1, ,m . 























 . Select 'm  training examples (without replacement) from D , to form the 
training set 'D . A learning algorithm is called on 'D  to learn a model h  and perform 
predictions on D , where predictions are then stored in '
' ' '
1y ( ,..., ).my y  Select the n  
genes in the target test set T  using positions in I , and store the selected data with n  
genes in 'T . Apply the model h  on the target test set 'T , to yield predictions, which are 
stored as the first row vector in a matrix G . Repeat the following j  times. (In this study, 
j = 6.) 
1.  Update the weights: ' 2( )i i iw y y  . for i =1,…,
'm . 
2.  Calculate probabilities '1 2p ( , ,..., )mp p p  of the training examples in D , where 
ip , 
'1 i m  , is as defined in Equation (3). 




4. Select training examples from D  where the weight of each selected example must 
be greater than or equal to v . Store the selected training examples in 'D . Let p*  
contain the probabilities corresponding to the selected training examples. 
5. Select 'm  training examples (with replacement) from 'D  according to the 
probabilities in p*  and store the selected training examples in ''D . The higher 
probability a training example is associated with, the more likely this training 
example will be included in ''D . 
6. A learning algorithm is called on ''D  to learn model h  and perform predictions on 
D . 
7. Store the predictions performed on D  in q . 
8. Let 'y  = 'y + q , which corresponds to the cumulative predictions on the training 
set D . 
9. Apply the learned model h  on the target test set 'T  and store the predictions as the 
(j +1)th row vector in G . 
(v) Output the final predictions as 
 Q e GT   (9.4) 
where G  is an ( 1)j r   matrix of predictions on the target test set 'T , the ith row vector 







   is a ( 1) 1j    column vector, and  Q is a 1 r   row vector 






Figure 9.2 Flowchart of the proposed boosted transfer learning approach to predicting in 
vivo drug sensitivity. 
 
 
9.4   Experiments 
9.4.1   Datasets 
Data Pertaining to Multiple Myeloma. The target training set 280  9115F   contains 280 
target training examples (i.e., cancer cell lines), 9,114 genes, and drug 50IC  values that 
correspond to a 280-dimensional column vector. The target test set  188  9114T   is 




values for bortezomib [151, 152] were downloaded from 
(http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/) [54], and the data for the 
cancer cell lines were downloaded from the ArrayExpress repository  
(accession number is E-MTAB-783 or available at 
https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-783/?query=EMTAB783) 
[131, 168, 169]. The clinical trial data corresponding to the test set were downloaded 
from the Gene Expression Omnibus (GEO) repository 
(http://www.ncbi.nlm.nih.gov/geo/) with accession number GSE9782. The data were 
downloaded, processed and mapped according to Geeleher et al. [54]. 
Data Pertaining to Breast Cancer. The auxiliary data correspond to an 482 6539  
matrix (i.e., 482 examples and 6538 genes plus labels, i.e., drug 50IC  values) for breast 
cancer patients. The drug 50IC values for docetaxel [130, 170]. (a chemotherapy drug) 
were downloaded from (http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/) [54]. 
The cell line expression data were downloaded from the ArrayExpress repository 
(accession number is E-MTAB-783, also available at 
https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-783/?query=EMTAB783) 
[131, 168, 169]. All the data were downloaded and processed according to the approach 
proposed by Geeleher et al. [54]. 
Data Pertaining to Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer. 
The auxiliary data correspond to an 258  9508  matrix (i.e., 258 examples and 9507 
genes plus labels) and an 497  9621  matrix (i.e., 497 examples and 9620 genes plus 




respectively. The data were downloaded from 
(http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/). 
9.4.2   Evaluation and Baseline Approaches 
The two proposed transfer learning approaches are compared with two different baseline 
approaches, which are described below. 
First Baseline (B1). This baseline employs the proposed approach by Geeleher et al. 
[54]. 
Second Baseline (B2). In this baseline, CUR matrix decomposition is applied to F.  Then, 
the indexes of the largest n  statistical leverage scores of F  are stored in I , as in the 
proposed approaches. The n  genes from the target training examples in F  are selected 
using positions in I . A learning algorithm is called on the auxiliary data with n genes 
combined with the target training set with n  genes, to learn a model h . Then, the n  
genes in the target test set are selected using positions in I . The model h  is applied to the 
target test examples with n  genes, to yield drug sensitivity predictions. Thus, this 
baseline, which does not have a transfer learning mechanism (cf. steps (iii) in Section 
9.3.1), differs from the proposed transfer learning approaches. 
The proposed transfer learning approaches and the baseline approaches employ 
two machine learning algorithms, namely support vector regression (SVR) and ridge 








Table 9.2 Summary of the Twelve Drug Sensitivity Prediction Algorithms in This 
Chapter 
 
Abbreviation Prediction Algorithm 
T+SVR+L The transfer learning approach using support vector regression with a linear kernel 
T+SVR+S The transfer learning approach using support vector regression with a sigmoid kernel 
T+RR The transfer learning approach using ridge regression 
BT+SVR+L The boosted transfer learning approach using support vector regression with a linear kernel 
BT+SVR+S The boosted transfer learning approach using support vector regression with a sigmoid kernel 
BT+RR The boosted transfer learning approach using ridge regression 
B1+SVR+L The first baseline approach using support vector regression with a linear kernel 
B1+SVR+S The first baseline approach using support vector regression with a sigmoid kernel 
B1+RR The first baseline approach using ridge regression 
B2+SVR+L The second baseline approach using support vector regression with a linear kernel 
B2+SVR+S The second baseline approach using support vector regression with a sigmoid kernel 
B2+RR The second baseline approach using ridge regression 
 
Each prediction algorithm was trained on a training set, whose labels were 
continuous, to yield a model. Then, each model was applied to the target test set to yield 
predictions. The target test set consists of patients' clinical trial expression data, which are 
baseline tumor expression data from primary tumor biopsies before treatment with 
anticancer drugs. The labels of the target test set are not translated from continuous to 
categorical. Instead, the labels of the target test set are categorical (i.e., either “sensitive” 
or “resistant”), where these labels were clinically evaluated by the degree of reduction in 
tumor size to the given drug. A cancer patient is categorized as “sensitive” to cancer drug 
(e.g., docetaxel or bortezomib) treatment if the cancer patient exhibits less than 25% 
residual tumor. A cancer patient is categorized as “resistant” to cancer drug treatment if 
the cancer patient exhibits greater than or equal to 25% residual tumor [54]. 
Using in vitro drug sensitivity of the training data to predict in vivo drug 
sensitivity of the target test set is a challenging task and main goal in precision medicine, 




human being [171]. If the clinical drug response (i.e., clinical response to anticancer 
drug) is incorrectly predicted, the tumor size of a cancer patient would increase 
significantly over the time, which cause sequelae that lead to death. If the clinical drug 
response is correctly predicted, the tumor size would decrease significantly over the time 
and that would save the patient. By predicting clinical outcomes in the target test set 
correctly, clinicians would benefit from understanding the relationship between in vivo 
and in vitro drug sensitivity, which leads to better personalized treatment. 
Ten-fold cross validation is not suitable in this study as labels of the target test set 
are categorical while the labels of the corresponding target training set are real numbers. 
Hence, to evaluate whether the proposed approach exhibits stable superior performances 
as sample size changes, the sample size for the target training set was randomly reduced 
by 1% for each run, until the reduction reached 4%. In other words, 5 runs were 
performed with sample sizes of  280, 278, 275, 272, 269, respectively. 
The accuracy of the prediction algorithms was measured using the area under the 
ROC curve (AUC), as described in [54]. The higher the AUC score an algorithm 
achieves, the better its performance is. MAUC is used to denote the mean of the AUC 
values averaged over the five runs of the target test set. A run of the target test set is 
defined as the predictions of a learned model on the target test set in which the model was 
learned from a training set whose size is varied to assess the stability of the prediction 
algorithms. A stable prediction algorithm is the one whose prediction accuracy on the 
target test set does not change dramatically owing to small changes of the training set size 




prediction algorithm is the one that outperforms the other algorithms many times on 
conducted experiments. The statistical significance of the approaches was measured. 
The software used in this work included support vector regression with linear and 
sigmoid kernels (with their default parameter values) in the LIBSVM package [104], 
ridge regression [54], gene selection using CUR and topLeverage functions in the rCUR 
package [150], and R code for processing the datasets and performance evaluation [54]. 
R is used to write code for the prediction algorithms and to perform the experiments. 
9.4.3   Experimental Results 
In this section, the performance of the proposed approaches is evaluated and compared to 
the baseline approaches. Each time the target training set of multiple myeloma is used 
with one of the auxiliary datasets pertaining to breast cancer, triple-negative breast 
cancer, and non-small cell lung cancer respectively to train  the approaches (except the 
B1 approach that uses only target training set), to yield prediction algorithms and perform 
prediction on the target test set. 
9.4.3.1   Exploiting Breast Cancer Auxiliary Data.  Table 9.3 shows details of the 
target training set and auxiliary dataset pertaining to breast cancer used by each 
prediction algorithm. The target training set is obtained from the target task (i.e., 
prediction of bortezomib sensitivity in multiple myeloma patients) and the auxiliary data 
are acquired from the related task (i.e., prediction of docetaxel sensitivity in breast cancer 
patients). Rows “ /m l ” shows the number of examples or cell lines in the target training 
set/auxiliary dataset used in each run. Row “ /p n ” shows the number of genes or 




the number of overlapped (i.e., intersected) genes between the target training set and the 
auxiliary data in each run. Rows “
/Pm l ” and “ /Pp n ” show the number of selected 
examples in the target training set/auxiliary dataset and the number of selected genes in 
the target training set/auxiliary dataset, respectively, that were used in the prediction 
algorithms employing the approaches during the training stage to learn models. Rows 
“ B1m ” and “ B1p ” show the number of selected examples and genes, respectively, in the 
target training set that were used during the training stage by the prediction algorithms 
employing the first baseline approach (B1). Row “ /B2m l ” and “ /B2p n ”Show the number 
of selected examples and genes, respectively, in the target training set/auxiliary dataset 
that were used by the prediction algorithms employing the second baseline approach 
(B2). In each run the target training set size is changed to train all machine learning 
algorithms employing the approaches as described in Sections 9.3 and 9.4.2, to yield 
models (i.e., prediction algorithms). 
 
Table 9.3 Details of the Target Training Set and Auxiliary Dataset Pertaining to Multiple 
Myeloma and Breast Cancer, Respectively, Used by Each Prediction Algorithm 
 
Run 1 2 3 4 5 
/m l  280/482 278/482 275/482 272/482 269/482 
/p n  9114/6538 9114/6538 9114/6538 9114/6538 9114/6538 
p n  5478 5478 5478 5478 5478 
/Pm l  280/100 278/100 275/100 272/100 269/100 
/Pp n  6538/6538 6538/6538 6538/6538 6538/6538 6538/6538 
B1m  280 278 275 272 269 
B1p  9114 9114 9114 9114 9114 
/B2m l  280/482 278/482 275/482 272/482 269/482 





Table 9.4 shows the AUCs of twelve prediction algorithms on the target test set of 
multiple myeloma patients. As shown in Table 9.4, BT+SVR+S performs better than the 
baseline prediction algorithms (i.e., B2+SVR+L, B2+SVR+S, B2+RR, B1+SVR+L, and 
B1+SVR+S and B+RR). In particular, BT+SVR+S achieves the highest AUC in 4 out of 
5 runs. The BT+SVR+S results were consistently good compared to the other prediction 
algorithms in terms of AUC on the target test set as the target training set size is reduced. 
These results indicate that the performance of BT+SVR+S is stable.  
 
Table 9.4 AUC Scores of the Twelve Prediction Algorithms on the Target Test Set of 
Multiple Myeloma Patients Where the Target Training Set and Auxiliary Dataset 
Pertaining to Multiple Myeloma and Breast Cancer Patients, Respectively, Are Used. The 
Algorithm with the Highest AUC Is Shown in Bold. Std is the Standard Deviation of the 
AUC Values Obtained from the Five Runs 
 
Run 1 2 3 4 5 
T+SVR+L 0.644 0.636 0.640 0.647 0.653 
T+SVR+S 0.643 0.642 0.654 0.659 0.666 
T+RR 0.653 0.655 0.652 0.657 0.652 
BT+SVR+L 0.658 0.657 0.678 0.665 0.675 
BT+SVR+S 0.682 0.682 0.687 0.695 0.703 
BT+RR 0.670 0.693 0.668 0.681 0.659 
B1+SVR+L 0.613 0.609 0.622 0.628 0.632 
B1+SVR+S 0.602 0.600 0.601 0.605 0.598 
B1+RR 0.614 0.611 0.603 0.607 0.606 
B2+SVR+L 0.440 0.491 0.466 0.501 0.549 
B2+SVR+S 0.449 0.485 0.487 0.506 0.500 
B2+RR 0.499 0.505 0.511 0.511 0.516 
 
Table 9.5 shows the P -values of a two-sample t -test on the target test set for 
each run, as in [54]. Each prediction algorithm with a highly statistically significant result 
is shown in red ( .001P  ). Each algorithm with a statistically significant result is shown 




highly statistically significant results, and these highly statistically significant results 
reflect the superior performance of the proposed prediction algorithms (see Table 9.4). 
 
Table 9.5 P -Values of a Two-Sample t-Test for the Twelve Prediction Algorithms on 
the Target Test Set Where the Target Training Set and Auxiliary Dataset Pertaining to 
Multiple Myeloma and Breast Cancer Patients, Respectively, Are Used. Each Prediction 
Algorithm with 0.001P    Is Considered As Highly Statistically Significant and Colored 
in Red. Each Prediction Algorithm with 0.05P   Is Considered Statistically Significant 
and Colored in Blue 
 
Run 1 2 3 4 5 
T+SVR+L  66088 10  6906 10  6674 10  6442 10  6372 10  
T+SVR+S 6765 10  6815 10  6498 10  6273 10  6219 10  
T+RR 6188 10  6218 10  6244 10  6194 10  6313 10  
BT+SVR+L 6218 10  6245 10  62396 10  6132 10  86888 10  
BT+SVR+S 54 10  82172 10  81506 10  81378 10  8527 10  
BT+RR 83382 10  99221 10  84307 10  81169 10  86069 10  
B1+SVR+L 36 10  37 10  34 10  32 10  32 10  
B1+SVR+S 38 10  21 10  311 10  39 10  314 10  
B1+RR 5261 10  34 10  36 10  34 10  35 10  
B2+SVR+L 3881 10  3665 10  3489 10  3724 10  3613 10  
B2+SVR+S 3784 10  3722 10  3708 10  3607 10  3633 10  
B2+RR 44992 10  3466 10  3398 10  3386 10  3342 10  
 
Figures 9.3(a), 9.3(b), and 9.3(c) show the predictions of BT+SVR+S, B1+RR, 
and B2+RR, respectively, on the target test set at the first run. The result of BT+SVR+S 
shown in Figure 9.3(a) was highly statistically significant ( 54 10P    from a two-sample 
t -test) between the trial-defined responder (i.e., sensitive) and non-responder (i.e., 
resistant) groups. The result of B1+RR shown in Figure 9.3(b) was statistically 
significant with 5261 10P    from a two-sample t -test. The result of B2+RR shown in 




t -test. In Figure 9.3(d), the ROC curves reveal AUC values of 0.682, 0.614, and 0.499 














































Figure 9.3 Predictions of bortezomib sensitivity on the target test set of multiple 
myeloma patients where the target training set and auxiliary dataset pertaining to 
multiple myeloma and breast cancer patients, respectively, are used. Strip charts and 
boxplots (a), (b), and (c) show the differences in predicted drug sensitivity to bortezomib 
treatment between the responder (i.e., sensitive) group and non-responder (i.e., resistant) 
group using BT+SVR+S, B1+RR, and B2+RR, respectively. (d) shows the ROC curves 
of the prediction algorithms, which reveal the proportion of true positives compared to 





Figure 9.4 shows the ranking of the twelve prediction algorithms based on their 
MAUC values.  The MAUC of an algorithm is calculated by taking the mean of the AUC 
values the algorithm receives from the 5 runs of experiments. As shown in Figure 9.4, the 
proposed prediction algorithms outperform the baseline prediction algorithms w.r.t. the 
MAUC. 
 
Figure 9.4 The Mean AUC (MAUC) values of the twelve bortezomib sensitivity 
prediction algorithms for multiple myeloma patients. The algorithms are ranked from left 
to right where the leftmost algorithm has the highest MAUC and the rightmost algorithm 
has the lowest MAUC. 
 
 
9.4.3.2   Exploiting Triple-Negative Breast Cancer Auxiliary Data.     Table 9.6 shows 
details of the target training set and the auxiliary dataset pertaining to triple-negative 
breast cancer patients used by each prediction algorithm. The target training set is 




myeloma patients) and the auxiliary dataset is obtained from the related task (i.e., 
prediction of cisplatin sensitivity in triple-negative breast cancer patients). The only 
difference between Table 9.3 and Table 9.6 is that Table 9.6 has different auxiliary data 
pertaining to triple-negative breast cancer patients, while the target test set is still the 
same. 
 
Table 9.6 Details of the Target Training Set and Auxiliary Dataset Pertaining to Multiple 
Myeloma and Triple-Negative Breast Cancer Patients, Respectively, Used by Each 
Prediction Algorithm 
 
Run 1 2 3 4 5 
/m l  280/497 278/497 275/497 272/497 269/497 
/p n  9114/9620 9114/9620 9114/9620 9114/9620 9114/9620 
p n  7911 7911 7911 7911 7911 
/Pm l  280/100 278/100 275/100 272/100 269/100 
/Pp n  9114/9114 9114/9114 9114/9114 9114/9114 9114/9114 
B1m  280 278 275 272 269 
B1p  9114 9114 9114 9114 9114 
/B2m l  280/497 278/497 275/497 272/497 269/497 
/B2p n  9114/9114 9114/9114 9114/9114 9114/9114 9114/9114 
 
Table 9.7 shows the AUCs of the twelve prediction algorithms on the target test 
set of multiple myeloma patients. As shown in Table 9.7, the proposed prediction 
algorithms employing the boosted transfer learning approach (BT) perform better than 
the baseline prediction algorithms. Specifically, BT+SVR+S and BT+RR yielded the 
highest AUC in 4 out of 5 runs. These results indicate that the proposed prediction 
algorithms employing BT approach achieve high performance in terms of AUC on the 





Table 9.7 AUC Scores of the Twelve Prediction Algorithms on the Target Test Set of 
Multiple Myeloma Patients Where the Target Training Set and Auxiliary Dataset 
Pertaining to Multiple Myeloma and Triple-Negative Breast Cancer Patients, 
Respectively, Are Used. The Algorithm with the Highest AUC Is Shown in Bold. Std Is 
the Standard Deviation of the AUC Values Obtained from the Five Runs. 
 
Run 1 2 3 4 5 
T+SVR+L 0.601 0.599 0.604 0.617 0.618 
T+SVR+S 0.62 0.621 0.629 0.634 0.632 
T+RR 0.615 0.615 0.614 0.62 0.623 
BT+SVR+L 0.628 0.635 0.665 0.627 0.669 
BT+SVR+S 0.683 0.641 0.659 0.695 0.667 
BT+RR 0.638 0.654 0.675 0.677 0.654 
B1+SVR+L 0.613 0.609 0.622 0.628 0.632 
B1+SVR+S 0.602 0.600 0.601 0.605 0.598 
B1+RR 0.614 0.611 0.603 0.607 0.606 
B2+SVR+L 0.528 0.528 0.538 0.536 0.523 
B2+SVR+S 0.472 0.466 0.473 0.477 0.471 
B2+RR 0.464 0.460 0.466 0.472 0.476 
 
In Table 9.8, the P -values of a two-sample t -test on the target test set are 
reported for each run. The proposed prediction algorithms BT+SVR+S and BT+RR yield 
highly statistically significant results in each run (see results colored in red in Table 9.8), 
and these highly statistically significant results reflect the high performance of 









Table 9.8 P -Values of a Two-Sample t-Test for the Twelve Prediction Algorithms on 
the Target Test Set Where the Target Training Set and Auxiliary Dataset Pertaining to 
Multiple Myeloma and Triple-Negative Breast Cancer Patients, Respectively, Are Used. 
Each Prediction Algorithm with 0.001P   Is Considered Highly Statistically Significant 
and Colored in Red. Each Prediction Algorithm with 0.05P   Is Considered Statistically 
Significant and Colored in Blue 
 
Run 1 2 3 4 5 
T+SVR+L 68701 10  69608 10  67425 10  64303 10  64126 10  
T+SVR+S 63877 10  63499 10  62547 10  61708 10  61897 10  
T+RR 63908 10  64911 10  65189 10  5363 10  63932 10  
BT+SVR+L 62698 10  61171 10  6188 10  62163 10  6132 10  
BT+SVR+S 82716 10  6719 10  6185 10  81185 10  6104 10  
BT+RR 6382 10  6111 10  82692 10  82774 10  6115 10  
B1+SVR+L 36 10  37 10  34 10  32 10  32 10  
B1+SVR+S 38 10  21 10  311 10  39 10  314 10  
B1+RR 5261 10  34 10  36 10  34 10  35 10  
B2+SVR+L 44249 10  3426 10  43987 10  43964 10  44338 10  
B2+SVR+S 48505 10  48672 10  48341 10  48028 10  48263 10  
B2+RR 46622 10  3694 10  46596 10  46066 10  257 10  
 
Figures 9.5(a), 9.5(b), and 9.5(c) show the predictions of BT+SVR+S, B1+RR, 
and B2+RR, respectively, on the target test set at the first run. BT+SVR+S (Figure 
9.5(a)) achieved a highly statistically significant result ( 82716 10P    from a  
two-sample t -test). The result of B1+RR (Figure 9.5(b)) was statistically significant with 
( 5261 10P    from a two-sample t -test). The result of B2+RR (Figure 9.5(c)) was not 
statistically significant ( 46622 10P    from a two-sample t -test). In Figure 9.5(d), the 


















































Figure 9.5 Predictions of bortezomib sensitivity on the target test set of multiple 
myeloma patients where the target training set and auxiliary dataset pertaining to 
multiple myeloma and triple-negative breast cancer patients, respectively, are used. 
Strip charts and boxplots (a), (b), and (c) show the differences in predicted drug 
sensitivity to bortezomib treatment between the responder (i.e., sensitive) group 
and non-responder (i.e., resistant) group using BT+SVR+S, B1+RR, and B2+RR, 
respectively. (d) shows the ROC curves of the prediction algorithms, which reveal 
the proportion of true positives compared to the proportion of false positives. ROC 




Figure 9.6 shows that the proposed prediction algorithms BT+SVR+S, BT+RR, 
BT+SVR+L, and T+SVR+S outperform the baseline prediction algorithms w.r.t. the 
MAUC. 
 
Figure 9.6 The Mean AUC (MAUC) values of the twelve bortezomib sensitivity 
prediction algorithms for multiple myeloma patients. The algorithms are ranked from left 
to right where the leftmost algorithm has the highest MAUC and the rightmost algorithm 
has the lowest MAUC. 
 
 
9.4.3.3   Exploiting Non-Small Cell lung cancer Auxiliary Data.     Table 9.9 shows 
details of the target training set and auxiliary dataset pertaining to non-small cell lung 




the target task (i.e., prediction of bortezomib sensitivity in multiple myeloma patients) 
and the auxiliary dataset is acquired from the related task (i.e., prediction of erlotinib 
sensitivity in non-small cell lung cancer patients). Here, different auxiliary dataset 
pertaining to non-small cell lung cancer patients is used, while the target test set still 
remains the same. 
Table 9.9 Details of the Target Training Set and Auxiliary Dataset Pertaining to Multiple 
Myeloma and Non-Small Cell Lung Cancer Patients, Respectively, Used by Each 
Prediction Algorithm 
 
Run 1 2 3 4 
/m l  280/258 278/258 275/258 272/258 
/p n  9114/9507 9114/9507 9114/9507 9114/9507 
p n  7855 7855 7855 7855 
/Pm l  280/100 278/100 275/100 272/100 
/Pp n  9114/9114 9114/9114 9114/9114 9114/9114 
B1m  280 278 275 272 
B1p  9114 9114 9114 9114 
/B2m l  280/258 278/258 275/258 272/258 
/B2p n  9114/9114 9114/9114 9114/9114 9114/9114 
 
Table 9.10 shows the AUCs of twelve prediction algorithms on the target test set 
of multiple myeloma patients. The proposed prediction algorithm BT+SVR+S achieved 
the highest AUC scores in 4 out of 5 runs. The high performance results indicate the 








Table 9.10 AUC Scores of the Twelve Prediction Algorithms on the Target Test Set of 
Multiple Myeloma Patients Where the Target Training Set and Auxiliary Dataset 
Pertaining to Multiple Myeloma and Non-Small Cell Lung Cancer Patients, Respectively, 
Are Used. The Algorithm with the Highest AUC Is Shown in Bold. Std Is the Standard 
Deviation of the AUC Values Obtained from the Five Runs 
 
Run 1 2 3 4 5 
T+SVR+L 0.6 0.598 0.604 0.617 0.617 
T+SVR+S 0.621 0.619 0.63 0.635 0.634 
T+RR 0.614 0.615 0.61 0.615 0.624 
BT+SVR+L 0.67 0.653 0.623 0.663 0.663 
BT+SVR+S 0.673 0.653 0.651 0.657 0.678 
BT+RR 0.658 0.639 0.619 0.594 0.627 
B1+SVR+L 0.613 0.609 0.622 0.628 0.632 
B1+SVR+S 0.602 0.6 0.601 0.605 0.598 
B1+RR 0.614 0.611 0.603 0.607 0.606 
B2+SVR+L 0.403 0.409 0.436 0.422 0.421 
B2+SVR+S 0.643 0.644 0.644 0.646 0.648 
B2+RR 0.641 0.641 0.642 0.641 0.642 
 
Table 9.11 reports the P -values of a two-sample t -test on the target test set for 
each run. The proposed prediction algorithm BT+SVR+S yields highly statistically 
significant result in each run (see results colored in red in Table 9.11), and these highly 
statistically significant results reflect the high performance of BT+SVR+S prediction 









Table 9.11 P -Values of a Two-Sample t-Test for the Twelve Prediction Algorithms on 
the Target Test Set Where the Target Training Set and Auxiliary Dataset Pertaining to 
Multiple Myeloma and Non-Small Cell Lung Cancer Patients, Respectively, Are Used. 
Each Prediction Algorithm with 0.001P   Is Considered Highly Statistically Significant 
and Colored in Red. Each Prediction Algorithm with 0.05P   Is Considered Statistically 
Significant and Colored in Blue 
 
Run 1 2 3 4 5 
T+SVR+L 68887 10  69892 10  67654 10  64282 10  64214 10  
T+SVR+S 63883 10  63735 10  62486 10  61606 10  61833 10  
T+RR 63887 10  449 10  66343 10  64458 10  63918 10  
BT+SVR+L 6135 10  6368 10  63893 10  6212 10  518 10  
BT+SVR+S 71195 10  6261 10  6394 10  6383 10  84695 10  
BT+RR 63887 10  449 10  66343 10  64458 10  63918 10  
B1+SVR+L 36 10  37 10  34 10  32 10  32 10  
B1+SVR+S 38 10  21 10  311 10  39 10  314 10  
B1+RR 5261 10  34 10  36 10  34 10  35 10  
B2+SVR+L 3939 10  49358 10  49073 10  49173 10  3926 10  
B2+SVR+S 65556 10  65455 10  65414 10  65493 10  65196 10  
B2+RR 63881 10  63855 10  63888 10  63905 10  63822 10  
 
 
Figures 9.7(a), 9.7(b), and 9.7(c) show the predictions of BT+SVR+S, B1+RR, 
and B2+RR, respectively, on the target test set at the first run. BT+SVR+S (Figure 
9.7(a)) yielded a highly statistically significant result ( 71195 10P    from a two-sample 
t -test). The result of B1+RR (Figure 9.7(b)) was statistically significant with 
( 5261 10P    from a two-sample t -test). B2+RR (Figure 9.7(c)) yielded a statistically 
significant result ( 63381 10P    from a two-sample t -test). In Figure 9.7(d), the ROC 
























































Figure 9.7 Predictions of bortezomib sensitivity on the target test set of multiple 
myeloma patients where the target training set and auxiliary dataset pertaining to 
multiple myeloma and non-small cell lung cancer patients, respectively, are used. 
Strip charts and boxplots (a), (b), and (c) show the differences in predicted drug 
sensitivity to bortezomib treatment between the responder (i.e., sensitive) group and 
non-responder (i.e., resistant) group using BT+SVR+S, B1+RR, and B2+RR, 
respectively. (d) shows the ROC curves of the prediction algorithms, which reveal 
the proportion of true positives compared to the proportion of false positives. ROC = 





Figure 9.8 shows that the proposed prediction algorithms BT+SVR+S and 
BT+SVR+L outperform the baseline prediction algorithms w.r.t. the MAUC. 
 
Figure 9.8 The Mean AUC (MAUC) values of the twelve bortezomib sensitivity 
prediction algorithms for multiple myeloma patients. The algorithms are ranked from left 
to right where the leftmost algorithm has the highest MAUC and the rightmost algorithm 
has the lowest MAUC. 
 
 
9.5   Discussion 
The experiments show that the proposed approaches significantly outperform existing 
approaches. Further, the proposed approaches are well-suited for a wide range of tasks, 




regulatory networks (GRN) inference [16, 110, 172, 173], and integration of different 
cancer data to improve the prediction performance in a given drug sensitivity task. 
As in [54], the mapping of predicted continuous values to categorical labels was 
performed using the ROCR package [174]. The details of the mapping algorithm can be 
found in [175]. In a nutshell, the algorithm sorts the predicted continuous values in 
increasing order. The algorithm works iteratively by examining one value at a time, from 
the smallest to the largest value. When examining a particular value v , the algorithm 
labels v  and all the values larger than or equal to v  as "resistant" (i.e., positive) and all 
the values smaller than v  as "sensitive" (i.e., negative). The algorithm compares these 
"resistant" and "sensitive" labels with the corresponding true labels in the target test set to 
build a confusion matrix. The true positive rate (TPR) and false positive rate (FPR) with 
respect to the value v  are then calculated and plotted. After all the predicted continuous 
values are examined, multiple points are plotted, where the x -coordinate of a point is a 
FPR and the y -coordinate of the point is a TPR. These points constitute the ROC curve 
of the prediction algorithm. 
The biological rationale behind the superior results of the approaches is that 
combining cancer drugs is often used to achieve enhanced therapeutic efficacy in the 
treatment [176]. For example, docetaxel (chemotherapy drug) is used to treat breast 
cancer in combination with other specific chemotherapy drugs [170] [177]. Bortezomib 
and docetaxel combination has been used as a therapy for breast cancer [178, 179]. 
Hence, the task of predicting bortezomib sensitivity in multiple myeloma patients is 
closely related to the task of predicting docetaxel sensitivity in breast cancer patients, 




are given an unseen example (i.e., test example). If the unseen example has an expression 
profile closer to given training example with corresponding response (i.e., drug value), 
then the unseen example is most likely to have a closer response to the response 
associated with the given training example. The same holds for combining bortezomib 
and cisplatin, which clinically led to synergistic killing of head and neck squamous cell 
carcinoma (HNSCC) cells [180]. In addition, erlotinib plus bortezomib showed 
synergistic antitumor activity against the H460 Non-small cell lung cancer (NSCLC) cell 
line [181]. 
In the proposed approaches, it is assumed that the number of features in the target 
training set is greater than the number of features in the auxiliary data. Then, the top q  
features in the target test set are selected using the highest q  statistical leverage scores 
computed on the target training set. However, If the number of features in the auxiliary 
data is greater than number of features in the target training set (as the case in  
triple-negative breast cancer and non-small cell lung cancer auxiliary data), then the top 
q  features are selected from the auxiliary data using the highest q  statistical leverage 
scores computed from the auxiliary data, where q  equals the number of features as in the 
target training set, and no further feature selection is performed on the target training and 
target test sets. 
In this work, differences in distributions between the target training set and 
auxiliary data have contributed to the degraded performance on the target test set for 
prediction algorithms employing the second baseline approach (B2), which does not have 




It is worth mentioning that the performance of other machine learning algorithms 
is also assessed, including random forests [121], support vector regression with a 
polynomial kernel of degree 2, and support vector regression with a Gaussian kernel. 
However, they exhibited poor performance; consequently, their results are not included in 
this paper. 
 
9.6   Summary 
In this paper, two approaches are presented to improve drug sensitivity prediction: a 
transfer learning approach and a boosted transfer learning approach. The transfer learning 
approach works by (1) performing a feature selection step to balance the number of 
features; (2) changing the representation of auxiliary data of a related task to a new 
representation that is closer to the target training set; and (3) combining the target training 
set with each one of the auxiliary data separately, and using the result as input to a 
standard machine learning algorithm. The boosted transfer learning approach boosts the 
performance of the transfer learning approach using a modified version of AdaBoost. 
The proposed approaches employ two machine learning algorithms: support 
vector regression and ridge regression. The experimental results demonstrate the stability 
of the proposed transfer learning approaches. The proposed approaches outperform the 
baseline approaches including an existing approach as measured by their higher and 







CHAPTER 10  
CONCLUSIONS AND FUTURE WORK 
 
 
In this dissertation, new machine learning and data mining algorithms have been 
developed and applied to solve two important biomedical problems: (i) gene network 
inference; and (ii) drug response prediction. 
Future work for gene network inference includes: (i) applying the proposed 
learning framework in the third chapter to other unsupervised network inference tools and 
evaluating its performance when used with those tools; (ii) exploring and assessing the 
feasibility of the framework using new feature learning and data classification methods 
including deep learning algorithms; (iii) applying the proposed hybrid approach in the 
fourth chapter to some well-studied organisms such as E. coli and yeast; (iv) assessing 
the feasibility of other unsupervised methods when using the hybrid approach;  
(v) exploring new data cleaning and link prediction algorithms such as matrix completion 
[182, 183] and evaluating their performance on both the DREAM datasets and datasets 
from the well-studied organisms; and (vi) extending sampling and boosting techniques in 
the fifth chapter to miRNA-mediated regulatory networks  [118, 119]. 
The work for drug sensitivity prediction opens possibilities for future work, e.g.,  
(i) exploiting signaling pathways to select the most important features and incorporating 
them into the proposed link prediction approach in the seventh chapter; (ii)  extending the 
transfer learning approaches in the ninth chapter to handle auxiliary data from multiple 
related tasks simultaneously; (iii) collaborating with domain experts, where signaling 




prediction task; and (iv) adopting new feature representation methods to improve the 

























EVALUATING PREDICTION ALGORITHMS ON CLINICAL  
TRIAL DATA OF NON-SMALL CELL LUNG CANCER  
AND TRIPLE-NEGATIVE BREAST CANCER 
 
 
Table A.1 shows the performance of 9 erlotinib sensitivity prediction algorithms on  
non-small cell lung cancer data of patients. The prediction algorithms were evaluated 
using Spearman correlation test, where statistical significant results of prediction 
algorithms on the test set are shown in bold. The results indicate that prediction 
algorithms of the baseline were not statistically significant compared to ours. 
Specifically, A1+RR statistically significantly outperforming the baseline prediction 
algorithms, where p are calculated according to Spearman correlation test. 
As the number of cell lines which respond to erlotinib is small and model is fitting 
a huge amount of noisy cell lines that affected the model, B+RR (proposed prediction 
algorithm via Geeleher et al.) results were not significant. Geeleher et al. [54] tackled this 
problem that caused poor performance as follows. They changed linear ridge regression 
and fitted model using logistic ridge regression model on the 15 most sensitive and 55 
most resistant samples and then applied model to the test set (i.e., clinical trial data), 
where their model then achieved significant results (rho = 0.64 45.3 10p   and from a 
Spearman’s correlation test). In contrast, the proposed prediction algorithms achieved 
statistical significant results using linear ridge regression and this shows that the proposed 
new feature representation is discriminative guiding the learning algorithm (RR) when 






Table A.1 Prediction of Erlotinib Sensitivity in NSCLC (Non-Small Cell Lung Cancer) 
Patients. Values with Statistical Significance (p<0.05) Are Shown in Bold. Results Are 
Shown As (p/rho) According to Spearman Correlation Test 
 
m 258 256 253 250 247 
d 9507 9507 9507 9507 9507 
A1+SVR+L 0.034/-0.368 0.099/-0.265 0.111/-0.252 0.047/-0.341 0.047/-0.341 
A1+SVR+S 0.053/-0.330 0.061/-0.315 0.078/-0.292 0.035/-0.367 0.065/-0.310 
A1+RR 0.007/-0.480 0.018/-0.421 0.013/-0.441 0.011/-0.453 0.010/-0.458 
m+A1 134 133 132 130 129 
d+A1 19014 19014 19014 19014 19014 
A2+SVR+L 0.394/-0.056 0.613/0.060 0.569/0.036 0.548/0.025 0.486/-0.007 
A2+SVR+S 0.275/-0.125 0.382/-0.063 0.348/-0.082 0.290/-0.115 0.320/-0.098 
A2+RR 0.028/-0.385 0.127/-0.236 0.070/-0.302 0.069/-0.304 0.122/-0.241 
m+A2 134 133 132 130 129 
d+A2 9507 9507 9507 9507 9507 
B+SVR+L 0.349/-0.081 0.399/-0.053 0.486/-0.007 0.426/-0.038 0.478/-0.011 
B+SVR+S 0.571/0.037 0.668/0.091 0.610/0.059 0.584/0.045 0.599/0.053 
B+RR 0.285/-0.119 0.350/-0.080 0.309/-0.104 0.266/-0.130 0.273/-0.126 
 
Table A.2 shows the performance of 3 cisplatin sensitivity prediction algorithms 
in triple-negative breast cancer patients’ data. The p-values used to evaluate prediction 
algorithms are from a linear regression model. Hence, approaches that employ ridge 
regression are evaluated. Geeleher et al. [54]  assessed the response of 24 triple-negative 
breast cancer patients to neoadjuvant cisplatin therapy. Each patient is assigned to one of 
four drug response categories based on RECIST [184]. B+RR did not capture variability 
in clinical response (see Table A.2 below). The proposed prediction algorithm achieved 








Table A.2 Prediction of Cisplatin Sensitivity in Triple-Negative Breast Cancer Patients. 
Results Are Recorded According to p-Values from a Linear Regression Model 
 
m 497 493 488 483 478 
d 9620 9620 9620 9620 9620 
A1+RR 0.1013 0.05781 0.08953 0.1775 0.1708 
m+A1 254 252 249 247 244 
d+A1 19240 19240 19240 19240 19240 
A2+RR 0.192 0.1413 0.192 0.09515 0.1213 
m+A2 254 252 249 247 244 
d+A2 9620 9620 9620 9620 9620 





















EVALUATING SIGNALING PATHWAYS AS A CONSTRAINT TO GET 
RELIABLE FEATURE SETS 
 
 
The performance of prediction algorithms employing ridge regression was assessed 
including, the baseline prediction algorithm of Geeleher et al. (B+RR) on the test sets of 
breast cancer and multiple myeloma. 
For Breast Cancer: Hedgehog (Hh), Notch, and Wnt signaling pathways were used, 
which have been reported as a novel therapeutic target in breast cancer [185-187]. These 
pathways consist of 217 unique genes and 113 of them could be found in our dataset 
which were used in the proposed model. For Multiple Myeloma (MM), Jak-STAT, 
PI3K-Akt, and NF-kappa B were used as the classic signaling pathways underlying MM 
[187, 188]. There are 512 unique genes in these pathways and 341 of them could be 
found in the dataset which were used in the proposed model. It is found found that the 
performance of B+RR (i.e., the baseline) and A1+RR has significantly degraded where 
all achieved AUC below 0.60 on both test sets for breast cancer and multiple myeloma. 
This shows that removing discriminative features significantly degrade the performance 
of all prediction algorithms including the baseline (B+RR) as these discriminative 
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